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ABSTRACT 
Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in 
NAD+ biosynthesis from nicotinamide, is one of the major factors regulating cell 
metabolism and NAMPT is considered a promising target for treating cancer. The 
NAMPT inhibitor (FK866) has exhibited anticancer activity in several preclinical 
models by depleting NAD+ and ATP levels. Recently, we showed that FK866 
induced translation arrest through the activation of 5’AMP-activated protein 
kinase (AMPK), inhibition of mTOR/4EBP1 signaling, and phosphorylation of 
EIF2a in leukemia cells. Cancer drug resistance continues to be a major 
challenge in medical oncology. Deregulated cellular metabolism is linked to such 
cell resistance. Indeed, both components of the glycolytic and mitochondrial 
pathways are involved in altered metabolism conferring chemoresistance in 
several cancers. In this study, we developed FK866-resistant models in T-
lymphoblastic leukemia (CCRF-CEM) and breast cancer (MDA-MB231) cell lines 
to investigate the molecular mechanism of pharmacoresistance to NAMPT 
inhibitor (FK866). Our resistant cells were not inhibited at the translational level 
by FK866 and the drug-induced metabolic adaptations of the resistant cells 
conferred an advantage to counteract FK866 toxicity. We reveal a molecular 
mechanism by which FK866 resistant CCRF-CEM cells utilize alternative 
sources for NAD production to fuel cell metabolism, and metabolic 
reprogramming was associated to the drug resistance. Importantly, the FK866-
induced metabolic alteration was overcome by the co-administration of FK866 
with compounds targeting metabolism, thereby rendering a synergistic outcome 
and restoring cell susceptibility towards FK866. We highlighted a molecular target 
that favors acquiring of resistance in leukemia and breast cancer cells. In 
conclusion, targeting metabolic alterations associated with drug resistance to 
FK866 may open up unexplored opportunities for the development of new 
therapeutic strategies as a combinatorial treatment for cancer. 
. 
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ABBREVIATIONS 
2DG 2-Deoxyglucose 
4EBP1 Eukaryotic translation initiation factor 4E-Binding Protein 1 
ADP adenosine diphosphate 
AKT RAC-alpha serine/threonine-protein kinase 
AML Acute Myeloid Leukemia 
AMP  Adenosine Mono Phosphate 
AMPK  AMP-activated Protein Kinase 
ATP  Adenosine TriPhosphate 
B-CLL  B-cell Chronic Lymphocytic Leukemia  
BAD BCL2-antagonist of cell death 
BCL-2 B-Cell Lymphoma 2 
CoQ Coenzyme Q 
CoQH ubisemiquinone 
COX cytochrome C oxidase 
EIF2a Eukaryotic translation Initiation Factor 2 alpha 
EIF4E Eukaryotic translation Initiation Factor 4E 
EMT Epithelial-Mesenchymal Transition 
eNAMPT extracellular form of NAMPT 
iNAMPT intracellular form of NAMPT 
ER Endoplasmic Reticulum 
FAD  Flavin Adenine Dinucleotide  
FADH2 Flavin Adenine Dinucleotide dihyrdrate  
FOXM1 Forkhead box protein 1 
G-6-P glucose-6-phosphate 
HIF1 Hypoxia-Inducible Factor 1 
HK  Hexokinase 
IDO Indoleamine-2,3,-Dioxigenase 
LAT1 L-type amino acid transporter  
LDHA Lactate Dehydrogenase isoform A  
LKB1 Liver Kinase B1 
MCL1 Myeloid Cell Leukemia 1 
MDR MultiDrug Resistance 
mRNA messenger Ribonucleid Acid 
mtDNA mitochondria DNA 
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ABBREVIATIONS 
mTORC1 Mammalian target of rapamycin complex 1 
mTORC2 Mammalian target of rapamycin complex 2 
MYC v-myc avian myelocytomatosis viral oncogene homolog 
NA Nicotinic Acid 
NAD+ Nicotinamide Adenine Dinucleotide 
NADH Nicotinamide Adenine Dinucleotide Hydrate 
NAM Nicotinamide 
NAMPT Nicotinamide PhosphoribosylTransferase 
NAPRT Nicotinic Acid PhosphoribosylTransferase 
NMN Nicotinamide MonoNucleotide 
NMNAT Nicotinamide/Nicotinic acid MonoNucleotide AdenylylTransferase 
NR Nicotinamide Riboside 
NRK Nicotinamide Riboside Kinase 
OXPHOS Oxidative phosphorylation 
PARP  Poly (ADP-Ribose) Polymerase 
PBEF Pre B-cell colony Enhancing Factor 
PDK1 Pyruvate dehydrogenase kinase 1 
PEP Phosphoenolpyruvate 
PFK-1 Phosphofructokinase-1 
PFKFB 6-phosphofruto-2-kinase/fructose-2,6-bisphosphatase 
PGI Phosphoglucose isomerase 
PI Propidium Iodide 
PI3K PhosphoInositide-3-Kinase 
PK Pyruvate kinase 
PPP Ppentose phosphate pathway 
QPRT Quinolinic acid phosphoribosyltransferase 
ROS Reactive Oxygen Species 
RT-PCR Reverse Transcription Polymerase Chain Reaction 
S6K1 ribosomal S6 kinase 
SIRT Sirtuin 
T-ALL T-cell Acute Lymphoblastic Leukemia  
TCA TriCarboxylic Acid  
TDO Tryptophan-2,3,-DiOxigenase 
TP53 Tumor Protein p53 
TSC2 Tuberous Sclerosis Complex-2 
UPR Unfolded Protein Response  
VDAC  voltage-dependent anion channel 
	 7	
CONTENTS 
ABSTRACT	.................................................................................................................	3	
FIRST	PROJECT	.........................................................................................................	11	
INTRODUCTION	.......................................................................................................	12	
Hallmarks	of	cancer	.........................................................................................................	12	
Metabolism	of	cancer	......................................................................................................	13	
Metabolic	difference	between	differentiated	cells	(normal)	and	proliferating	cells	
(Cancer)	.............................................................................................................................	14	
The	Warburg	effect	in	cancer	............................................................................................	14	
NAD	metabolism	and	NAMPT	enzyme	activity	................................................................	17	
NAD	....................................................................................................................................	17	
NAMPT/PBEF/visfatin	........................................................................................................	19	
TRYPTOPHAN	.....................................................................................................................	22	
NAMPT	INHIBITORS	...........................................................................................................	24	
Glutamine	pathway	and	Asparagine	synthetase	..............................................................	26	
Drug	resistance	...............................................................................................................	28	
Oxidative	phosphorylation	..............................................................................................	30	
Signal	transduction	in	cancers	.........................................................................................	33	
MTOR	.................................................................................................................................	34	
The	PI3K/AKT/mTOR	signaling	pathway	............................................................................	35	
Regulation	of	AMPK	...........................................................................................................	36	
Protein	translation	control	................................................................................................	38	
CHOP	activation	..............................................................................................................	39	
MATERIAL	AND	METHODS	.......................................................................................	41	
RESULTS	..................................................................................................................	46	
Development	of	NAMPT	inhibitor	(FK866)	resistant	models	............................................	47	
Characterization	of	NAMPT-dependent	CEM	resistant	model	..........................................	47	
Translation	control	was	not	inhibited	during	FK866	treatment	in	CEM	RES	cells	..............	49	
Metabolic	alteration	in	FK866	CEM	RES	...........................................................................	51	
Utilization	of	Tryptophan;	an	alternative	pathway	for	NAD	production	in	CEM	RES	.........	55	
Characterization	of	L-Asparaginase	response	...................................................................	66	
Development	of	a	comparative	NAMPT	inhibitor	resistant	model	in	MDA-MB231	cell	line.
	.......................................................................................................................................	72	
Genetic	evidences	deciphering	the	mechanism	of	FK866	pharmacoresistance	.................	77	
NAMPT	...............................................................................................................................	77	
Lactate	dehydrogenase	(LDH)	............................................................................................	80	
DISCUSSION	............................................................................................................	90	
CONCLUSION	...........................................................................................................	97	
SECOND	PROJECT	....................................................................................................	99	
Background	...................................................................................................................	100	
Results	and	discussion	...................................................................................................	104	
Figure	1,	figure	title	“Importance	of	YAP	in	PDAC	cell	lines”.	..........................................	104	
Figure	2,	figure	title	“Identification	of	modulators	of	YAP	localization”	.........................	105	
Figure	3,	figure	title	“BIS	I	treatment	phenocopies	YAP	functional	ablation”	.................	105	
Figure	4,	figure	title	“The	CTGF	expression	level	was	modulated	by	the	TGF-β	and	Hippo	
pathways	in	PDAC”	..........................................................................................................	106	
	8	
Figure	5,	figure	title	“BIS	I	activates	β-catenin	and	downregulates	the	expression	level	of	
cancer	staminality	genes”	................................................................................................	106	
Figure	6,	figure	title	“BIS	I	reverts	YAP-induced	EMT	in	PDAC	cell	lines”	........................	107	
Figure	7,	figure	title	“Genetic	ablation	of	YAP	and	BIS	I	treatment	regulate	cell	migration”
	.........................................................................................................................................	108	
Conclusion	....................................................................................................................	108	
CONTRIBUTION	PROJECTS	.....................................................................................	109	
LIST	OF	PUBLICATIONS	..........................................................................................	110	
REFERENCES	..........................................................................................................	111	
APPENDIX	..............................................................................................................	126	
Zucal	et	al.	(2015)	BMC	cancer	.......................................................................................	128	
Thongon	et	al.	(2016)	Oncotarget	..................................................................................	142	
GRANT	SUPPORT	...................................................................................................	158	
ACKNOWLEDGMENT	.............................................................................................	159	
 
  
	 9	
FIGURE INDEX 
Figure 1 Emerging Hallmarks of cancer ....................................................................... 12 
Figure 2 Overview of core metabolic pathways and metabolic enzymes involved in 
cancer metabolism. .............................................................................................. 13 
Figure 3 The Warburg effect ........................................................................................ 15 
Figure 4 Schematic of mammalian NAD metabolism ................................................... 19 
Figure 5 Circadian regulation of the NAD salvage pathway ......................................... 20 
Figure 6 Physiological actions of NAMPT .................................................................... 22 
Figure 7 Simplified diagram of NAD de novo pathway from tryptophan . ..................... 24 
Figure 8 Chemical structures of NAMPT inhibitors ...................................................... 26 
Figure 9 The biosynthetic reaction catalyzed by ASNS ............................................... 28 
Figure 10 Schematic representation of LDH……………………………………………… 30 
Figure 11 OXPHOS system in mammalian mitochondria  ........................................... 32 
Figure 12 Glycolysis and TCA cycle in tumors ............................................................. 33 
Figure 14 PI3K/AKT/mTOR Signaling pathways .......................................................... 36 
Figure 15 LKB1-AMPK signaling pathway ................................................................... 37 
Figure 16 Activation of translation initiation by mTOR ................................................. 39 
Figure 17 Mammalian UPR and CHOP activation pathways ....................................... 40 
Figure 19 FK866 significantly decreases NAD and ATP levels in CEM cells. .............. 49 
Figure 20 Signaling cascades controlling protein translation in CEM RES cells. ......... 50 
Figure 21 A decrease in mitochondria function in CEM RES cells ............................... 52 
Figure 22 CEM RES cells display an enhanced glycolysis dependency. ..................... 53 
Figure 23 Down-regulation of genes involved in mitochondria function in CEM RES 
cells ...................................................................................................................... 54 
Figure 24 CEM RES cells are more vulnerable to glucose deprivation. ....................... 55 
Figure 25 FK866 potentiates QRPT enzymatic activity in CEM RES cells. ................. 56 
Figure 26 Effect of JPH203 a selective LAT1 inhibitor in CEM cell viability ................. 58 
Figure 27 Drug combination of FK866 and JPH203 in CEM PA cells .......................... 59 
Figure 28 Drug combination of FK866 and JPH203 in CEM RES cells ....................... 60 
Figure 29 Drug combination screens identify synergistic effect of FK866 and JPH203 in 
CEM cells ............................................................................................................. 61 
Figure 30 Characterization of LAT1 expression in CEM cells ...................................... 62 
Figure 31 Tryptophan prevents CEM RES cell death under energetic stress. ............. 65 
Figure 32 Utilization of tryptophan as an alternative source to rescue cell survival and 
sustain ATP and NAD production in the resistance during stress conditions. ...... 66 
Figure 33 Effect of L-Asparaginase induced cell death in CEM cells ........................... 68 
	10	
Figure 34 Drug combination screens of FK866 and L-Asparaginase in CEM cells ...... 69 
Figure 35 L-glutamine prevents cell death during energetic stress. ............................. 70 
Figure 36 L-Glutamine exhibits rescues effect on ATP and NAD production during 
stress condition in CEM RES cells. ...................................................................... 71 
Figure 37 Characterization of NAMPT dependent-FK866 resistant MDA cells ............ 73 
Figure 38 Evaluation of ATP and NAD levels in MDA cells .......................................... 73 
Figure 39 Protein translation control is not inhibited in MDA RES cells ....................... 74 
Figure 40 Down-regulation of de novo NAD synthesis target genes in MDA RES cells
 .............................................................................................................................. 76 
Figure 41 Drug sensitivity test in MDA MB231 cells ..................................................... 76 
Figure 42 Expression levels of genes involved in glycolytic and OXPHOS ................. 77 
Figure 43 Overexpressed NAMPT in MDA cells .......................................................... 78 
Figure 44 Differential expression of NAMPT levels and NAD activity in a panel of 
cancer cell lines .................................................................................................... 79 
Figure 45 Resistant cells are susceptible to a LDH inhibitor. ....................................... 81 
Figure 46 Inhibition of LDH impacts ATP and NAD production in CEM RES cells. ..... 82 
Figure 47 GSK induces apoptosis in CEM RES cells .................................................. 83 
Figure 48 Inhibition of LDHA by GSK induces the CHOP/ATF4 activation. ................. 85 
Figure 49 Drug combination between FK866 and GSK ............................................... 86 
Figure 50 Ablation of LDHA by siRNA leads to a decrease in ATP production in MDA 
cells. ..................................................................................................................... 88 
Figure 51 Treatment of FK866 coordinated with down-regulation of LDHA potentiates 
the activation of CHOP/ATF4 in the resistant cells. .............................................. 89 
Figure 52 Genetic progression model of pancreatic adenocarcinoma. ...................... 102 
Figure 53 Schematic model of the Hippo signaling cascade in mammals 204. ........... 103 
Figure 54 Schematic model of CTGF promoter activation through TGF-β/Smad 
signaling and Hippo pathway .............................................................................. 103 
 
 
 
TABLE INDEX 
 
Table 1 Cell cycle analysis by PI staining in CEM PA and CEM RES cells ................. 84 
Table 2 Summary of the characterization in parental and FK866 resistant models ..... 98 
Table 3 Sequences of primers ................................................................................... 127 
 
 
	 11	
 
 
 
 
 
FIRST PROJECT 
 
 
 
 
 
 
MOLECULAR MECHANISM OF PHARMACORESISTANCE TO 
THE NAMPT INHIBITOR (FK866) IN CANCERS 
  
	12	
INTRODUCTION 
Hallmarks of cancer  
Uncontrolled cell division and acquired aberrant function of normal cells have 
been associated with vital causes of cancer development 1. The factors that 
gradually transforms a normal cell into a precancerous or premalignant stage 
then ultimately becomes a cancer cell, have been described as the “Hallmarks of 
Cancer” 1,2. Reprogramming of energy metabolism is one of the significant 
hallmarks contributing to cancer. Adaptations of cellular metabolism pathways is 
frequent in cancer rather more than in normal tissue (Figure 1) 2. Enhanced 
aerobic glycolysis, reduction of oxidative phosphorylation (OXPHOS) function 
and increased generation of biosynthetic intermediate substances to meet the 
metabolic demands are frequently found in cancer to maintain cell growth and 
proliferation 3,4.  
 
 
Figure 1 Emerging Hallmarks of cancer 
The capability to modify or reprogram cellular metabolism to support cancer proliferation 
reflecting the deregulation of cellular energy is one of a significant hallmarks of cancer. 
Metabolic alterations have been considered as a part of oncogenesis and tumor 
progression 2. 
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Metabolism of cancer 
Metabolic reprogramming in cancer cells are commonly revealed by 
dysregulation of metabolic enzymes or oncogenic signaling 3. As illustrated in 
Figure 2, phosphatidylinositol 3−kinase (PI3K)-AKT and mammalian target of 
rapamycin (mTOR) are canonical oncogenic signaling pathways which directly 
regulate the core carbon metabolism in the cells 5. Several metabolic enzymes, 
including hexokinase 2 (HK2), lactate dehydrogenase A (LDHA) and pyruvate 
dehydrogenase kinase 1 (PDK1), are well-known transcriptional targets of MYC 
and hypoxia-inducible factor-1 (HIF-1), oncogenic transcription factors 6. Tumor 
cells have aberrant activation of mTOR 7 that induces anabolic growth by 
nucleotide, protein, and lipid synthesis. Loss of tumor suppressor like p53 or 
activation of oncogenes such as MYC further promotes anabolism through the 
transcriptional regulation of metabolic genes 6. 
 
 
Figure 2 Overview of core metabolic pathways and metabolic enzymes involved 
in cancer metabolism. 
This figure illustrates various aspects of energy metabolism regulation, including 
glycolysis, TCA cycle, pentose phosphate pathway (PPP), glutaminolysis, fatty acid 
biosynthesis pathway, PI3K/mTOR, AMPK signaling cascade and apoptosis pathways. 
Three transcription factors, HIF-1, c-MYC and p53 are key regulators of cancer 
metabolism in many cell lines 6. 
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Metabolic difference between differentiated cells (normal) and proliferating 
cells (Cancer) 
Aberrant biochemical features and the abnormal metabolism of glucose have 
been found to be common and revealed consequences of oncogenic signaling 
and adaptation in cancer cells 8. Glucose has been well described as a main 
source of energy and an initiated carbon source for various anabolic pathways in 
mammalian cells 9. Glycolysis-derived pyruvate predominantly occurs in the 
normal cells or quiescent cells whereas the conspicuous alteration in glucose 
metabolism by strongly increased glucose uptake and glycolysis yielding 
intermediate glycolytic metabolites has been found in most of cancer cells 9. In 
the presence of sufficient oxygen, most pyruvate can be converted to lactate 
through LDH enzyme and this metabolic phenomenon referring to aerobic 
glycolysis was first described by Otto Warburg, a German scientist in 1930 which 
has been later known as the ‘‘Warburg effect’’ (Figure 3) 10. 
The Warburg effect in cancer 
Warburg experiment was primarily described and focused on glycolysis 
demonstrating a reversed Pasteur effect (the inhibition of fermentation by O2) in 
all of the investigated cancer cells at that moment 9,10. Cancer cells produce lactic 
acid from glucose even under non-hypoxic conditions. Thus, they determined that 
under aerobic conditions, tumor tissues metabolite approximately ten-fold more 
glucose to lactate in a given time than normal tissues 10,11. Metabolic switch from 
OXPHOS towards aerobic glycolysis (Warburg effect) is now a well-established 
link between cancer and peculiar glucose metabolism. Indeed, glycolysis 
dependent metabolism to generate ATP as a primary source for cellular energy 
has been consistently observed in most cancer from different tissue origins 12,13, 
suggesting that the metabolic alteration commonly occurs in cancers. Several 
factors have been suggested as potential mechanism leading to increase 
glycolysis in cancer cells and thus contribute to the Warburg effect including (i) 
mitochondrial defects, (ii) hypoxic environment in cancer, (iii) oncogenic signaling 
induced cancer and alteration of metabolic enzymes 12.  
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Figure 3 The Warburg effect 
Schematic representation of the metabolic differences between a normal cell and a 
malignant cell. In normal cells, pyruvate is generated through glycolysis pathway in 
cytosol and then it is transported into mitochondria and further metabolized via TCA 
cycle. In cancer cells, a high rate of glycolysis and increased of glycolytic enzyme are 
observed. Glucose is metabolized to pyruvate and the production of lactate occurs even 
in the presence of oxygen condition 14.  
(i) Mitochondria respiration damage  
Dysfunction or damage of mitochondria by mutation is contributed to an enhance 
of glycolysis 12. Mitochondria DNA (mtDNA) has high mutation rate in several 
cancers such as in leukemia 15 colon cancer 16 and prostate cancer 17. For instant, 
mutation of mtDNA strongly induces malfunction of OXPHOS and affects the 
cellular respiratory. Moreover, low capacity of histone protection, and impairment 
of DNA repair were found in mtDNA mutation 12. Since, glycolysis in the cytosol 
and OXPHOS in mitochondria are two major metabolic pathways responsible for 
ATP generation from molecules of glucose. To this regard, malfunction of the 
mitochondrial respiratory chain or mitochondria damage possibly potentiate the 
cancer cells to rely more and become addicted to glycolytic metabolism for ATP 
production. Despite, OXPHOS generates ATP much more efficient (36 ATP per 
a molecule of glucose) than by glycolysis (only 2 ATP) but a small loss of 
mitochondria function is strongly influent cellular respiration. Therefore, 
increased glycolytic activity is extensively required to sustain the energy balance 
especially in cancer cells 18.  
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(ii) Hypoxia 
When oxygen is limited or in a hypoxic condition, cancer cells might be forced to 
rely more on glycolytic pathway instead of mitochondria respiration to generate 
ATP 16. Hypoxia is highly-present in human malignancies, especially has 
frequently been found in solid tumor tissue due to the penetration of oxygen 
becomes limited when the tumor mass reaches certain size 19. Moreover, solid 
tumors display less well-oxygenated in respect to normal tissues from the same 
origins which they arose 20. Under such conditions, OXPHOS may not proceed 
normally and hampers this metabolic pathway by hypoxia resulting in cell death 
due to the very low level of oxygen as well as an insufficient of cellular ATP levels 
21. Consequently, increase of glycolysis may reflect to cellular adaptation to 
oxygen insufficient condition. Hypoxia inducible factor 1 (HIF-1) regulates cellular 
response to hypoxia leading to the activation of genes associated to glucose 
uptake, apoptosis, and metastasis 19. In normal cells, hypoxia plays a role in 
translation inhibition either through mTOR pathway activation or regulation of 
EIF2a. The activation of AMPK or PERK in response to metabolic alteration by 
hypoxia is HIF-independent 22. AY87-2243 is presented as an inhibitor of HIF-1 
activity and of HIF-1a stability and now this compound has been entering into 
Phase I clinical trial 13. However, validation of HIF-1 as druggable anticancer 
target is still pending.  
(iii) Oncogenic signals and alteration of metabolic enzymes  
The Warburg effect has been interconnected with activation of certain 
oncogenes, such as MYC, Ras, and Akt. Loss of tumor suppressor genes results 
in the deregulated conversion of glucose to lactate 23. In cancer, genetic 
deregulation of MYC expression and loss of checkpoint components, such as 
P53, permitted MYC to drive malignant transformation 24. A decrease of 
phosphoglucomutase (PGM) by p53 exhibited a decrease in glycolysis. However, 
enhanced glycolytic flux has been reported in some p53 mutant cancer 25,26. 
GLUT1 and GLUT4 genes are regulated by p53 27. Inhibition of H-Ras by trans-
farnesylthiosalicylic acid results in inhibition of glycolysis by decreasing HIF-1a 
regulated genes such vascular endothelial growth factor and GLUT1, inhibiting 
glycolytic enzymes such as PFKFB4 and PFKFB3 and leading to cell death in 
human glioblastoma U87 cells 28. The signaling through the insulin receptor 
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activates PI3K/Akt inducing glucose uptake and glycolysis 29. Recently, Yu and 
colleagues found that the proviral insertion in murine lymphomas 2 (PIM2) 
oncogene promotes PKM2-dependent glycolysis and reduces mitochondrial 
respiration in HEPG2 and HEK293 cell lines 30. Alterations of metabolic enzymes 
has been considered as a cause of metabolic changes in cancer 31. Increase of 
HK2 expression in cancer led to an elevate of glycolysis 32. Fumarate hydratase 
(FH) and succinate dehydrogenase (SDH) are two important enzymes which play 
fundamental roles in ATP production in mitochondria 33. Mutant of SDH subunit 
leads to an accumulation of succinate in cytosol where it inhibits prolyhydroxylase 
(PHD). Stabilization and activation of HIF-1a are regulated by PHD 33. A tumor 
suppressor gene N-Myc downstream regulated gene 2 (NDRG2) inhibits cancer 
growth, metastasis and cell invasion. NDRG2 was found to regulate also glucose 
transporters and glycolytic enzymes such as GLUT1, HK2, PKM2 and LDH 34. In 
addition, increased ROS generation and intrinsic oxidative stress may lead to 
suppression of ROS-sensitive enzymes involved in TCA cycle enzymes, 
therefore increased ROS generation spontaneously forces cells to increase 
glycolysis in order to maintain cellular energy level 12.  
NAD metabolism and NAMPT enzyme activity  
NAD 
In addition to enzymes such as HK2 or LDH that play important roles in aerobic 
glycolysis, nicotinamide adenine dinucleotide (NAD) is also a fundamental 
cofactor for the redox reactions in the metabolic pathways, especially in cancer 
35. NAD is used as a substrate for several families of enzymes including poly 
ADP-ribose polymerases (PARPs) and sirtuins, that involved in numerous 
biological functions including cell survival and death 36. The mammalian NAD+ 
dependent protein deacetylase SIRT1, and systemic NAD+ biosynthesis 
mediated by nicotinamide phosphoribosyltransferase (NAMPT) are two critical 
components comprising in NAD regulation 35. SIRT1 displays its function as a 
key mediator controlling metabolism in various types of tissues, while NAMPT-
mediated NAD biosynthesis regulates circadian-oscillatory of NAD+ production 
36. NAD can be synthesized through two metabolic pathways which are the de 
novo pathway starting from amino acids or in salvage pathways by recycling 
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nicotinamide (NAM) back to NAD 35,37. As illustrated in Figure 4, NAD synthesis 
in mammalian cell comprises of multiple steps and the first rate-limiting step of 
the de novo pathway is catalyzed by TDOs (mainly in the liver) or IDOs through 
de novo pathway starting from tryptophan. L-tryptophan is converted to nicotinic 
acid mononucleotide (NAMN). Nicotinic acid (NA) enters the de novo pathway 
and is phosphoribosylated to NAMN by nicotinic acid phosphoribosyl transferase 
(NAPRT). Then the conversion of NAMN to nicotinic acid adenine dinucleotide 
(NAAD) is performed by nicotinamide/nicotinic acid mononucleotide adenylyl-
transferases 1-3 (NMNAT1-3) enzyme. At the final stage, NAAD is amidated by 
NAD synthase (NADS) to generate NAD.  
For the NAD salvage pathway, NAM is another important NAD precursor and a 
product of deacetylation and ADP-ribosylation reactions which are catalyzed by 
several NAD-dependent enzymes including SIRTs, PARPs, and MARTs as well 
as some ADP-ribosylcyclases enzyme such as CD38 38. The key enzyme 
NAMPT has been considered as the rate-limiting step enzyme in the NAD 
salvage pathway. NAMPT catalyzes the formation of nicotinamide 
mononucleotide (NMN) from NAM and PRPP. NMN is then converted into NAD 
by NMNAT1-3. Moreover, NR enters to cell via nucleoside transporter then NR 
is re-phosphorylated to NMN by nicotinamide riboside kinases (NRK1) 37. 
Recently, Ratajczak and colleagues demonstrated a crucial role of NRK1 which 
is necessity for the use of exogenous NR and also NMN for NAD biosynthesis. 
However, the NRK1 function is dispensable from NAM in regulation of NAD 
production 39. 
Sirtuins are a family of protein deacetylases and adenosine diphosphate (ADP)-
ribosyltransferases. NAD is required for sirtuin function. Among sirtuin protein 
family, SIRT1 plays important roles in regulation of many cellular functions. Fatty 
acid metabolism, cell proliferation, and glucose homeostasis are associated by 
SIRT regulation 36,40. As illustrated in Figure 5, SIRT1 prevents cell from the 
oxidative stress by deacetylation of substrates such as P53 and FOXO1 
transcriptional factors 40. In addition, SIRT1 is overexpressed in many primary 
solid tumors and especially hematopoietic malignant cells 41 and serves as a key 
physiological downstream effector for NAMPT in regulating cell metabolism, 
differentiation and circadian clock 40,41.  
	 19	
 
 
 
Figure 4 Schematic of mammalian NAD metabolism 
NAD can be synthesized through two metabolic pathways. NAD is produced either in a 
de novo pathway from Tryptophan or in salvage pathways by recycling substrate such 
as nicotinamide back to NAD. By-product of the PARSylation of proteins PARP reactions 
is performed by utilized β-NAD as a substrate to generate NAM. β-NAD is largely 
provided in high-active PARPs cells by the salvage pathway 37. 
NAMPT/PBEF/visfatin  
Preiss and Handler firstly described the NAMPT enzyme activity in 1957 42. 
Based on the enzymatic activity reflecting different pathological functions, 
NAMPT, PBEF, and visfatin, these three different nomenclatures have been 
given to this NAMPT protein. Later, NAMPT was approved and has been used 
as the official name for both gene and protein 35. Human NAMPT protein consists 
491 aminoacids and the molecular weight of NAMPT is approximately 55 kDa 42. 
Both intracellular and extracellular forms of NAMPT has been found to be 
expressed in mammal 35,43 and to avoid misunderstanding, eNAMPT and 
iNAMPT are used as terms referring to the extracellular and intracellular forms of 
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NAMPT, respectively. eNAMPT has been found in human 44 and mouse 
circulation 45 which appears to be modified post translationally and is secreted 
possibly by hepatocytes and fully differentiated adipocytes 35. iNAMPT has been 
definitely established as an NAD biosynthetic enzyme 45 while eNAMPT functions 
as a growth factor 35,38. As describe in the review 46, iNAMPT overexpressed has 
been demonstrated in variety of human malignant tumors. For example, high 
expression of iNAMPT results in an increase of cellular stromal cell-derived 
factor-1 (SDF1) level in colon cancer 47, promotes gastric cancer progression 48 
and also correlates with greater aggressive malignant lymphoma 49. Levels of 
iNAMPT reflects to a worse prognosis in many cancer cells such as endometrial 
adenocarcinoma 50 and prostate cancer 41. Interestingly, several reports 
demonstrated that overexpression of iNAMPT confers resistance to 
chemotherapeutic agents such as doxorubicin 51, etoposide 41, and fluorouracil 
48.  
 
Figure 5 Circadian regulation of the NAD salvage pathway 
NAMPT is a rate-limiting enzyme in mammalian NAD+ biosynthesis from NAM. NAMPT 
catalyses the transfer of PRPP to NAM to produce NMN, then NMN is further converted 
to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs; there are 
three NMNAT genes 1-3). The activity of SIRT1 and PARPs are determined by the 
oscillations in NAMPT levels and variations of NAD+ levels. SIRT1 can also deacetylate 
and regulate proteins involved in cellular metabolism and cell proliferation. 40. 
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Systemic NAD synthesis is mediated by eNAMPT which its level is not only 
critical for normal β-cell function but also associates to macrophage survival 
during ER stress through activation of IL6 secretion and stat3 52. In this regard, 
eNAMPT exerts function independently of NAD synthesis with low catalytic 
activity under normal condition. However, overexpression and high-secretion of 
eNAMPT have been described as causes of cardiac hypertrophy in murine 
cardiomyocytes 46,53 and in advance stage of hepatocellular carcinoma 54. 
As illustrated in Figure 6, physiological levels of cellular NAD and NAM recycling 
are regulated by NAMPT activity. SIRT1, 6, 7 and PARP-1 are NAD-dependent 
enzymes which are found to be expressed in nucleus while SIRT1 and SIRT2 
are expressed in the cytoplasm, and SIRT3, 4, 5 are expressed in mitochondria 
35. The ectoenzyme CD38 produces cyclic adenosine diphosphate ribose 
(cADPR) which regulates intracellular Ca2+ signaling. CD38 is broadly 
expressed as a transmembrane protein which catalyzes the breakdown of NAD 
and NADP to generate cADPR 55. It has been reported that NAMPT expression 
is regulated by the circadian CLOCK and BMAL1 transcription factors which form 
complex with SIRT1 in the nucleus 38,56. A feedback loop involving NAMPT/NAD+ 
and SIRT1/CLOCK:BMAL1 complex has been described by inhibition of NAMPT 
that activates clock gene Per2. However, transcription factor CLOCK can also 
bind to NAMPT and up-regulates NAMPT expression 56,57. Nevertheless, NAMPT 
could be stimulated by other stimuli such as the mechanical stress and pro-
inflammatory cytokines including TNF-a, IL-1 and IFN 58. Interestingly, NAMPT is 
secreted from different cell types and is probably released from damaged cells 
together with ATP and PRPP. Extracellular production of NMN potentially occurs 
from the conversion of NAM and NMN. NMN enters to the cell, possibly after 
conversion to NR by the ectocellular enzymes CD38 and CD73 38.  
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Figure 6 Physiological actions of NAMPT 
Two forms of NAMPT have been found in mammalian cells. Intracellular form of NAMPT 
or iNAMPT is ubiquitously expressed whereas extracellular form of NAMPT or eNAMPT 
is positively secreted from adipose tissue and expressed with higher enzymatic activity 
in respect to iNAMPT. Nicotinamide ribose (NR) is another key of NAD intermediate 
which can be produced from extracellular NMN by CD73. NR enters to cell via 
nucleoside transporter then NR is rephosphorylated to NMN by NRK1. Then, NMN is 
further converted to NAD by NMNAT1-3 35,38.  
TRYPTOPHAN 
Mammalian NAD biosynthesis can be synthesized via de novo synthesis pathway 
starting from tryptophan (Trp) 38,55. As illustrated in Figure 7, multistep reactions 
are required for NAD production. The de novo pathway is comprised into two 
parts; the first part has been called as the kynurenine pathway (KP) which 
involves metabolic conversion of tryptophan to α-amino-β-carboxymuconate-ε-
semialdehyde (ACMS), thereby produces picolinic acid at the final step before 
entering TCA cycle via acetyl-CoA. Metabolic conversion of ACMS to NAD is the 
second part of the de novo pathway of NAD synthesis 59. The initial step of the 
KP is mainly regulated by two key enzymes which are indoleamine 2,3-
dioxygenase 1 (IDO-1) and tryptophan 2,3-dioxygenase (TDO) 60. TDO 
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metabolites tryptophan to kynurenine, which is then converted to either kynurenic 
acid (KYNA) by kynurenine aminotransferase (KAT) or 3-hydroxykynurenine by 
kynurenine monooxygenase (KMO). Kynureninase (KYNU) metabolites 3-
hydroxykynurenine to 3-hydroxyanthranilic acid which then further converts to 
acetyl CoA. Non-enzymatically transformed to quinolinic acid is the final step 
producing the precursor for NAD+ synthesis 59–61.  
IDO-1 is broadly expressed in most tissues and is involved in the metabolism of 
Tryptophan 60 while TDO is constitutively expressed in liver and brain 59. In 
addition, IDO1 responses are found to be mediated by downstream stress 
response pathways including GCN2 and mTORC1 which are important 
regulators activated under insufficient of amino acids 60,62. In 2013, Wu wei and 
colleagues reported that lack of tryptophan caused by the over-activation of IDO 
induced an accumulation of uncharged tryptophan transfer RNA (Trp-tRNA). 
Silencing IDO by shRNA exerts antitumor efficiency in murine lung cancer model 
63. Depletion of tryptophan resulted in the blockade of activated T-cells at the G1 
phase preventing lymphocyte proliferation 64. In addition, phosphorylation of 
EIF2α mediated by GCN2 concurrently inhibits protein synthesis and arrests cell 
growth 62,65. 3-hydroxyanthranilic acid and quinolinic acid can induce apoptosis 
by exerting cytotoxic properties on T-cells 66. Quinolinic acid phosphoribosyltransferase 
(QPRT) is an enzyme in “de novo” NAD synthesis pathway which is responsible 
for the conversion of quinolinic acid an important NAD precursor to NAD+ 67,68. 
QPRT was associated with malignancy and elevated expression level of QPRT 
increase resistance to oxidative stress induced by radiochemotherapy in glioma 
cells, conferring a poor prognosis 68.  
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Figure 7 Simplified diagram of NAD de novo pathway from tryptophan 59.  
 
NAMPT INHIBITORS 
Inhibitors of NAMPT have been considered as promising cancer drugs and some 
of them are currently in clinical trials such as FK866, CHS-828 and the CHS-828 
prodrug EB1627/GMX1777 69. NAMPT belongs to a dimeric class of type II 
phosphoribosyltransferase enzyme 45,69. Indeed, NAMPT is mostly present as a 
dimer in cells and is profoundly affected by histidine autophosphorylation at 
residue His247. Interestingly, the crystal structures of the complexes with either 
NMN or FK866/APO866 (N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2E-
propenamide) (Figure 8) was shown to directly compete with NAM and acted as 
a competitive substrate binding to the catalytic pocket 70 deliberating the 
anticancer effect of FK866. Depletion of intracellular NAD content and thereby 
markedly replenishing ATP levels have been denoted as pharmacological 
signatures of NAMPT inhibitors contributing cell death in particular of FK866 69,71. 
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FK866 is a specific, competitive, and potent inhibitor of NAMPT that displays 
cytotoxicity in a broad panel of cancer cell lines 38,49,69. Informatively, FK866 
potentiated cell death inducing apoptosis in HepG2 (human liver carcinoma cells) 
and caused gradual NAD+ depletion through specific inhibition of NAPRT but it 
did not directly inhibit mitochondrial respiratory activity 72. Anti-tumor activity of 
FK866 has been found to prevent and abrogate tumor growth both in vivo and in 
vitro 23,73. Interestingly, FK866 displayed toxicity to human AML, lymphoblastic 
lymphoma, and leukemia but there was no report regarding to the significant 
toxicity to the animals 74. Assessment of FK866 has been suggested for the 
potential prevention of plaque vulnerability due to it reduced CXCL1 production 
associated neutrophil infiltration in atherosclerotic mice 75. FK866 induced the 
delayed energy stress in hepatocarcinoma cells, by triggering the activation of 
AMPKα and downregulation of mTOR signaling resulting in cancer cell death 76. 
FK866 strongly induced AMPK activation and inhibits of protein translation via 
EIF2a-dependent pathway in leukemia and EIF2a was highlighted as an early 
response to energy stress induced by FK866 71. To date, FK866 has successfully 
passed phase I and II clinical trials as single-agent therapies for several different 
cancers. The recommended phase II dose of FK866 is 0.126 mg/m2/h given as 
a continuous 96h infusion every 28 days 77. Unfortunately, recent results of 
FK866 have not been promising due to its constantly exposes side effect induced 
thrombocytopenia 73. CHS-828 (Figure 8), a pyridyl cyanoguanidine, is another 
small molecule inhibitor of NAMPT displaying cytotoxicity in many cell lines 
including breast, lung, fibroblasts and endothelial cancer cells 78. In 2010, Olesen 
and coworkers revealed that APO866/FK866, CHS-828 and TP201565 shared 
the same binding site in the active site of NAMPT enzyme 69. A prodrug 
EB1627/GMX1777 is currently also in phase I trials. CHS-828 has completed 
phase I of clinical trial with a dose of 420mg of CHS-828 administered every 3 
weeks is recommended for treatment 79. Adverse effects of CHS-828 and 
GMX1777 such as hematuria, leucopenia and thrombocytopenia were also 
notable during clinical trial 79. As NAMPT is essential for the replenishment of the 
intracellular NAD and ATP, thus targeting NAMPT activity may serve as a 
potential therapeutic strategy for treating leukemia and human solid tumors. 
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Specially, combining FK866 to other drugs targeting metabolism may enhance 
therapeutic efficacy of NAMPT inhibitors particularly in hematopoietic cancer. 
 
 
Figure 8 Chemical structures of NAMPT inhibitors 
FK866 (APO866), CHS-828, and TP201565. FK866, CHS-828, and GMX1777 are 
chemically distinct whereas TP201565 is an synthetic analogue of CHS-828 69. 
Glutamine pathway and Asparagine synthetase 
Beside glucose metabolism, glutamine (Gln) is a major nutrient consumed in 
cancer cells and it is the most abundant free amino acid in the body 80. Glutamine 
pathway has also been interested as a potent target of cancer therapy and its 
transport rate is higher in cancer in respect to normal cells 81,82. Glutamine 
belongs to a group of conditionally essential amino acid. In particular, under 
stress condition the dependency of growing cancer cells on glutamine is 
observed in intestinal mucosa cells 83. In fact, glutamine can be considered as a 
non-essential amino acid due to, it can be synthesized by the metabolism of other 
amino acids during recycling and scavenging of ammonia in muscle and other 
organs 83. The maintenance of high levels of glutamine in the blood provides a 
source of carbon and nitrogen to support biosynthesis and cellular homeostasis. 
Glutamine is transported into cells mainly through L-type amino acid transporter 
EB1627 / GMX1777 
APO866 / FK866 
CHS-828 / GMX1778
TP201565
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(LAT1, a heterodimer of SLC1A5 and SLC3A) a similar channel where facilitated 
tryptophan transportation 84,85. High levels of L-glutamine evades the need for  
L-glutamine uptake influencing the activation of mTOR. Thus, L-glutamine level 
predominantly modulates mTOR activation, protein translation and autophagy to 
maintain growth and proliferation of mammalian cells 83,84. mTOR itself regulates 
glutamine metabolism by cell-type specific mechanisms, either by inhibiting 
expression of mitochondrial SIRT4, or relieving repression of glutamate 
dehydrogenase (GLUD) 85. Glutamine input associates to overall support of 
amino acid pools of the cell under stress response. GCN2 or aminoacid-sensing 
kinases (encoded by EFF2AK4) are activated during amino acid deprivation or 
amino acid starvation conditions 83,86. Glutamine deprivation leads to uncharged 
tRNAs, or to a depletion of downstream products such as asparagine. GCN2 can 
be bound and activated by uncharged tRNAs, subsequently phosphorylates 
EIF2a and enhances ATF4 and ATF5 expression 83,87,88. Moreover, oncogenic 
insults such as MYC was found to upregulate glutamine transporters and induced 
the expression of kidney-type glutaminase (GLS) at both mRNA and protein 
levels 83,85.  
The Asparagine synthetase (ASNS) is an enzyme catalyzes conversion of L-
aspartate and L-glutamine into L-asparagine and L-glutamate. It is an ATP 
dependent conversion reaction (Figure 9) 80,87. L-asparaginase was synthesized 
by Escherichia coli at constant rates under anaerobic conditions 89. Bacteria L-
Asparaginase (L-Asp) has been approved from FDA and applied for ALL cells 
treatment. ALL cells express very low level of asparagine synthetase enzyme 90. 
Up-regulation of ASNS expression can be caused by the activation of GCN2-
EIF2a-ATF4 signaling pathway. Increased of ASNS might be one of metabolic 
response coordinating solid tumor adaptation to nutrient deprivation and/or 
hypoxia 87. However, the high-glutaminase activity of l-asparaginase from 
Acinetobacter glutaminasificans showed non-specificity towards cancer cells 
81,89. Depletion of glutamine largely increases toxicity that is greater than its 
anticancer activity resulting in a low therapeutic index of L-Asparaginase. 
Moreover, leukemic cells have found to become resistant to the treatment 91.  
L-Asparaginase therapy is often limited by toxic side effects 80. Therefore, 
another L-Asparaginase from Erwinia chrysanthemi (ErA) was engineered with 
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the design of mutants diminished the ability to hydrolyze L-glutamine and in order 
to reduce the glutaminase activity, which is holding promise as a novel L-
Asparaginase with fewer side effects for hematopoietic cancer therapy 81. 
 
Figure 9 The biosynthetic reaction catalyzed by ASNS  
The Asparagine synthetase (ASNS) is an enzyme catalyzes the conversion of L-
aspartate and L-glutamine into L-asparagine and L-glutamate 80. 
Drug resistance 
Chemotherapy is the common approach to cancer treatment, however, drug 
resistance and the distant metastasis remain unresolved clinical problems 92.  
Many cases of drug resistance have been revealed in clinical observations such 
as patients with breast cancer developed resistance to adriamycin, doxorubicin 
and docetaxel 93,94, ibrutinib resistance in chronic lymphocytic leukemia (CLL) 95, 
Imatinib resistance in chronic myeloid leukemia (CML) 96, Bromodomain and 
extraterminal domain (BET) inhibitors are promising epigenetic drug for acute 
myeloid leukemia (AML) treatment, but the resistance to BET inhibitors in 
leukemia stem cells population becomes a major limitation of these drugs 97, 
PARP inhibitors resistance in breast cancer 98. In 2015, the drug-resistance 
profile in multiple-relapsed ALL was examined from 154 pediatric ALL samples 
demonstrating high incidence of patient becomes resistant to those common 
therapeutic agents. ALL were more drug resistant to dexamethasone (>1.5 
times), L-asparaginase (5 times), etoposide (2.6 times), vincristine (3.1 times) e.g 
99. The resistance to a standard chemotherapy of T-ALL, L-asparaginase has 
been found to link to ASNS expression which can be silenced through 
methylation 100. 
 
Asparaginase
synthetase
(ASNS)
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Although extensive studies for understating drug resistance and the mechanism 
of chemoresistance have been carried out but many questions remain 
undiscovered. Due to aforementioned NAD metabolism, NAMPT expression 
correlates with cancer malignancy. NAD+ dependent network governed self-
renewal and radiation resistance in glioblastoma through NAMPT-E2F2-
differentiation axis 101. However, the link between tumor metabolism and drug 
resistance in particular to a NAMPT inhibitor (FK866) has not been intensively 
investigated yet. Therefore, the aim of thesis was to elucidate the molecular 
mechanism of pharmacoresistance to a NAMPT inhibitor (FK866) and metabolic 
alteration associated drug resistance as well as identify therapeutic targets that 
could contribute to overcome the cancer resistance or improve the therapeutic 
outcome in T-lymphoblastic and breast cancer cells. Targeting lactate 
dehydrogenase has been widely interested for cancer therapy. High level of LDH 
is correlated with poor prognosis in many cancers 102,103 and caused of drug 
resistance in breast cancer 104. Lactate dehydrogenase (LDH) is composed of 
two major subunits, LDHA (muscle, M) and LDHB (heart, H). LDH is a tetrameric 
enzyme that are encoded by two separate genes, LDHA and LDHB, respectively 
105 (Figure 10A). This enzyme function as a catalytic enzyme to convert pyruvate 
into lactate coupled with an oxidation of NADH to NAD+ 106. Under hypoxic 
condition, HIF-1 was found to activate LDH and coordinately increased the 
conversion pyruvate to lactate 23. Human LDHA or hLDH5 is highly expressed in 
many cancer cells as the result of hypoxic condition as well as mutation of 
mitochondria genes 107. LDHA not only accelerates cancer cell proliferation by 
regulating ATP production, but also plays a role in NAD+ regeneration driven 
glycolysis 23. An increased expression of forkhead box protein 1 (FOXM1) 
upregulated hLDHA expression coordinately with increased LDH activity, lactate 
production, and glucose utilization in pancreatic cancer 108. As illustrated in 
Figure 10B, in normal cells, glucose is metabolized into pyruvate then enters to 
TCA by acetyl Co-A under normoxia. While under hypoxic condition, OXPHOS 
remains inactive and LDH catalyzes the conversion of pyruvate together with 
oxidation of NADH to NAD+ to produce lactate 107. Tumor cells have developed 
the ability to function in more acidic microenvironment than normal cells, thus 
elevated levels of hLDH5  causes higher lactate production, which also triggers 
an increase in extracellular acidosis, resulting in a low pH allowing tumor invasion 
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and metastasis (Figure 10B) 107,109. On the other hand, the silencing of hLDHA 
expression by shRNA displayed a reduction in the ability of tumors to proliferate 
under hypoxic conditions, markedly delayed tumor formation and stimulated 
mitochondrial respiration 23,103. A few selective hLDHA inhibitors have been 
developed, GSK2837808A (GSK) recently showed potent NADH-competitive to 
hLDH5 exhibiting inhibitory activity in the nanomolar range in hepatocarcinoma 
cells 110,111. MicroRNAs (miRNAs) can play as oncogenes or tumor suppressors, 
accordingly to the differential expression in diverse cancers. Recently, miR-383 
has been reported to regulate LDHA expression in which the direct binding of 
miR-383 to its 3'-untranslated region (3'UTR) suppressed LDHA mRNA 
expression affecting glycolysis in ovarian cancer cells 112. As well as, miR-34a, 
miR-34c, miR-369-3p, miR-374a, and miR-4524a/b were reported as target 
LDHA regulating glycolysis in colorectal cancer cells 113. Thus, targeting LDH 
may progressively support the development of new strategies to treat metabolic 
cancers. 
	
Figure 10 Schematic representation of LDH	
A. LDH isoforms in human, B metabolic pathway in normal and cancer cells 107. 
Oxidative phosphorylation  
Multiple step flow of electrons through mitochondrial respiratory chain has been 
known as oxidative phosphorylation (OXPHOS). As illustrated in Figure 11, 
OXPHOS comprises five multisubunit protein complexes (I-V) and two electron 
carriers localized on the inner mitochondrial membrane which are Coenzyme Q 
and cytochrome c 114. Critical complexes of electrontransport chain and other 
protein subunits have been documented and known by their enzymatic reactions 
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including complex I (NADH-ubiquinone oxidoreductase), complex II (succinate-
ubiquinone oxidoreductase), ubiquinone (CoQ), ubisemiquinone (CoQH), 
ubiquinol (CoQH2), complex III (ubiquinol-cytochrome c oxidase reductase), 
complex IV (cytochrome c oxidase or COX), and inorganic phosphate (Pi) 114. 
Coordinated transport of electrons and protons resulted in the production of ATP 
has been considered as the main function of this system. Intermediary 
metabolism of protein, carbohydrate, and fat are used to generate NADH and 
FADH2 and then continuously donate electrons to complex I and complex II, 
respectively. Electrons pass sequentially to ubiquinone in order to form 
ubisemiquinone and ubiquinol. Transferred electrons to complex III and 
cytochrome c and then move to complex IV. A molecule of water can be 
generated by the donation of an electron to oxygen during this process. Energy 
transformation is liberated by the flow of electrons which is used by complexes I, 
III and IV for protons pump. Moreover, complex V plays a role in regulation of 
proton gradient to generate the mitochondrial membrane potential for ATP 
synthesis. ATP can be produced from cytosolic ADP and Pi 18,114.  
Glycolytic enzymes 
Aerobic glycolysis is one of the well-defined metabolic phenotype of cancer via 
transcriptional upregulation of glycolytic enzymes 10. As illustrated in Figure 12, 
glucose is converted to fructose-1,6-bisphosphate by two molecules of ATP and 
then sequential reactions of glucose is catalysed by specific enzymes in each 
step including hexokinase (HK), phosphoglucose isomerase (PGI), and 
phosphofructokinase (PFK) in the first phase of glycolysis. Apart from LDH, HK2 
also plays a role in the regulation of the mitochondria-initiated apoptotic events 
inducing cell death 32. HK2 is directly regulated by HIF and considered as a HIF-
1 target gene product 115. Increased expression of HK2 contributing to an 
elevated glycolysis was observed in most of immortalized and malignant cells26. 
Moreover, activity of mitochondrial hexokinase somehow regulates and is 
required for the growth factor-induced cell survival 3,116. Transactivation of HK2 
by the cooperation of HIF-1 with c-Myc is occurred under hypoxia condition 115.  
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Figure 11 OXPHOS system in mammalian mitochondria 114. 
Phosphofructokinase-1 (PFK1) is a catalyses enzyme in the committed steps of 
the glycolytic pathway by converting fructose-6-phosphate to fructose-1,6-
bisphosphate, using ATP as the energy source 12. PFKFB enzyme can be 
activated through phosphorylation at serine 462 of AMPK during hypoxia 117. 
Moreover, inhibition of PFK by lactate reveals an important mechanism of the 
feedback inhibition in glycolysis 118. Pyruvate kinase (PK) is a key enzyme in final 
step of glycolysis which it catalyzes the irreversible phosphoryl group and 
transfers from PEP to adenosine ADP, yielding pyruvate and ATP 12. PKM2 is 
predominantly expressed in tumor cells and it has been used as a marker of 
intestinal inflammation 119. Nuclear translocation of PKM2 leads the cooperation 
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with HIF-1 and concurrently triggers transactivated genes and further enhances 
glycolysis 120. Tumors frequently appear to enhance glycolysis and suppressed 
OXPHOS 6. Therefore, evaluation of glycolytic enzyme activity and OXPHOS 
function are important for understanding metabolic reprogramming in the cancer 
drug resistance in particular to FK866 resistance.	
	
 
Figure 12 Glycolysis and TCA cycle in tumors 
Glycolysis breaks down glucose into pyruvate, which is then converted to lactate. 
Pyruvate fuels either the production of lactate or it can be used to replenish the TCA 
cycle 13,121.	
Signal transduction in cancers 
Signaling transduction is responsible to maintain cell growth advantage in cancer 
as well as drug-resistant cancer. Canonical oncogenic signaling pathways, such 
as phosphatidylinositol 3−kinase (PI3K)-AKT/Protein Kinase B (PKB) and 
mammalian target of rapamycin (mTOR), these two signaling pathways have 
been consider as major players which directly regulate the core carbon 
metabolism resulting in the larger nutrient uptake supporting cell proliferation 122. 
PI3K has also profound effects on tumor metabolism by providing strong growth 
and survival signal for cancer 123. Therefore, we investigated the relevance of 
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drug resistance to MTOR/AMPK pathway activation and protein translation 
control. 
MTOR 
Signal transduction in mammalian cancers frequently involves the association or 
constitutive activation of receptor tyrosine kinases (RTKs) which are 
serine/threonine kinase including phosphatidylinositol 3-kinase (PI3K)/AKT 
kinase cascade 124,125, the protein kinase C (PKC) family 126, and the mitogen-
activated protein kinase (MAPK)/Ras signaling cascades 127. mTOR has been 
known as FRAP, RAFT1, and RAP1. mTOR is a Ser/Thr kinase that functions as 
a master switch between anabolic and catabolic metabolism in cancer 124. It plays 
roles in the regulation of cell proliferation, metabolism and also apoptotic cells 
death, which is mainly dictated by cellular context and downstream targets 
including p53, B-cell lymphoma (BCL2), BCL2-antagonist of cell death (BAD), 
and c-MYC 128.  
mTOR comprises two biochemically and functionally distinct complexes which 
are mTORC1 and mTORC2 124. As illustrated in Figure 13, mTORC1 includes 
regulatory-associated protein of mTOR or Raptor. Raptor acts as a scaffold 
protein to recruit downstream substrates of mTOR, which are eukaryotic 
translation initiation factor 4e-binding protein 1 (4EBP1) and ribosomal S6 kinase 
(S6K1). 4EBP1 and S6K1 are generally attributed to mTORC1-dependent 
protein translation control 5,124. mTORC1 displays as a complex of mTOR, 
Raptor, PRAS40, mLST8 and Deptor while mTORC2 complex contains Rictor, 
mSIN1, mLST8 and Protor1. mLST8 binds to the mTOR kinase domain in both 
complexes, where mLST8 seems to be important for the complex assembly. 
Deptor acts as an inhibitor of both complexes mTOR1 and mTOR2 [57]. 
Dependent-phosphorylation at T2446/S2448 of mTOR is mediated by PI3K/Akt 
125. In addition, CyclinD1, HIF1a, and MYC, which in turn promoted cell cycle 
progression, cell growth and angiogenesis are controlled by mTORC1 5. In 
contrast, mTORC2 contains the rapamycin-insensitive companion of mTOR or 
Rictor subunit but Rictor is neither sensitive to nutrients nor inhibition of 
rapamycin 5,124. mTOR2 has been documented to participate in cell survival and 
actin cytoskeleton rearrangements 125. 
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Figure 13 Composition of mTORC1 and mTORC2 [57]. 
The PI3K/AKT/mTOR signaling pathway 
Regulation of the PI3K/AKT/mTOR pathway can be resulted from both 
exogenous or endogenous activation such as an exogenous activation by Ras 
which has been reported in a broad variety of solid tumors 129. On the other hand, 
endogenous activation of PI3K/AKT/mTOR pathway could be triggered from 
either PTEN loss function or gene mutation/amplification 7. Activation of various 
receptor tyrosine kinase (RTK) leads to auto-phosphorylation of intracellular 
component of these receptors. In particular, phosphorylation of PI3K subunits 
(p85 is a regulatory subunit and p110 is a catalytic subunit) by RTK can induce 
the allosteric activation of PI3K (Figure 14). Moreover, PI3K can also be 
indirectly activated by Ras 7. Activation by Ras is mostly restricted to 
gastrointestinal malignancies whereas RTK activation has been widely reported 
in hematological and also solid tumors 7,130. Reduction or loss of PTEN 
expression incidentally triggers PI3K signaling, thereby coordinating to 
oncogenesis in some human cancer 124,131. Thus, PTEN has also been identified 
as a negative regulator of PI3K signaling contributing to the regulation of cell 
growth, proliferation, metabolism and also the survival of cancer 131. Akt-
mediated phosphorylation of TSC2 on S939/S981 directly inhibits the 
TSC1/TSC2 complex, thereby relieving inhibition of Rheb and activating 
mTORC1 125. TSC2 regulates mTOR1 by acts as a central receiver of inputs to 
stimulate mTOR1. Thus it was evident that cells which lack of TSC2 function still 
profound mTOR suppression due to the following AMPK activation 132.  
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Figure 14 PI3K/AKT/mTOR Signaling pathways 
Dysregulation of the PI3K/AKT/mTOR pathway can result from exogenous or 
endogenous activation. MTOR is activated by Rheb, resulting in modulation of protein 
synthesis by phosphorylating S6K1 and 4EBP1. Phosphorylation of 4EBP1 by MTOR 
signaling resulting in dissociation of MTOR from eIF4E 7,130. 
Regulation of AMPK 
AMPK has been well-defined as a central metabolic sensor in mammalian cells 
and it plays roles in regulation of many cellular energy supplies including lipid, 
cholesterol, and glucose metabolism 133. An essential role of AMPK in balancing 
glycolysis and mitochondrial metabolism has been reported in T-ALL cells134. 
Mechanistically, AMPK is directly phosphorylated on T172 by LKB1 leading to 
activation of AMPK. LKB1-AMPK signaling pathway has a dominant role in 
regulation of glucose metabolism especially in metabolic tissues such as muscle, 
liver, and adipose tissues 5,135. AMPK composes of hetero-trimer subunits which 
are a catalytic subunit (AMPKα) and two regulatory subunits (AMKPβ and 
AMPKγ). Hypoxia induction and nutrient deprivation are two important factors 
that activate AMPK thereby impact to intracellular ATP and AMP levels. A decline 
of ATP level concomitants an increase in intracellular AMP in AMPK activated 
cells 135. mTOR is controlled by LKB1-AMPK activation 130,136. AMPK can also be 
activated by two known AMPK activators which are CaMKK and TAK1. AMPK 
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activates mTOR by phosphorylation of raptor on S722/792. Activation of AMPK 
by energy stress further phosphorylates Raptor and induces the binding of raptor 
to 14-3-3 subsequently inhibits of mTORC1 activity 125,136. In addition, inhibition 
of mTORC1 can be mediated by both AMPK and the signaling from GSK3β. The 
phosphorylation of TSC1/2 complex further exerts the positive regulation of TSC2 
towards Rheb, thereby abrogates its simulative activity towards mTORC1 
pathway (Figure 15) 125. AMPK associates with inhibition of fatty acid and 
cholesterol synthesis by phosphorylating certain metabolic enzymes such as 
acetyl-CoA carboxylase 1 (ACC1) and HMg-CoA reductase (HMgCR) 133. 
Nevertheless, AMPK has been found to regulate glycolysis though the 
modulation of phosphorylated PFK2 at Ser466 leads to an increases the levels 
of Fru-2,6-P2 thereby enhancing glycolytic flux 137. Hypoxia directly activates 
AMPK which further inhibits mTORC1 in two ways by through Raptor inhibition 
and direct negative phosphorylation of TSC2 125. 
 
 
Figure 15 LKB1-AMPK signaling pathway 
Schematic representation of the Liver Kinase B1(LKB1) dependent regulation of growth. 
Metabolism and mitochondrial homeostasis are regulated through AMPK and mTOR 
signaling pathways. Activation of LKB1/AMPK/mTOR pathway can be induced by 
energy stress 125. 
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Protein translation control 
Control of mRNA translation plays an important role in several cellular processes 
including cell growth, proliferation, and differentiation138,139. Signaling by the 
PI3K/AKT/mTOR pathway mediates mRNA translation through modulation of 
S6K1 and 4EBP1 which are two distinct downstream signaling pathways (Figure 
13 and 14) 5,135. S6K1 and 4EBP1 control specific subsets of mRNA translation. 
4EBP1 is a small protein which inhibits the initiation of protein translation by 
associating with eIF4E which is one of mRNA cap-binding subunit of eIF4F 
complex as illustrated in Figure 16. A review by Mamane et al., has been well 
summarized the interaction of mTOR with translation proteins 5. Under growth 
factor-deprivation such as lack of nutrients and hormone, unphosphorylated 
4EBP1 binds tightly to eIF4E leading to inhibition the initiation of protein 
translation in normal cells. While in the presence of stimuli from several factors 
such as nutrients, hormones, growth factors, mitogens, cytokines and G-protein-
coupled agonists response, induce the dissociation of eIF4E from mTOR 
complex (Figure 16) 5. There are a number of protein subunits involved in cap 
translation such as eIF3, eIF4A (an ATP-dependent RNA helicase), eIF4B, 
eIF4E, and eIF4G (a large scaffolding protein). However, phosphorylation and 
activation of S6K1 further phosphorylates eIF4B at S422 then promotes its 
association with eIF3 7. Phosphorylation of 4EBP1 occurs at multiple sites and 
proceeds in a hierarchical manner (first at Thr37 and Thr46, then Thr70 and last 
at Ser65) 140. In generally, under growth factor induction free eIF4E from the 
dissociation of mTOR can bind eIF4G, eIF4A, and eIF4B to form the multi-subunit 
of eIF4F complex. This complex facilitates cap-dependent protein translation 138–
140 and induces translation of 5′-UTR (the 5′-untranslated terminal regions) 136. 
On the other hand, treatment with rapamycin (a potent mTOR inhibitor) has been 
found to impact many events such as dephosphorylation of 4EBP1, increases in 
eIF4E binding, no forming of eIF4F multi-subunit complex and concomitant with 
impairment of 5′−UTRs translation initiation which is crucial for cell cycle 
transition from G1-to-S phase 7,138,139.  
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Figure 16 Activation of translation initiation by mTOR 
Regulation of Cap-Dependent Translation Initiation by 4EBP1. In general, mTOR 
phosphorylates 4EBPs and S6Ks which are two downstream targets of mTOR pathway. 
In condition with no extracellular stimuli, S6K1 associates with eIF3, and 4EBP1 
associates with eIF4E. Growth factors, nutrients as well as insulin signaling, recruit the 
mTOR complex in order to phosphorylate S6K1 and 4EBP1. Phosphorylated 4EBP1 by 
mTOR results in dissociation of 4EBP1 from eIF4E and dissociation S6K1 from eIF3. 
S6K1 further phosphorylates eIF4B at S422 contributing to the association of eIF4B with 
eIF3 subunit. These multiple interactions enhance cap-dependent translation 5. 
CHOP activation 
Endoplasmic reticulum (ER) stress has a profound impact to unfolded and 
malfolded client proteins leading to cell death in pathophysiological conditions 
141. Cell frequently adapt to ER stress by activating an integrated signal 
transduction pathway called the unfolded protein response (UPR) 142. UPR is 
generally involved by 3 signaling pathways emanating from ER including IRE 
(inositol-requiring protein 1), PERK (PKR-like ER kinase), and ATF6 (activating 
transcription factor 6). All of them are integral ER membrane proteins 141,142. The 
C/EBP homologous protein or CHOP is a transcription factor that is induced by 
ER stress. Phosphorylates EIF2a by PERK decreases EIF2a activity 
paradoxically activates ATF4 mRNA expression (Figure 17) 86. GADD34 or 
CHOP is a direct target gene of ATF4. Phosphorylation of EIF2a by general 
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control non-depressible 2 (GCN2) inhibits global protein synthesis and blocks 
cap-dependent translation 87. It has been reported that multiple basic-region 
leucine zipper (bZIP) transcriptional regulators, including ATF4, ATF3, and ATF2, 
work in concert to mediate activation of CHOP expression during nutrient 
limitation. But there are different mechanisms of CHOP regulation during amino 
acid starvation and ER stress 86,141. Briefly, in response to ER stress, EIF2a is 
phosphorylated by PERK and induces ATF4 expression whereas during nutrient 
limitation or amino acid deprivation, the uncharged tRNA binds to GCN2 and 
activates GCN2. Activation of GCN2 kinase sequentially induces expression of 
ATF4, ATF3 and CHOP 86,87,141. In addition, ER stress activates IRE1 by 
dissociation of IRE1 from BiP then the activated IRE1 further induces splicing of 
XBP1 which is a transcription factor regulated downstream target genes such as 
ER chaperones 143.  
 
Figure 17 Mammalian UPR and CHOP activation pathways 
The UPR encompasses signaling pathways which is triggered by the activation of ER 
stress transducers including IRE1, ATF6, and PERK. These transcription factors mainly 
upregulate the adaptive UPR pathway and normalize ER function via the ATF6, PERK–
EIF2α–ATF4 or IRE1–XBP1 pathways. The adaptive UPR pathway fails to rescue the 
cells, and the apoptotic UPR pathway under long term stress condition 141.	
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MATERIAL AND METHODS 
Chemicals and Reagents 
Cell culture media were obtained from Invitrogen (Carlsbad, CA). Fetal bovine 
serum (FBS), L-glutamine, and penicillin-streptomycin were obtained from 
Lonza. All other chemicals and reagents used in this study were purchased from 
the following sources: FK866 (sc-205325;santa cruz), CHS-828 (200484-11-3) 
from Cayman chemical, JPH203 (a LAT-1 inhibitor) and L-asparaginase were 
kindly gifted from Dr. Jean-Francois Peyron 144, 2-Deoxyglucose (D3875;sigma), 
Oligomycin A (S1478;Selleckchem), MTT assay (M5655;Sigma), Ozblue cell 
viability kit (OZbiosciences), NAD/NADH Assay (G9071;Promega), Cell-tite Glo 
(G7570;promega), and GSK2837808A (GSK;Trocris). 
Cell culture and development of NAMPT resistant cell models 
Human T-cell acute lymphoblastic leukemia (CCRF-CEM) cells were purchased 
from the Interlab Cell line Collection bank (ICLC HTL01002) and human breast 
adenocarcinomar (MDA-MB231) cells were obtained from our in-house tissue 
culture cell bank (original source was ATCC). CCRF-CEM were grown in RPMI 
1640 supplemented with 10% FBS, 2mM L-glutamine, and 100 U/ml penicillin-
streptomycin. MDA-MB231 cells were grown in DMEM supplemented with 10% 
FBS, 2mM L-glutamine, and 100 U/ml penicillin-streptomycin. All lines were 
cultured at 37°C in a humidified atmosphere of 5%CO2. NAMPT resistant CCRF-
CEM and MDA-MB231 models were gradually developed by increasing the 
concentration of FK866 up to 500nM of FK866. Cell viability was determined by 
exclusion of 0.2% trypan blue and MTT assay (Sigma). The FK866 resistant 
sublines were always maintained as static suspension in RPMI 1640 medium or 
DMEM medium supplemented with 10%FBS, 2mM L-glutamine, 100 U/ml 
penicillin-streptomycin and with 100nM FK866. A final concentration of the 
resistance subline selected for all experiments was a 100nM FK866 Resistant 
sublines.  
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Transfection, plasmids and siRNA 
Transient transfection, pcDNA-PBP and NAMPT1 plasmids were kindly provided 
from Dr. Alessio Nencioni (Genova). Plasmids were transiently overexpressed in 
MDA MB231 cells using lipofectamin 3000 (Thermoscientific). LDHA siRNA 
(sc43893) and control siRNA-A (sc37007) were purchased from santacruz. Down 
regulation of LDHA, siRNAs targeting human LDHA were transfected via 
interferin transfection reagent (Polyplus) to transiently knock-down the LDHA 
expression in MDA PA and MDA RES cells which were detected by 
immunoblotting against LDH antibody. 
In vitro cell viability and drug combination assays 
Cell viability was measured by the colorimetric methyl-thiazolyltetrazolum (MTT) 
assay (sigma), XTT proliferation kit (sigma), Ozblue cell viability kit 
(OZbiosciences) and cytotoxicity assay based on LDH levels. Release of LDH 
from damaged cells is measured by suppling lactate using LDH kit (Pierce LDH 
cytotoxicity Assay; PG202275), NAD+ and iodonitro tetrazolium violet (INT) a 
tetrazolium salt as substrates. A red formazan product is proportional to the 
number of lysed cells which indicates dead cells. Dose response was calculated, 
plotted as a non-linear regression curve and EC50 values determined using 
Prism 5 (GraphPad software Inc). Percentage of cell inhibition was subjected for 
drug combination analysis as described as Combination index (CI) according to 
the Chou-Tala-lay 145. Measure of synergism is given as CI where CI<1, CI=1, 
and CI>1 indicate drug synergism, additivity, and antagonism, respectively.  
Flow cytometric cell cycle analysis 
CEM cells were treated with Mock, GSK 10µM and GSK 20µM. Forty-eight hours 
after treatment they were resuspended in 1500 ml and lyzed with 0.5% Triton X 
for 15 min. Thereafter, they were then incubated with the DNA-staining chemical 
propidium iodide (PI) (FITC/Annnexin V Apoptosis detection kit; BD Pharmingen) 
for DNA content-based assessment of cell-cycle distribution for 10 min. Cell cycle 
analysis was performed using flow cytometric. Cell starvation was prepared in 
medium without FBS for overnight and treatment with 100ng/ml Nocoldazole for 
24h were used as positive controls. Percentage of G1 phase, S phase, and G2 
phase were analyzed using FACS.  
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Determination of NAD+-NADH and ATP levels 
Intracellular NAD+-NADH levels were determined by luciferin-luciferase-based 
assay. Cells were treated with FK866 for 48h or other indicated treatments, 
harvested. Aliquots containing equal number of cells were processed using the 
NAD/NADH Assay (G9071;Promega) following the standard protocol. 
Intracellular ATP level was assessed using Cell titer-Glo Luminescent readout 
(G755A;Promega). NAD+-NADH and ATP values were measured by multilabel 
plate reader (Tecan infinite M200) and normalized to total amount of protein of 
cell lysates (Bradford Reagent, Sigma).  
Immunoblotting Analysis 
Cells were treated with FK866 or indicated treatments for 48h and at the end of 
the treatment periods, cells were harvested, lysed in RIPA buffer. Equal amount 
of cell extracts (20 µg of total proteins) were diluted in Laemmli sample solution 
(6X), resolved on SDS-PAGE gels, transferred to PVDF membranes and probed 
overnight at 4°C using the following primary antibodies including 4EBP1 (sc-
6936), p-4EBP1(Ser65/Thr70; sc-12884), EIF4E (sc-9976), p-EIF4E Ser209 (sc-
12885), MTOR (sc-8319), NAMPT(sc-130058), LDHA (sc-137243) from Santa 
Cruz; EIF2S1 (ab26197), p-EIF2S1 Ser51 (ab32157), and p-MTOR Ser 2448 
(ab1093) from Abcam; AMPKα (2603), p-AMPKα Thr 172 (2531), and CHOP 
(2895) and anti-β-actin antibody (s3700) from Cell Signaling. Appropriated 
secondary antibodies (Santa cruz) were used to detect interested protein using 
a ECL select western blotting detection reagent (RPN2235; GE healthcare). 
Immunoblotting for β-actin was performed to verify equivalent amounts of loaded 
protein. Densitometric analysis of immunoreactive bands was analyzed using 
ImageJ software (NIH, USA). 
Amino acid depletion experiment 
The experiment was performed in amino acid depletion mixture composing 
Eagle’s Balance salt solution, (E3024; Sigma) to normal 10% FBS in RPMI 
medium supplemented with 2mM L-glutamine (ratio 80:20). CEM Cells were 
treated with indicated treatments for 24h, lysed in RIPA lysis buffer and then 
equal amounts of proteins were separated by SDS–PAGE. Immunoblotting 
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against CHOP expression was detected and anti-β-actin antibody was used as a 
protein loading control. 
Enzymatic activities, oxygen consumption, and ATP concentration 
CCRF-CEM and MDA MB231 cells were incubated (or not) with FK866 for 48h. 
Cells were homogenized as described in 146. The supernatants were immediately 
used for the assays of enzymatic activities. The simultaneous measurement of 
the enzymatic activities was performed by using the coupled fluorometric assay. 
The enzymes’ activity of NAD biosynthesis pathway was referred to the protein 
concentration determined 146. (This experiment was conducted in collaboration 
with Prof. Nadia Raffaelli (University of Politecnica Delle Marche, Ancora, Italy).  
Oxygen consumption was measured at 25°C in a closed chamber (1.7 ml 
capacity) using a thermostatically controlled oxygraph apparatus equipped with 
amperometric electrode (Microrespiration, Unisense A/S, Århus, Denmark) as 
previously described 147. ATP concentration was measured in a luminometer 
(Lumi-Scint, Bioscan) by the luciferin/luciferase chemiluminescent method as 
previously described 147. In both cases, 5 mM pyruvate +2,5 mM malate or 20 mM 
succinate were used as respiring substrates to assess the activity of the pathway 
formed by Complexes I, III and IV and the pathway composed by Complex II, III 
and IV, respectively. (This experiment was conducted in collaboration with Dr. 
Silvia Ravera, Istituto Giannina Gaslini, Genova, Italy). 
Mitochondria ATP measurement 
CCRF-CEM parental and CCRF-CEM FK866 resistant subclones were directly 
treated with control (PBS), oligomycin A (10 µg/ml; Sigma), sodium iodoacetate 
(100 µM; Sigma) or both. Following a 1-hour incubation at 37°C, 25 µL of 
luciferine (150 µg/ml, Promega) was added to each well for a final volume of 125 
µL. Plates were then analyzed (1sec measurement/well) for luminescence with a 
Berthold Technologies Luminoscan (in our model, emitted light start to decrease 
after 1min). By comparing the different conditions, percentages of glycolytic and 
mitochondrial ATP produced by CCRF-CEM-luc cells were determined as 
described in 148. (This experiment was conducted in collaboration with Dr. Jean-
Francois Peyron, Ruxandra Moschoi and Johanna Chiche, U1065/C3M, Nice, 
France) 
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Quantitative Real-time PCR 
Total RNA was extracted using RNA extraction kit and contaminant DNA was 
removed by RNase-Free DNase kit (ZYMO research). cDNA synthesis was 
carried out with RevertAid RT kit (K1622;Themoscientific). Quantitative real-time 
PCR analyses were performed with triplicate using KAPA SYBR FAST Universal 
qPCR Kit on a CFX96-Real time PCR Detection system (BioRad). Primers’s 
sequences are provided in Appendix Table 3 and expression level are analyzed 
relative to 18S or GAPDH as housekeeping genes. 
Data management and statistical analysis 
Data analysis was performed using Microsoft excel 2016 and plotted by 
GraphPad Prism 6 (Graphpad software Inc., San Diego, CA). Data are 
represented as the Mean with SD or SEM. Statistical analysis was performed by 
one-way analysis of variance (ANOVA) with Bonferroni’s corrected t-test for post-
hoc pair wise comparison and Student’s t-test. ***p<0.001, **p<0.01, and *p<0.05 
were considered statistically significant. 
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RESULTS 
In 2015, our group published a research article “EIF2a-dependent translational 
arrest protects leukemia cells from the energetic stress induced by NAMPT 
inhibition” in BMC Cancer Journal 71. This publication reflects my personal 
contribution to the work, and provides background for my thesis study regarding 
to pharmacological effect of NAMPT inhibitor (FK866) in leukemia.  
In this article, we showed that FK866 induces a translational arrest in leukemia 
cells through inhibition of MTOR/4EBP1 signaling and of the initiation factors 
EIF4E and EIF2a. Specifically, treatment with FK866 is shown to induce AMPK 
activation, together with EIF2a phosphorylation, is responsible for the inhibition 
of protein synthesis. Notably, such an effect was also observed in patients’ 
derived primary leukemia cells including T-cell Acute Lymphoblastic Leukemia. 
We concluded that tumors exhibiting an impaired LBK1-AMPK-EIF2a response 
may be especially susceptible to NAMPT inhibitors in particular in leukemia 71.  
A hard copy of this article is enclosed in appendix (page 128). In this work we 
provided new insights into the molecular mechanism of NAMPT inhibition in 
leukemia cells. However, the mechanism of FK866 resistance in cancer has not 
been widely investigated. We aimed to investigate how cancer cells can escape 
from FK866 toxic insult. All presented results in this thesis body are unpublished 
data. For clarify, I myself performed and have been involved in all experiments 
except enzymatic activity assay which I was involved in sample preparation, 
thereby biochemical analysis was kindly conducted by the collaboration of Dr. 
Silvia Ravera (Istituto Giannina Gaslini, Genova, Italy) and Prof. Nadia Raffaelli 
(University of Politecnica Delle Marche, Ancora, Italy).  
Emergence of drug resistance in cancer cells is a major impediment of 
chemotherapy and metabolic alteration has been frequently perceived in cancer 
cells of various tissues. Thus, the aim of my thesis was to investigate the 
molecular mechanism of pharmacoresistance to FK866 and metabolic 
alterations associated with drug resistance in cancer cell lines. 
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Development of NAMPT inhibitor (FK866) resistant models 
FK866 CCRF-CEM resistant cells were developed in our laboratory to investigate 
the molecular mechanism beneath the insurgence of pharmacoresistance to the 
NAMPT inhibitor. In-house CCRF-CEM parental cells (CEM PA) were gradually 
exposed into an initial dose of 0.1nM FK866 and cultured those surviving 
daughter cells with increasing doses until they acquired resistant to final 
concentration of 500nM FK866 as described in Chara Zucal’s thesis 149. We 
generated three populations of FK866 resistant cells which were resistant to 
FK866 at 10, 40 and 100nM, respectively. Cell viability test was performed in all 
FK866 resistant CCRF-CEM (CEM RES) along with FK866 administration for 48 
and 72h. Unlikeness of FK866 resistant subclones (CEM RES 10, 40 and 100) 
were discriminated by differential resistance to FK866, while CEM RES 100 cells 
showed fully drug resistance (Figure 18A and B). Afterward, CEM RES 100nM 
subclone (referred as CEM RES in my thesis) was selected as a model for this 
study. CEM RES cells eventually gained the ability to proliferate during drug 
exposure for 4 days of treatment with 500nM FK866 (Figure 18C) 149. CHS-828 
or GMX1778 is an another known NAMPT inhibitor was tested in CEM cells. 
Potential anti-proliferative effects of CHS-828 was observed only in CEM parental 
cells (CEM PA) while CEM RES cells were not sensitive to the drug (Figure 18D) 
assuming that we accomplished generating a NAMPT-dependent CEM resistant 
model.  
Characterization of NAMPT-dependent CEM resistant model 
To address the pharmacological effect of FK866, NAD and ATP levels in CEM 
cells were measured. Cells were treated with 5nM FK866 for 48h. As shown in 
Figure 19A and 19B, FK866 significantly decreased both NAD and ATP levels 
in CEM PA (***p<0.001). Therefore, inhibition of NAMPT by FK866 significantly 
impacted NAD and ATP levels. In collaboration with Prof. Nadia Raffaelli 
(University of Politecnica Delle Marche, Ancona, Italy), we managed to evaluate 
enzymatic levels of NAMPT. NAMPT enzymatic activity was decreased in CEM 
RES cells in respect to CEM PA while FK866 treatment did not affect to NAMPT 
activity (Figure 19C). In parallel, we evaluated NAMPT mRNA levels in both CEM 
PA and CEM RES cells. A significant decrease in NAMPT mRNA level (**p<0.01) 
was observed in CEM RES cells in comparison with CEM PA cells whereas, there 
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was no alteration in NAMPT mRNA levels along with FK866 administration in 
both parental and resistance (Figure 19D). Development of drug resistance to 
NAMPT inhibitors commonly depends on gene mutation 150. However, we did not 
observe any mutations in NAMPT coding region neither in our CRM resistant nor 
CEM parental cells. 
 
 
Figure 18 Insensitivity of NAMPT-dependent CCRF-CEM resistant cell lines to 
FK866 
A and B, Effect of NAMPT inhibitor (FK866) in a panel of different CEM RES subclones 
including CEM RES resistance to FK866 at 10, 40, and 100nM indicated as CEM RES 
10, 40, and 100, respectively. Cells were treated with FK866 for 48h and 72h. C, Four-
day FK866 survival curve of CEM RES 100 cells are shown. D, Effect of a NAMPT 
inhibitor (CHS-828) on CEM PA and CEM RES cell lines. Cells were treated with CHS-
828 for 48h. Cell viability was conducted by MTT assay. Values are normalized to 
untreated cells (Mock). Mean with SD of three independent experiments with technical 
triplicates were plotted.  
C D
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Figure 19 FK866 significantly decreases NAD and ATP levels in CEM cells. 
A, Total NAD-NADH level was measured in CEM PA and CEM RES cells after 48h 
treatment with mock control (DMSO 0,01%) and 5nM FK866. B, Intracellular ATP levels 
were measured in CEM PA and CEM RES cells after 48h treatment with Mock, and 5nM 
FK866 for 48h. C, NAMPT enzymatic activity, Cells were treated with Mock and 5nM 
FK866 for 48h then NAMPT enzymatic level was measured. D, Quantitative RT-PCR 
targeting NAMPT was analyzed in CEM cells treated with mock and 5nM FK866 for 48h, 
18S expression was served as a housekeeping genes. Relative values are normalized 
to Mock. Data is represented as Mean with SD of three biological experiments with 
technical triplicates (***, p<0.001). 
 
Translation control was not inhibited during FK866 treatment in CEM RES 
cells 
Recently, our group demonstrated that FK866 induces a translational arrest in 
leukemia cells through inhibition of MTOR/4EBP1 signaling and of the initiation 
factors EIF4E and EIF2a. Specifically, treatment with FK866 is shown to induce 
AMPK activation, concomitant with EIF2a phosphorylation, is responsible for the 
inhibition of protein synthesis 71. We asked whether translation regulation still 
functions when cells become resistant to FK866. To address this point, both CEM 
PA and CEM RES cells were treated with FK866 for 48h, phosphorylation of 
AMPK, mTOR1, 4EBP1, and EIF2a were evaluated by western blot analysis. In 
A B
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CEM PA, phosphorylation of AMPK induced by FK866 was significantly 
increased subsequently inhibited mTOR/4EBP1 signaling, and increased the 
phosphorylation of EIF2a (Figure 20A). In contrast, the drug treatment did not 
activate AMPK and no alteration of protein translation mediated neither by 
phosphorylation of 4EBP1 nor phosphorylation of EIF2a were observed in the 
CEM RES cells reactivated by FK866 (Figure 20C). This supports the fact that 
these cells acquired detoxifying mechanism to pharmacological NAMPT 
inhibition.  
 
Figure 20 Signaling cascades controlling protein translation in CEM RES cells. 
A, CEM PA and CEM RES cells were treated with DMSO (Mock), and indicated 
concentrations of FK866 for 48h. C, CEM RES cells were treated with DMSO (Mock) 
and 5nM FK866 for 48h. Levels of p-AMPK (Thr-172), p-mTOR1 (Ser-2448), p-4EBP1 
(Ser-65 and Thr-70), and p-EIF2a (Ser-51) and β-actin were detected by immunoblotting 
and a representative blotting from 3 biological experiments is shown. B and D, 
Densitometric analysis was conducted by Image J software. Protein expression was 
normalized by β-actin and relative expression level was plotted by Mean with SEM from 
3 biological experiments (**p<0.001 compared to Mock).  
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Metabolic alteration in FK866 CEM RES 
Drug resistance in cancer cells is recognized as the primary cause of failure of 
chemotherapeutic treatment in most human cancers. Development of cell 
resistance may be accompanied by deregulation of cellular metabolism. Given 
the low level of NAD/NADH in resistant cells (Figure 18A) we reasoned that 
oxidative metabolism could be impaired. To investigate drug adaptation in the 
resistant cells and to establish a potential correlation between CEM resistance 
and metabolic reprogramming, in collaboration with Dr. Jean-Francois Peyron 
(INSERM, Nice, France) we obtained the ATP output as a percentage of 
mitochondrial ATP and glycolytic ATP. Higher ATP production rates from 
glycolysis was found in CEM RES which was approximately 70% whereas in 
CEM PA was about 50-55% (Figure 21A). We hypothesized that metabolic 
adaptation in the resistant cells relies on glycolysis rather than OXPHOS. To 
address this issue, sample of CEM PA and CEM RES cells in different degree of 
resistance including CEM RES at 10nM, 40nM and 100nM of FK866 were 
subjected for biochemical analysis evaluating some critical markers reflecting 
metabolic functions and enzymes involved in glycolysis. In collaboration with Dr. 
Silvia Ravera (Istituto Gaslini, Genova, Italy) we managed to analyze oxygen 
consumption rate, and level of ATP synthesis in CEM PA and RES cells. ATP 
synthesis by Fo-F1 ATP synthase and the oxygen consumption rate (OCR) were 
reduced in fully resistant cells at 100nM as shown in Figure 21B and 21C. Both 
pathways, made by complexes I, III and IV and complexes II, III and IV, were less 
functioning as shown by enzymatic activity evaluation in the presence of 
pyruvate/malate or succinate, respectively. Parental and resistant cells show a 
coupled OXPHOS as the P/O rate was within standard values. 
As aerobic glycolysis is important for survival and proliferation of cancer cells, we 
speculated that CEM RES cell metabolism relies more on glycolysis, and to 
address this metabolic rewiring we investigated markers reflecting glycolysis 
pathway including glucose consumption and lactate production. Indeed, the 
decrease of OXPHOS activity accompanied with an increase of glucose 
consumption and lactate production were clearly observed in fully resistant CEM 
RES cells to 100nM FK866 (Figure 22A and 22B). To confirm an enhanced 
glycolysis dependency, we further evaluated the activity of key glycolytic 
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enzymes including HK, PFK, PK, and LDH. All enzyme activities were 
significantly boosted in fully resistant cells (p<0.001), showing an enhancement 
in aerobic glycolysis in respect to parental cells (Figure 22C). These data 
suggested that the activation of aerobic glycolysis compensates the decrease of 
activity of the oxidative phosphorylation chain in the resistance. 
 
 
Figure 21 A decrease in mitochondria function in CEM RES cells 
A, Percentage of ATP generated by Mitochondria and glycolysis in CEM PA and CEM 
RES cells, Data are plotted as percentage of ATP generated by mitochondria and 
glycolysis from two biological experiments with technical triplicate. B, ATP synthesis in 
CEM PA and CEM RES cells. C, Oxygen consumption in CEM PA and CEM RES cells. 
Values are represented as Mean with SD. of three independent experiments with 
technical triplicates. (***, p<0.001). 
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Figure 22 CEM RES cells display an enhanced glycolysis dependency. 
CEM PA and CEM RES of 10nM, 40nM, and 100nM FK866 cells were subjected for the 
following analysis; A, glucose consumption, B, lactate production, and C, key glycolysis 
enzymatic activity including HK, PFK, PK, and LDH. The following parameters are 
determined as described in material and methods. Data is conducted and plotted as 
Mean with SD. from three biological experiments with technical triplicates (***p<0.001). 
 
Therefore, induced FK866 resistance enhances glycolysis flux in CEM RES cells. 
We next analyzed mRNA expression of key enzymes involved in glycolysis (HK2 
and LDHA) and several genes associated with mitochondria oxidative 
phosphorylation (ND1, ND2, ND3, ND3, NDL4, COX3, and ATP8). A key 
glycolysis’ enzyme, LDHA mRNA expression was slightly increased in the CEM 
RES in respect to CEM PA whereas HK2 remained stable (Figure 23A). 
Inversely, a dramatic decrease in the mRNA level of all candidate mitochondrial 
genes were significantly detected in CEM RES cells (Figure 23B) providing a 
strong support that the resistant cells required less mitochondria function for their 
metabolic reprogramming. Nonetheless, we further investigated if resistant cells 
become addicted to and rely on glycolysis. Supporting data were obtained from 
test of two well-known metabolic inhibitors including 2-deoxyglucose (2DG) and 
C
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oligomycin A, well characterized inhibitors of glucose metabolism and 
mitochondria ATP synthase, respectively. We observed that CEM RES cells were 
more sensitive to 2DG treatment than parental cells (Figure 24A) while no 
differential sensitivity was observed between CEM PA and CEM RES cells during 
oligomycin A administration (Figure 24B). At 48h of treatment, EC50 of 2DG in 
CEM RES was 0.92 µM (R2=0.967) whereas EC50 of 2DG in CEM PA was 2.11 
µM (R2=0.972). Therefore, the use of those inhibitors strongly distinguishes 
glucose addiction of CEM RES cells from CEM PA cells.  
Taken together, CEM RES model primarily relies on aerobic glycolysis, 
consistent with the features of Warburg phenotypes, which can be tracked by 
decreased mitochondrial ATP generation, enhanced glycolytic rate, increased 
glucose consumption and concomitant with increased in lactate output. 
 
Figure 23 Down-regulation of genes involved in mitochondria function in CEM 
RES cells 
A, Quantitative RT-PCR of CEM PA and CEM RES samples were performed to evaluate 
a panel of genes that encode glycolysis enzymes including HK2 and LDHA. B, genes 
involved in mitochondria function including ND1, ND2, ND3, ND3, NDL4, COX3, and 
ATP8 were analyzed. Level of 18S mRNA expression was used to normalized the gene 
expression. Data is represented as Mean with SD of three biological experiments with 
technical triplicates (**p<0.01). 
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Figure 24 CEM RES cells are more vulnerable to glucose deprivation. 
A, CEM RES cells are sensitive to glycolysis inhibitor (2-deoxyglucose). CEM PA and 
CEM RES cells were grown in the presence of various concentration of 2DG as indicated 
for 48h. B, An inhibitor of mitochondria ATP synthase has no impact on cell viability. 
CEM PA and CEM RES cells were treated with various concentration of oligomycin A 
for 48h. Cell viability was assessed by ozblue cell viability kit as describe in material and 
method. A representative viability curve from two independent experiments with 
technical triplicates is shown. Relative values of Mean with SD are normalized to 
untreated cells (Mock). 
Utilization of Tryptophan; an alternative pathway for NAD production in 
CEM RES  
As shown in Figure 19A, the reversion of NAD production in the resistant cells 
along with FK866 treatment was not caused by the mutations of the NAMPT 
enzyme, therefore cancer cells have developed different mechanism to acquire 
FK866 pharmacoresistance. Given the restoration of NAD levels, we 
hypothesized that other mechanisms of NAD production are actively working in 
CEM RES cells. An alternative pathway to produce NAD than the NAMPT-
dependent pathway, is through the “de novo” pathway starting from Tryptophan 
151. Tryptophan is transported within the cells by the L-type amino acid transporter 
1 (LAT1) and then metabolized to kynurenine and, through a number of reactions, 
to generate NAD 144. In particular quinolinic acid phosphoribosyltransferase 
(QPRT), QPRT is an enzyme in “de novo” NAD synthesis pathway. We next 
validated several enzymes involved in NAD synthesis pathway in CEM cells. To 
investigate whether CEM RES cells activate an alternative NAD biosynthesis 
disregarding of NAMPT-dependent pathway. NADS activity was increased in 
CEM RES in respect to CEM PA whereas NMN activity was shown to be 
decreased in CEM RES. FK866 inhibits NMN activity in dose dependent manner 
A B
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(Supplementary Figure 1). It was difficult to draw the correlation of all enzymatic 
activities in one direction. However, among of those investigated enzymes only 
QPRT activity was increased during FK866 treatment in the resistant cells 
(Figure 25A). This point attributes to the NAD biosynthetic pathway and a 
following question arises if CEM resistant cells obtain NAD from the de novo 
pathway to compensate the diminished NAD synthesis by NAMPT inhibitor. To 
test this hypothesis, mRNA expression level of QPRT was also investigated, 
treatment with FK866 did not affect QPRT mRNA expression levels in resistant 
cells, while its level decreased in parental cells (Figure 25B).  
 
Figure 25 FK866 potentiates QRPT enzymatic activity in CEM RES cells. 
CEM PA and CEM RES cells were treated with DMSO (Mock) and 5nM FK866 for 48h. 
A, QPRT enzymatic activity was measured in CEM cells. B, Relative mRNA expression 
level of QRPT normalized by 18S is shown. Data was conducted and represented as 
Mean with SD. from two biological experiments with technical triplicates. (**p<0.05) 
Metabolite of tryptophan is necessary for the synthesis of essential cellular 
cofactor NAD and nicotinic acid. Tryptophan is transported into the cells via LAT1 
transporter 152. LAT1 is over-expressed in murine lymphoma cells 144. Recently, 
laboratory of Dr. Jean-Francois Peyron reported that overexpressed LAT1 in T-
ALL/T-LL cancer cells reflects a cancer addiction towards increased nutrients 
uptake for mTOR1 and Akt activation and reprogrammed metabolism 144. 
Importantly, they showed that JPH203, a potent LAT1 selective inhibitor 
decreased leukemic cell viability and proliferation. JPH203 also interfered with 
constitutive activation of mTORC1 and Akt, induced CHOP activation and 
showed the highest synergy with rapamycin induced-proliferation arrest and 
apoptosis. Interestingly, JPH203 was non-toxic to normal murine thymocyte and 
human peripheral blood lymphocyte 144. 
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Collaboration with Dr. Jean Francois Peyron group brought me an opportunity to 
do my research internship at INSERM institute, in Nice, France. My research 
focus during my period aboard was aimed to investigate the involvement 
of LAT1 to the mechanism of pharmacoresistance to FK866.  
Effect of a selective LAT1 inhibitor JPH203 was determined in CEM PA and CEM 
RES cells. Cells were treated with various concentrations of JPH203 (0.1 to 100 
µM) for 72h. Interestingly, results showed that resistant cells were more sensitive 
to the drug as evident by the low IC50 than the parental one (Figure 26A). EC50 
of JPH203 at 72h in CEM PA was 5.23 µM (R2=0.90) and in CEM RES 2.76 µM 
(R2=0.80). To understand more a role of LAT1 in resistant cells contributing cell 
viability, drug combination between FK866 and JPH203 was conducted. 
Combination of 4x4 concentrations of FK866 (0, 1, 3, and 5nM) and JPH203 (0, 
1, 5, and 10 µM) were tested in CEM cells. Seventy-two hours of treatments, cell 
viability was estimated by XTT proliferation assay (Figure 26B and 26C) and 
together with percentage of live and dead cells detecting by FACS analysis of 
DAPI staining (Figure 27 and 28). Percentage of cell inhibition was subjected for 
drug combination analysis as evaluated by combination index (CI). Drug 
combination was analyzed by Compusyn software 145. Additive effects of drug 
combination between JPH203 and FK866 was shown at low doses of FK866 in 
CEM PA cells and appeared an antagonistic effect at higher concentrations. 
Interestingly, synergistic effect of JPH203 and FK866 (at 5µM of JPH203 with 
1µM of FK866) was found to improve toxicity in CEM RES cells as evident by a 
low combination index (CI=0.65) (Figure 29) suggesting the synergistic effect of 
FK866 and JPH203. Higher efficacy of JPH203 appeared in the resistant rather 
than parental cells in both individual and also drug combination treatment.  
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Figure 26 Effect of JPH203 a selective LAT1 inhibitor in CEM cell viability 
A, CEM RES is more sensitive to JPH203. Cells were treated with JPH203 for 72h. B 
and C, drug combination of FK866 and JPH203 was conducted with 4x4 concentrations 
of FK866 (0, 1, 3, and 5nM) and JPH203 (0, 1, 5, and 10µM) for 48h in CEM PA and 
CEM RES cells, respectively. Cell viability was conducted by XTT assay. Data is 
represented Mean with SD of three biological experiments with technical triplicates. 
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Figure 27 Drug combination of FK866 and JPH203 in CEM PA cells 
CEM PA cells were treated with 4x4 concentrations of FK866 (0, 1, 3, and 5nM) and 
JPH203 (0, 1, 5, and 10µM) drug combination for 72h. A, Flow cytometry analysis of 
DAPI staining for live cells following drug combination was evaluated. B, A 
representative experiment from three biological experiments evaluating percentage of 
live and dead cells obtained from flow cytometry analysis were plotted as Mean with SD.  
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Figure 28 Drug combination of FK866 and JPH203 in CEM RES cells 
CEM RES cells were treated with 4x4 concentrations of FK866 (0, 1, 3, and 5nM) and 
JPH203 (0, 1, 5, and 10µM) drug combination for 72h. A, Flow cytometry analysis of 
DAPI staining for live cells following drug combination was evaluated. B, A 
representative experiment from three biological experiments evaluating percentage of 
live and dead cells obtained from flow cytometry analysis were plotted as Mean with SD. 
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Figure 29 Drug combination screens identify synergistic effect of FK866 and 
JPH203 in CEM cells 
Drug combination of FK866 and JPH203 was conducted with 4x4 concentrations of 
FK866 (0, 1, 3, and 5nM) and JPH203 (0, 1, 5, and 10µM). Cell viability was estimated 
after 72h of drug treatment by XTT assay and percentage of cell inhibition was subjected 
for combination index (CI) analysis. CI scores for a drug synergy screen was calculated 
by Compusyn software. (CI<1 indicates synergistic effect, CI=1 indicates additive effect, 
CI>1 indicates antagonistic effect). Each CI score represents data from two biological 
experiments with technical triplicates per condition. 
Expression of ABC transporters prevents drug accumulation in the resistant cells 
by improving drug efflux 153. Due to the limitation of instrument, I could not 
perform an amino acid uptake experiment. Alternatively, we investigated 
expression levels of LAT1 in parental and resistant cells. LAT1 (SLC7A5) and 
CD98 (SLC3A2) constitute a heterodimeric transmembrane protein complex that 
catalyzes amino acid transport 154. The mRNA expression of genes encoded 
LAT1 including SLC7A5 (a light chain of LAT1) and SLC3A2 (a heavy chain) 
using qRT-PCR, and CD98 staining by FACS analysis were conducted. There 
was no difference in LAT1 encoded (SLC7A5) and (SLC3A2) mRNA expression 
between CEM RES and CEM PA cells (Figure 30). We assumed that expression 
levels of LAT1 might not be directly involved in the establishment of 
phamacoresistance to FK866. However, supporting evidence from JPH203 
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experiment indicated that blocking amino acid transportation through inhibition of 
LAT1 impacted cell viability, ATP and NAD levels in the resistant cells. 
 
 
Figure 30 Characterization of LAT1 expression in CEM cells 
A, CEM PA and CEM RES cells were stained with a FITC-labeled CD98 (LAT1) antibody 
and then were analyzed for LAT1 expression by flow cytometry. A representative data 
from two biological experiment was shown. B, Quantitative RT-PCR was performed in 
CEM PA and CEM RES cells targeting SLC7A5 (a light chain of LAT1) and SLC3A2 (a 
heavy chain of LAT1). Ribosomal protein (RPLRO) was used as a housekeeping gene. 
Data was conducted and represented as Mean with SD. from three biological 
experiments with technical triplicates.  
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Amino acids are obligatory for cellular functions and survival as they are 
recognized as important precursors for protein synthesis 155. Some of these 
amino acids can be synthesized in mammalian cells from a variety of metabolic 
precursors (non-essential) and others need to be obtained from extracellular 
sources due to the absence of metabolic pathway for their synthesis de novo 
(essential) 155. Thus, amino acid deprivation experiment was performed to 
address the roles of amino acids with regard to the acquiring for resistance. 
CHOP activation was chosen as a marker indicating cell death. We found that 
with conditional defects in cell viability induced CHOP activation appeared when 
CEM RES cells were cultured in amino acid deprivation (AA depletion) as well as 
supplemented with non-essential amino acid (AANE) (Figure 31A). Interestingly, 
an attenuated induction of CHOP was also noted in medium contained essential 
amino acids (AAE) suggesting a crucial role of AAE which was preferentially 
required for resistant cell survival. 
L-tryptophan (Trp) is one of eight essential amino acids that cannot be 
synthesized in the human body and it is critical in a number of metabolic functions 
156. Earlier we hypothesized that “de novo” NAD synthesis pathway starting from 
L-tryptophan may serve as an alternative pathway of NAD production responsible 
for resistant cell survival during energetic stress. Thus, L-tryptophan was the first 
candidate to investigate this hypothesis. We focused our attention on the 
resistant model. Informatively, we attempted to clarify the hypothesis by 
performing numerous related experiments, the following experiments were 
conducted under a diluted amino acid free medium (see material and method). 
Firstly, supplemented with L-tryptophan (Trp) or Tryptophan together with a 
complete AAE solution (Trp+AAE) were introduced into treatment conditions. 
Immunoblotting of CHOP expression was detected 24h after treatment in CEM 
RES cells. As expected, FK866 did not affect CHOP activation due to those cells 
are resistant to FK866, unlikely a single JPH203 treatment and drug combination 
of FK866 and JPH203 significantly stimulated CHOP activation (Figure 31B). 
Importantly, a remarkable result was observed in tryptophan supplementation 
which we could appreciate significant suppression of CHOP activation in 
combined FK866 and JPH203 treatment indicating the rescues effect of 
tryptophan responsible for resistant cell survival during energetic stress 
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induction. Secondly, we further analyzed CHOP mRNA expression along with 
those indicated treatments in CEM RES cells. A relative increase in CHOP mRNA 
expression was induced by JPH203, and co-treatment of FK866 and JPH203 
(Figure 31C). Accordingly, treatment with single JPH203 and the co-treatment 
activated the ATF4/CHOP pathway that was inhibited by tryptophan 
complementation. Thirdly, we investigated whether the presence of tryptophan 
could prevent the resistant cell death from the stress conditions induced by 
treatment. The addition of tryptophan potentiated the rescues of cell viability from 
combined JPH203+FK866 treatment (Figure 32A). Finally, we evaluated two 
important parameters including ATP and NAD+ levels in treated CEM RES cells. 
As expected, treatment with JPH203 and combined of the two drugs caused a 
dramatic drop in ATP and NADH levels in CEM RES cells. But those ATP and 
NADH levels were significantly elevated by tryptophan supplementation (Figure 
32B and 32C) indicating the dependency of resistant cells on tryptophan 
metabolism for the production of these key metabolic molecules.  
Taken all together, these data indicate that the development of FK866 resistance, 
by decreasing the production of NAD/NADH via NAMPT down-regulation is 
leading to the upregulation of alternative mechanism of NAD+ synthesis via 
tryptophan/QPRT pathway. CEM resistant cells utilized tryptophan as an 
alternative source to sustain NAD biosynthesis and to fuel cell metabolism during 
stress conditions. 
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Figure 31 Tryptophan prevents CEM RES cell death under energetic stress. 
A, CEM RES cells were incubated in different conditions of medium including normal 
RPMI medium (Ctrl), amino acid depletion medium (AA depletion) supplemented with 
essential amino acid (AAE) or non-essential amino acid (AANE) for 24h. Immunobloting 
analysis of CHOP was performed from whole cell lysate,  β-ACTIN was used as a protein 
loading control. A representative blot from three biological experiments is shown. 
Densitometry analysis of CHOP was normalized by β-ACTIN. B, CEM RES cells were 
incubated in normal RPMI medium (Ctrl) and following treatments was prepared in AA 
depletion medium including DMSO (Mock), 5nM FK866, 10µM JPH203, combination 
treatment of FK866 and JPH203 in the presence of 0.5mM Tryptophan (Trp) or Trp and 
AAE (Trp+AAE) for 24h. Immunoblotting analysis of CHOP was performed from whole 
cell lysate, β-ACTIN was used as a protein loading control. C, CEM RES cells were 
treated with the different conditions as indicated above in Figure 31B. Quantitative RT-
PCR of CHOP mRNA expression was conducted in CEM RES cells. 18S was used as 
a housekeeping gene. Data is represented as Mean with SD. from three independent 
experiments with technical triplicates (***,p<0.001). 
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Figure 32 Utilization of tryptophan as an alternative source to rescue cell survival 
and sustain ATP and NAD production in the resistance during stress conditions. 
CEM RES cells were treated with DMSO (Mock), 5nM FK866, 10µM JPH203, 
cotreatment of FK866 and JPH203 with and without supplementation of 0.5mM L-
tryptophan (Trp) or Trp and essential amino acid (Trp+AAE) for 24h. A, Cell viability was 
analyzed by XTT proliferation kit. B, Intracellular ATP levels were measured in CEM 
resistant cells after 24h treatment using Cell-titer glo kit. C, Total NAD-NADH levels were 
measured in CEM resistant cells after 24h treatment. Values are normalized to Mock 
condition. Relative value of Mean with SD from three biological experiments with 
technical triplicates was plotted. (***, p<0.001). 
Characterization of L-Asparaginase response 
Asparaginase is widely used in chemotherapeutic regimens for the treatment of 
acute lymphoblastic leukemia (ALL) and has led to a substantial improvement in 
cure rates, especially in children 157. To provide another example of an amino 
acid interference impacted metabolism of the resistance, we evaluated whether 
the resistant cells are also more sensitive to L-glutamine depletion than parental 
cells. We initially started evaluating L-Asparaginase (L-Asp) efficacy, exploiting 
its ability specifically to degrade L-glutamine 158,159. Indeed, CEM RES cells 
exhibited higher sensitivity toward L-Asp treatment than parental cells (Figure 
33A) as indicated by IC50 which was 1.04 U/ml (R2=0.97) and 0.50 U/ml 
A
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(R2=0.97) in CEM PA and CEM RES cells at 48h, respectively. Furthermore, drug 
combinations of FK866 and L-Asp was performed in CEM cells. Combined 
treatment of FK866 and L-Asp impeded cell viability in both CEM PA (Figure 
33B) and CEM RES cells (Figure 33C). Strong synergistic effect was obtained 
in the resistance as indicated by low CI score CI=0.26, CI=0.22, and CI=0.21 at 
low concentration of L-Asp (0.1U/ml L-Asp) with 1nM, 3nM, and 5nM of FK866, 
respectively (Figure 34). These results implicate the fundamental role of amino 
acid that generally attributes to cancer cell growth. Enzymatic activity of Asp is 
deamidatation of asparagine to aspartic acid and ammonia, but it also 
deamidates glutamine to glutamic acid and ammonia 160. To investigate the 
contribution of L-glutamine (Gln) to cell survival. We performed experiments 
under amino acid free medium to exclude the possibility that retained Gln in the 
medium would interfere the system inducing cancer cell growth. CEM PA and 
CEM RES cells were treated with 1U/ml L-Asp in the presence and absence of 
Gln for 48h. Supplementation of Gln showed a modest but reproducible trend 
toward elevated cell viability in particular the resistant cell which revealed a 
higher response to Gln than that of CEM PA cells (Figure 35A). We asked 
whether the presence of Gln would selectively contribute to an impediment of 
CHOP activation in the resistant cells. CEM RES cells were treated with indicated 
treatment. Activation of CHOP protein and CHOP mRNA expression were 
intensely pronounced in replenishment of L-glutamine in resistant cells in 
particular along with L-Asp treatment (Figure 35B and Figure 36A). 
Supplementation of Gln functioned as a guardian to prevent the activation of 
CHOP mRNA expression (Figure 36A). Gln blocked the activation of CHOP 
during co-administration of the two drugs,. There was significant different in ATF4 
and ANS1 mRNA expression during drug administration (Figure 36A). We next 
expendably examined if Gln could restore ATP and NAD levels during L-Asp or 
drug cotreatment. Depletion of ATP and NAD was found in 48h after L-Asp 
treatment in MDA RES cells (Figure 36B and 36C). A well-defined impact of Gln 
in generating ATP and NADH production was observed in all treatment conditions 
suggesting that Gln results in broad defects in resistant cell mortality and 
declining in ATP and NAD production. Taken together these results indicate that 
FK866 resistant cells are relying on the presence of glutamine in the medium to 
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complement the reduction of endogenous NAD and, notably, the increased 
addiction to glutamine causes increased sensitivity to L-Asp. 
 
 
Figure 33 Effect of L-Asparaginase induced cell death in CEM cells 
A, CEM cells were treated with various concentrations of L-Asparaginase (U/ml) for 48h. 
Cell viability was analyzed using XTT proliferation assay. B, Drug combination of FK866 
(0, 1, 3, and 5nM) and L-Asp (0, 0.1, 0.3, and 1 U/ml) was performed in CEM PA cells 
for 48h. C, Drug combination of FK866 (0, 1, 3, and 5nM) and L-Asp (0, 0.1, 0.3, and 1 
U/ml) was performed in CEM RES cells for 48h. Relative cell viability was measured and 
calculated from XTT proliferation assay. Data was plotted as relative of Mean with SD. 
of three biological experiments with technical triplicates. 
A
C
B
	 69	
 
Figure 34 Drug combination screens of FK866 and L-Asparaginase in CEM cells 
Drug combination of FK866 and L-Asp was conducted with 4x4 concentrations of FK866 
(0, 1, 3, and 5nM) and L-Asp (0, 0.1, 0.3, and 1 U/ml). Cell viability was measured after 
48h of drug treatment by XTT proliferation assay. and percentage of cell death was 
subjected for combination index (CI) analysis. CI scores for a drug synergy screen was 
calculated by Compusyn software. (CI<1 indicates synergistic, CI=1 indicates additive 
effect, CI>1 indicates antagonistic effect). CI score from a representative experiment of 
two biological experiments with technical triplicates per condition is shown. 
CEM PA                                            CEM RES
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Figure 35 L-glutamine prevents cell death during energetic stress. 
A, CEM PA and CEM RES cells were treated with 1U/ml L-Asp in the presence or 
absence of 2mM L-glutamine (Gln) supplementation for 48h. Cell viability was analyzed 
using XTT proliferation assay. B, CEM RES cells was treated with 5nM FK866, 1U/ml L-
Asp, co-treatment with FK866 and L-Asp in the presence or absence 2mM Gln for 48h. 
CHOP protein level was verified by western blot analysis, β-ACTIN was used as a protein 
loading control. A representative of immunoblotting is shown and densitometric analysis 
of relative CHOP level was analyzed and normalized by β-ACTIN. Relative data of Mean 
with SD from three biological experiments with technical triplicates was represented. 
(***p<0.001). 
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Figure 36 L-Glutamine exhibits rescues effect on ATP and NAD production during 
stress condition in CEM RES cells. 
A, CEM RES cells were exposed to 5nM FK866, 1U/ml L-Asp, cotreatment with FK866 
and L-Asp in the presence or absence 2mM Gln for 48h. CHOP, ATF4, and ASN1 mRNA 
expression were verified by RT-PCR, 18S was used as a house keeping gene. B, CEM 
RES cells were treated for the indicated treatments for 48h, and ATP levels were 
quantified by Cell Titer-glo assay. C, CEM RES cells were treated for the indicated 
treatments for 48h, and were then subjected for NAD measurement. Relative data with 
SD was conducted from three biological experiments with technical triplicates. 
(***p<0.001). 
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Development of a comparative NAMPT inhibitor resistant model in MDA-
MB231 cell line. 
To investigate the degree of generality of the identified resistant mechanism, we 
developed another strain of FK866 resistant cells derived from triple negative 
breast cancer MDA MB231 cell line, that is particularly sensitive to FK866 
exposure 37. We determined comparative mechanism of action of FK866 as 
depletion of NAD, likely through inhibition of NAMPT in MDA-MB231 parental 
cells (MDA PA) and MDA-MB231 FK866 resistant cells (MDA RES). MDA PA 
cells were sensitive to FK866 treatment (Figure 37A). We obtained a complete 
MDA RES model in which the resistance was resistant to FK866 treatment at 
indicated times (Figure 37B). To determine whether developed MDA RES cells 
are NAMPT-dependent resistance, MDA RES cells were tested to another 
NAMPT inhibitor (CHS-828) for 48h. Similar result with CEM RES cells was 
observed, CHS-828 strongly induced MDA PA cell death whereas it did not 
affected MDA RES cell viability (Figure 37C). Thus, we accomplished 
development of the NAMPT-dependent resistance MDA model that was clearly 
indicated by insensitivity to both FK866 and CHS-828 treatment. FK866 
dramatically decreased ATP and NADH levels in MDA PA cells (Figure 38A and 
38B) but no change in ATP levels along with FK866 re-stimulation was obtained 
in MDA RES (Figure 38A). We noted that restoration of NAD levels was also 
found when MDA RES cells re-exposed to FK866 treatment corroborating with 
the previous observation in a CEM RES cell model (Figure 19A). However, the 
resistance to NAMPT could be caused by some mutation in NAMPT 157. 
Additionally, we sequenced the NAMPT gene in the resistant and the parental 
cell lines. Apparently, no mutation of NAMPT genes were present in our CEM 
RES and MDA RES models. 
Protein translation markers were investigated in comparison between MDA PA 
and MDA RES. Insensitivity to FK866 treatment in MDA RES was also evidence 
by the continuous activation of the translation machinery that was not affected by 
the stress response mediated by EIF2a, AMPK or by 4EBP1 phosphorylation 
(Figure 39). These results suggested the loss of protein translation inhibition in 
the MDA resistance as well as observed in CEM RES cells. 
	 73	
 
Figure 37 Characterization of NAMPT dependent-FK866 resistant MDA cells 
A, Does-response sensitization to a NAMPT inhibitor (FK866) in MDA PA cells. Cells 
were exposed to various concentration of FK866 as indicated time points. Percentage 
of cell viability was analyzed by MTT assay. B, MDA RES cells were also exposed to 
FK866 as indicated times, then cell viability was determined by MTT assay. C, MDA PA 
and MDA RES cells were expose to another NAMPT inhibitor (CHS-828) for 48h. Cell 
viability was analyzed by MTT assay. Relative value of Mean with SD compared to mock 
control was plotted. A representative data from two biological experiment with technical 
triplicates is presented. 
 
Figure 38 Evaluation of ATP and NAD levels in MDA cells 
A, ATP levels was measured in MDA PA and MDA RES cells 48h after treatment with 
DMSO (Mock), 10 and 100nM FK866. B, Total NAD levels were measured in MDA PA 
and MDA RES cells 48h after treatment with DMSO (Mock), 10 and 100nM FK866. Data 
was represented as relative of Mean with SD conducted from three biological experiment 
with technical triplicates. (***p<0.001) 
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Figure 39 Protein translation control is not inhibited in MDA RES cells 
Immunoblotting analysis of whole protein extract from MDA PA and MDA RES cells after 
48h treatment with DMSO (Mock), 10 and 100nM FK866 was performed. A 
representative of immunoblotting from three biological experiments expressed levels of 
p-AMPK (Thr-172), p-mTOR1 (Ser-2448), p-4EBP1 (Ser-65 and Thr-70), p-EIF2a (Ser-
51) and total form of those were shown. β-ACTIN was used as a protein loading control.  
MDA RES cells share a number of common characteristic similar to those of CEM 
RES cells including insensitivity to NAMPT inhibitors (FK866 and CHS-828), no 
effect on ATP and an elevated NAD levels during FK866 treatment, no protein 
translation inhibition, and down-regulation of NAMPT mRNA expression in the 
resistant cells in respect to MDA PA cells (Figure 40). Although many similar 
phenotypes of the CEM resistance was observed in MDA RES cells, but a 
number of dissimilarities were found at the mRNA expression levels. FK866 
treatment strongly decreased the expression levels of the enzymes involved in 
the de novo pathway for the synthesis of NAD such as QPRT, IDO and KYNE 
and of NAMPT itself (Figure 40). However, in this case we speculated that the 
alternative pathway may be not going through the de novo pathway since the 
enzymes involved are not overexpressed in respect to the parental cells. To 
address this question we evaluated the effect of amino acid deprivation in MDA 
RES. First, the LAT1 inhibitor JPH203 was tested in both parental and resistant 
cells to reproduce circumstances occurring in the cells during amino acid 
deprivation, tryptophan included. Indeed, MDA RES cells did not show differential 
sensitivity to JPH203 administration in respect to MDA PA cells (Figure 41A). 
Second, another amino acid deprivation was addressed in MDA cells using  
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L-Asparaginase treatment. Consistent with JPH203 treatment, drug sensitivity of 
MDA RES displayed no difference in sensitivity neither to JPH203 nor to L-Asp 
treatment (Figure 41A and 41B) pointing out to a distinct mechanism governing 
cell metabolism between MDA RES and CEM RES cells. 
We next investigated whether MDA resistance cells showed metabolic shift 
towards glycolysis. We first determined both glycolytic and mitochondrial 
pathways which may be involved in altered metabolism linked to mechanism of 
chemoresistance in MDA RES cells by testing with well-known metabolic 
inhibitors. No difference in drug sensitivity among MDA PA and MDA RES cells 
was detected neither with 2DG nor oligomycin treatments (Figure 41C and 41D) 
supporting the idea that no specific dependency in metabolic reprogramming 
takes place in MDA RES cells. We further explored more the expression levels 
of glycolytic and mitochondria involved genes in MDA PA and MDA RES cells. 
Accordingly, the pattern of expression level of metabolic genes as the 
mitochondrial genes COX3 and ATP8 was unchanged or ND was shown much 
less affected (Figure 42A) compared to CEM RES cells (Figure 23A). To our 
surprise, LDHA was up-regulated in MDA RES whereas HK2 was downregulated 
in MDA RES cells (Figure 42A). We next investigated the effect of FK866 on 
LDHA level, FK866 was no significantly affected in LDHA mRNA levels in the 
resistant cells (data not shown). Consistently, we found a significant increase in 
LDH release toxicity test toward FK866 treatment only in MDA PA but not in MDA 
RES cells (Figure 42B) as coherent with mRNA levels. Notably, MDA RES cells 
were not responding to glucose inhibitor treatment, suggesting a dynamic and 
differential ways of producing and sustaining NAD that may cause addiction in 
different cell lines. 
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Figure 40 Down-regulation of de novo NAD synthesis target genes in MDA RES 
cells 
MDA PA and MDA RES cells were treated with 20nM FK866 for 48h. Quantitative RT-
PCR targeting de novo NAD synthesis genes including QRPT, KYNE, IDO, and salvage 
pathway NAMPT was analyzed. Data was represented as Mean with SD of two biological 
experiments with technical triplicates. 18S was served as a housekeeping gene. 
 
Figure 41 Drug sensitivity test in MDA MB231 cells 
MDA PA and MDA RES cells were treated with various concentration of JPH203 (A), L-
Asparaginase (B), 2DG (C), and oligomycin (D). Forty-eight hours after treatment, 
relative cell viability was analyzed using ozblue cell viability kit compared to mock 
(DMSO). Data was represented as relative of Mean with SD of three biological 
experiments with technical triplicates. 
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Figure 42 Expression levels of genes involved in glycolytic and OXPHOS 
A, Quantitative RT-PCR targeting glycolytic genes (HK2, LDHA) and mitochondria 
genes (COX3, ATP8, ND1) were analyzed in MDA cells. 18S was served as a 
housekeeping gene. B, FK866 exhibited toxicity in MDA PA cells. Cytotoxicity test was 
performed by LDH cytotoxicity kit measuring a release of LDH from damaged cells. Data 
was represented as relative of Mean with SD conducted from three biological 
experiments with technical triplicates. 
Genetic evidences deciphering the mechanism of FK866 
pharmacoresistance 
NAMPT 
By characterization of the resistance, we descriptively obtained many significant 
comparative data of the parental and resistance. To this regard, the simplest but 
hardest question then arises as to how cells acquire pharmacoresistance to 
FK866? Since, significant down regulation of NAMPT mRNA and enzymatic 
activity levels were commonly observed in both CEM RES and MDA RES cells 
in respect to the parental cells, we first reasoned that a relevance of this depletion 
in NAMPT level in the resistant cells. We sought to examine whether the acquired 
resistance is primarily caused by the genetic ablation of NAMPT. We created a 
robust over expression of NAMPT in MDA cells (Figure 43A). Cell viability, ATP, 
and NAD levels were experimentally analyzed. Overexpressed of NAMPT 
displayed functional effect in which it increased ATP and NADH levels in the 
resistant cells (Figure 43C and D). However, transient over-expressed NAMPT 
failed to reestablish or restore sensitivity toward FK866 treatment in MDA RES 
cells (Figure 43B-D).  
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Figure 43 Overexpressed NAMPT in MDA cells  
MDA PA and MDA RES cells were transiently transfected with empty vector control 
(MDA RES/PBP) and NAMPT overexpressed-plasmids (MDA RES/NAMPT). A. NAMPT 
mRNA level was analyzed by RT-PCR, GAPDH was used as a housekeeping gene. 
Twenty-four hours after transfection, cells were treated with indicated concentrations of 
FK866 for 48h. B, Cell viability was measured using ozblue cell viability kit. C, ATP levels 
was determined by luciferin-luciferin based assay. D, NAD levels was determined. Data 
was represented as relative of Mean with SD conducted from two biological experiments 
with technical triplicates. 
 
It has been reported that depletion of NAMPT directly induced cell death 161. We 
further examined the expression level of NAMPT by RT-PCR and cellular NAD 
activity detecting by a biochemical assay in numerous cancer cell lines. 
Differential expression of NAMPT mRNA levels and NAD enzymatic activity 
across a panel of nine cancer cell lines were illustrated in Figure 44A and 44B, 
respectively. Among those lines, MDA cell line expressed the highest level of 
NAMPT and correlated with NAD activity. Furthermore, we attempted to 
understand the correlation of NAMPT expression or cellular NAD levels in 
respond to FK866 sensitivity. Thus, FK866 drug screening was performed in all 
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those cell lines. Depletion of NAD by FK866 induced cell death in most of 
indicated cell lines except CEM RES and MDA RES cells (Figure 44C). FK866 
potentiated B-ALL (NALM and 697) cell mortality. Unfortunately, it was difficult to 
draw a correlation between NAMPT mRNA expression and NAD level with cell 
susceptibility to FK866 in those panel of cell lines. However, we could appreciate 
the significant effect of FK866 strongly induced cell death suggesting a crucial 
role of NAMPT in various types of cancer cells. 
 
 
Figure 44 Differential expression of NAMPT levels and NAD activity in a panel of 
cancer cell lines 
A, NAMPT mRNA levels of indicated cell lines was analyzed by quantitative RT-PCR, 
GAPDH was served as a housekeeping gene. B, Cellular NAD activity was measured 
by NAD biochemical assay. C, Cytotoxicity of FK866 in a panel of nine human cell lines, 
cells were exposed in various concentration of FK866 for 72h. Cell viability was 
measured by ozblue cell viability kit. Curve fitting and parameter estimation were 
performed with a standard sigmoidal concentration-response model with variable slope 
using Graph Prism software. The value was represented as relative of Mean with SD 
conducted from three biological experiments with technical triplicates for A and C and 
two biological experiments with technical triplicates for B.   
A B
C
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Lactate dehydrogenase (LDH) 
MDA RES cells revealed differently from leukemia cells (CEM) in metabolic 
control, the latter cells find alternative metabolic solution to the production of NAD 
from tryptophan. Among of those key glycolysis enzymes, dose dependent 
enhanced LDH activity in CEM RES sub-clones mounting an evidence to 
intensively explore functional effect of LDH. We speculated whether a key 
glycolytic enzyme LDH possibly contributes to the acquisition of resistance of 
both CEM and MDA cells. To assess the role of putative LDH in tumor, the effect 
of a small potent molecule inhibitor of LDH, GSK2837808A (GSK) 111 was initially 
determined in both CEM and MDA cell lines. We observed that the resistant cells 
were more susceptible to LDH inhibition in respect to the parental one as 
evidence by lower in EC50 of GSK (Figure 45A and B) as well as the number of 
viable cells (Figure 45C and D) both in CEM and MDA resistant cells. EC50 at 
48h of GSK was 19.2µM (R2=0.994) in CEM PA and 12.1µM (R2=0.95) in CEM 
RES cells. We evaluated if downregulation of LDH enzyme levels upon GSK 
treatment resulted in depletion of cellular energy production. ATP and NAD levels 
were analyzed in CEM and MDA cells. Results showed marked reduction in ATP 
and NAD levels toward GSK treatment in CEM cells. Interestingly, we could 
appreciate a greater impact of GSK in the depletion of ATP and NAD levels in 
CEM RES than CEM PA (Figure 46A and B) suggesting that LDH might play a 
significant role in promoting glycolysis facilitated resistant phenomenon in 
leukemia. GSK significantly decreased ATP levels in MDA cells (Figure 45C). In 
contrast, no significant different in NAD level was observed in MDA cells (Figure 
45D). In addition, the effect of GSK on cell cycle distribution of CEM PA and CEM 
RES cells were determined by flow cytometry and showed alteration in G0/G1, 
S, and G2/M phase of cell cycle under the different treatment conditions. 
Treatment with GSK slightly increase G2/M phase accumulation in CEM PA cells 
(Figure 47 B-D). In comparison to parental cells, a dramatic increase in S and 
G2/M phase arrest was observed in the resistant population (Figure 47 and 
Table 1). Importantly, GSK induced apoptosis was obviously detectable only in 
the CEM resistant not in the CEM parental one (Figure 47G and H). These 
results mounting an evidence to an important role of LDH in cell cycle progression 
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in CEM RES cells. CEM RES cells displayed a tendency to be more sensitive to 
the inhibition of LDH than MDA RES cells. 
 
 
Figure 45 Resistant cells are susceptible to a LDH inhibitor. 
A, CEM PA and CEM RES cells were exposed to various concentrations of GSK a potent 
LDH inhibitor. B, MDA PA and MDA RES cells were exposed to various concentrations 
of GSK. Cell viability was determined after 48h of treatment using ozblue cell viability kit. 
C, CEM cells were treated to GSK as an indicated concentration for 48h. D, MDA cells 
were treated to GSK as an indicated concentration for 48h. Relative of cell number was 
conducted from automate counting device (Invitrogen). Data was represented as relative 
of Mean with SD from three biological experiments (A, B, C) and a preliminary 
experiment for figure 45D. 
A B
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Figure 46 Inhibition of LDH impacts ATP and NAD production in CEM RES cells. 
A, CEM cells were exposed to DMSO (Mock) and 20µM GSK. ATP levels was measured 
48h after treatment. B, NAD levels was measured 48h after treatment DMSO (Mock) 
and 20µM GSK in CEM cells. C, MDA cells were exposed to indicated concentrations of 
GSK. ATP levels was measured 48h after treatment. D, NAD levels was measured 48h 
after treatment with DMSO (Mock) and indicated concentrations of GSK in MDA cells. 
Data was represented as Mean with SD conducted from four biological experiments with 
technical quadruplicates (A, B) and three biological experiments with technical 
quadruplicates (C, D). (***p<0.01) 
A B
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Figure 47 GSK induces apoptosis in CEM RES cells 
FACS-mediated cell-cycle analysis by propidium iodide (PI) staining of CEM PA and 
CEM RES cells. CEM cells were treated with following conditions; serum free starvation, 
DMSO (Mock), GSK 10µM, and GSK 20µM in CEM PA cells (A, B, C and D) and in CEM 
RES cells (E, F, G and H), respectively. Forty-eight hours after treatment cell were lyzed 
with 0.5% Triton X, then incubated with the PI and thereby cell cycle analysis was 
performed using flow cytometry. A representative data of FACS from two biological 
experiments was shown. 
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Table 1 Cell cycle analysis by PI staining in CEM PA and CEM RES cells 
Cells Treatments %G1 %S %G2 G2/G1 %CV %Apoptosis 
CEM PA Starvation 48.62 51,38 0 2.00 8.41 - 
Colchicine 100ng/ml 51.91 47.91 0.18 1.94 4.93 - 
DMSO 52.04 47.69 0.32 1.91 4.92 - 
GSK 10uM 58.21 40.82 0.97 1.97 4.41 - 
GSK 20uM 46.67 45.87 7.46 2.00 4.06 - 
CEM RES Starvation 31.89 68.11 0 2.00 6.80  
DMSO 44.15 52.24 3.61 1.95 4.88 - 
GSK 10uM 26.65 59.99 13.36 1.96 4.22 8.15 
GSK 20uM 13.71 63.57 22.72 1.97 4.33 11.81 
 
GSK administration significantly down-regulated LDHA mRNA expression in the 
parental cells of both CEM and MDA cells (Figure 48A and 48D). We found that 
GSK significantly activated of CHOP/ATF4 in both CEM PA and CEM RES cells 
(Figure 48B and 48C). In contrast, GSK slightly activated ATF4 mRNA 
expression in MDA cells (Figure 48F) but no activation of CHOP activation was 
in MDA resistant (Figure 48E). This highlights a difference in the 
pharmacological response to the LDH inhibition between CEM and MDA cell 
lines, in which GSK is more potent in CEM cells than MDA cells.  
Drug combination has been applied as a potential therapeutic platform for cancer 
therapy. It usually gives better and more reliable therapeutic outcomes than 
single anti-cancer treatment. To evaluate if GSK restore FK866 sensitivity and 
improve the toxicity outcome. We performed drug combination experiment 
between NAMPT inhibitor (FK866) and a metabolic drug targeted lactate 
dehydrogenase enzyme (GSK). Although MDA cells was not strongly susceptible 
to GSK single treatment but we observed the synergistic effect in the combined 
treatment of GSK and FK866 (Figure 49B and 49C). EC50 of GSK single 
treatment and GSK+20nM FK866 were 29.1 nM (R2=0.97) and 17.7 nM 
(R2=0.96) in MDA 48h, respectively (Figure 49B). However, we did not observe 
a clear enhanced toxicity of GSK+FK866 co-treatment in CEM cells (Figure 
49A). We observed the difference in drug sensitivity toward GSK treatment 
between CEM and MDA cells. Combination of FK866 and GSK was not improve 
the toxicity in CEM cells whereas the presence of GSK could resensitize the 
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FK866 susceptibility in MDA RES cells. Since, CEM cell displays as a low 
glycolytic cell and the metabolic enhanced glycolysis occurs once CEM cells 
became pharmacoresistant to FK866 whereas MDA-MB231 cell has been 
characterized as a high glycolytic cell. Therefore, initially difference between 
these two cell lines may cause the different mechanism in acquiring FK866 
resistance. However, LDH plays a pivotal role in both cell line. 
	
 
Figure 48 Inhibition of LDHA by GSK induces the CHOP/ATF4 activation. 
CEM PA and CEM RES cells were treated with 20µM GSK for 48h. Expression levels of 
LDHA (A), CHOP (B), and ATF4 (C) were measured using qRT-PCR. MDA PA and MDA 
RES cells were exposed to 25µM GSK for 48h. Expression levels of LDHA (D), CHOP 
(E), and ATF4 (F) were measured by qRT-PCR. GADPH was served as a house keeping 
gene. Data is represented relative of Mean with SD compared to MOCK of each cell line 
of three biological experiments with technical triplicates. 
A D
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Figure 49 Drug combination between FK866 and GSK 
A, CEM PA and CEM RES cells were treated with combination of 50nM FK866 and vary 
concentrations of GSK (0-50µM). B, MDA PA and MDA RES cells were co-treated with 
20nM FK866 and vary concentrations of GSK (0-50µM). C, MDA PA and MDA RES cells 
were co-treated with various concentration of FK866 (0-100nM) and 25µM GSK. Cell 
viability was measured and analyzed 48h after treatment by ozblue cell viability kit. Data 
was plotted as relative Mean with SD of three biological experiments with technical 
triplicates.  
	
Apoptosis contributes to cell death in the CEM RES cells treated with a LDH 
inhibitor GSK concurrently with a significant depletion of ATP and NAD levels, 
indicate critical roles of LDH contributing to metabolic regulation and gaining 
resistance to FK866. Therefore, we sought to investigate genetic data supporting 
of LDHA mediated metabolic adaptations that able to confer advantages to 
FK866 resistance. We performed a transiently knock-down the LDHA expression 
in MDA PA and MDA RES cells (Figure 50A and 50B). To further evaluate if 
downregulation of LDHA by siRNA targeting human LDHA results in depletion of 
cellular energy production. Level of ATP and NAD were examined in scramble 
siRNA Control (MDA SCR) and LDHA silencing MDA (MDA siLDHA). A 
significant depletion of ATP but not NAD levels were obtained in MDA RES cells 
silenced LDHA. (Figure 50C and 50D). We appreciate the synergy of GSK and 
A
B C
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FK866 treatment in MDA RES displaying an enhanced in cancer cell growth 
inhibition in respect to the single treatment of GSK (Figure 49C and 49D) 
revealing an imperative role of LDHA involved in establishing the resistance to 
FK866 of MDA RES cells. We thus speculated that the loss of LDHA may 
resensitize the drug sensitivity toward FK866 especially in the resistant cells. To 
address this hypothesis, we performed transiently knock-down of LDHA in MDA 
RES cells by siRNA targeting human LDHA to down-regulated LDHA expression 
both protein and mRNA levels (Figure 50A and 51A). Loss function of LDHA 
mediated cancer cell death through the activation of CHOP/ATF4 mRNA 
expression (Figure 51B and 51C). Interestingly, a genetic evidence showing that 
the ablation of LDHA by siRNA coordinated treatment of FK866 significantly 
improve toxicity by activation of CHOP/ATF4 (Figure 51B and 51C) in consistent 
with pharmacological outcome of an LDH inhibitor (GSK) and FK866 combined 
treatment in MDA resistant cells.  
Taken together, a potent NAMPT inhibitor FK866 targets the most active pathway 
of NAD biosynthesis in several cancers. However, lack of tumor-selectivity for the 
use of FK866 as a single drug treated leukemia has been deteriorated its 
therapeutic potency. We revealed the significant function of LDH mediated 
metabolic adaptions or conferred advantage to FK866 acquiring resistance in 
cancer cells. Combination treatments targeting metabolic functions could open 
the potential therapeutic window for cancer therapy in particular T-lymphoblastic 
leukemia. However, deepen investigation regarding to cancer acquiring LDH 
inhibitor resistance could be considered for further investigation. 
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Figure 50 Ablation of LDHA by siRNA leads to a decrease in ATP production in 
MDA cells. 
Down regulation of LDHA, siRNAs targeting human LDHA were transfected via interferin 
transfection reagent (Polyplus) to knock down the LDHA expression transiently in MDA 
PA and MDA RES cells. A, Immunoblotting was performed on whole cell lysates, probed 
with mouse-monoclonal anti-LDHA, and reprobed with anti-β-actin as a loading control. 
B, Densitometric analyasis of LDHA silencing in MDA PA and MDA RES. C, ATP levels 
was determined after 48h of silencing with siLDHA in MDA cells. D, NAD levels was 
determined after 48h of silencing with siLDHA in MDA cells. Data is represented as Mean 
with SD of three biological experiments with technical triplicates. (***p<0.01) 
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Figure 51 Treatment of FK866 coordinated with down-regulation of LDHA 
potentiates the activation of CHOP/ATF4 in the resistant cells. 
siRNAs targeting human LDHA were transfected via interferin transfection reagent to 
knock down LDHA expression in MDA RES cells. Twenty-four hours after silencing, MDA 
RES cells were treated with 50nM and 100nM of FK866 for 48h. Expression levels of 
LDHA (A), CHOP (B), and ATF4 (C) were determined by qRT-PCR. GAPDH expression 
was served as a housekeeping gene. Relative expression level of genes compared to 
MOCK condition was analyzed. Data was represented as relative of Mean with SD. from 
three biological experiments with technical triplicates.  
	
	
FUTURE PERSPECTIVES 
Pharmacological characterization and metabolic function were evaluated in the 
NAMPT inhibitor resistant cells. Expression of ABC transporters prevents drug 
accumulation in the resistant cell by improving drug efflux 153. However, (i) 
investigation of mitochondria function, (ii) analysis metabolomic function, (iii) 
involvement of amino acid uptake of parental and resistant cells, as well as (vi) 
involvement of the existence of cancer stem-like cells which may represent a 
resistant subpopulation of cancer cells with high tumor or metastasis-forming 
ability and drug resistance to NAMPT or LDH inhibitors would be highly interested 
for further investigation. 
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DISCUSSION 
In the current study, we provide evidence for understanding molecular 
mechanism of pharmacoresistance to NAMPT inhibitor in leukemia and breast 
cancer cell lines. This is based on 5 lines of evidence; (i) protein translation 
control was not inhibited in the resistant cells during FK866 treatment, (ii) the 
molecular mechanism by which FK866 resistant CCRF-CEM cells utilized L-
tryptophan as an alternative source for NAMPT-independent NAD production to 
fuel cell metabolism, (iii) we highlighted metabolic reprogramming of the CEM 
resistance enhances toward glycolysis (Warburg effect), (iv) two remarkable 
evidences of amino acid interference impacted cell survival and synergistic effect 
of the NAMPT inhibitor with amino acid inhibitors in the resistance (v) We 
proposed LDH as a pivotal target having functional effects responsible for cell 
survival. Inhibition of LDHA expression in resistant cells are more vulnerable to 
deplete ATP, NAD synthesis than in parental cells rendering a synthetic lethality 
and drug susceptible towards FK866.  
Development of drug resistance by cancer cells is one of the major causes of 
therapy failure limiting the effectiveness of chemotherapy. Growing evidences 
support the idea that deregulated cellular metabolism or metabolic alteration is 
linked to such resistance 162. Indeed, both components of the glycolytic and 
mitochondrial pathways are involved in altered metabolism. Understanding 
metabolic alterations associated with drug resistance opens up unexplored 
opportunities for the development of new strategy for cancer therapy. During the 
past decade, FK866 has also been evaluated in a broad variety of tumor cells 
including leukemia and solid tumors namely in gastric cancer 48, T-ALL 71, small 
lung carcinoma 157, triple-negative breast cancer 37, murine tumor 163,164, 
neuroblastoma 165, hepatocarcinoma 76 and prostate cancer 166. Interestingly, 
FK866 is much less toxic in non-tumor cell cultures and animal model 74. 
Similarly, high sensitivity to the drug is displayed by leukemia and lymphoma 
cells, but not by normal hematopoietic progenitors 14,74. However, the link 
between tumor metabolism and drug resistance to FK866 has not been deeply 
investigated. Therefore, we applied a selection strategy to obtain a cancerous 
CCRF-CEM ALL cell designated CEM RES that was capable of tolerating 
exposure to a NAMPT inhibitor FK866. MDA-MB231 resistant cells (MDA RES) 
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were also generated as a comparative model for intensive understanding the 
generality of molecular mechanism of pharmacoresistance to FK866 in other 
cancers. However, the precise pattern of the acquisition of bona fide drug 
resistance heterogeneity is unknown. It has been proposed that the drug-tolerant 
cancer could be expanded from a pre-existing cells, which may even provide a 
latent reservoir of cells for the emergence of heterogeneous drug resistance 
mechanism 167. Dramatically decrease of NAD level and thereby drop of ATP 
levels are the distinctive drug signature of FK866 (Figure 18A and 18B). In 
agreement with several studies highlighted a crucial role of a NAMPT inhibition 
FK866 which led to depletion of NAD, secondarily displaying a decrease in ATP 
subsequent cell death in many cell lines 69,149. 
AMPK actively restrained aerobic glycolysis in T-ALL cells through inhibition of 
mTORC1 while promoting oxidative metabolism and mitochondrial Complex I 
activity 168. Here in, we observed no activation of AMPK/mTOR mediated protein 
translation during reactivation with FK866 treatment in the resistant cells of both 
CEM and MDA resistant models (Figure 20 and 39). An inhibition of mTOR 
subset (FKBP12) led to an impaired functions of mitochondria and increased 
lactate production, concurrent enhanced aerobic glycolysis in Jurkat cells 169. 
Interestingly, decrease in AMPK activity can be rescued by leucine and glucose 
supplementation 170. Accordingly, we postulated that dysfunction of 
AMPK/mTOR signaling pathway might be one of explanation contributing to an 
increase in aerobic glycolysis and suppressed mitochondria function in the 
resistance.  
In this study, we revealed different metabolic adaptation of CEM RES and MDA 
RES cells in which CEM RES cells displayed an enhanced glycolysis 
dependency to confer metabolic advantage to FK866. Although 2DG inhibits 
cancer cell growth through an oxidative stress mechanism in multiple cancer cell 
lines including MDA-MB231cells 171, but we did not observe metabolic alteration 
in MDA RES cells in respect to the parental one. This glycolysis dependency 
feature in CEM RES cells was confirmed by upregulation of key glycolytic 
enzyme activity, coupled with increased in lactate production, and higher level of 
glucose consumption. In contrary, switch of bioenergetics back from aerobic 
glycolysis to mitochondrial oxidative phosphorylation has also been known to 
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increase tumor resistance 162. Reverse Warburg effect in which metabolic shifts 
from Warburg (aerobic glycolysis) to OXPHOS has been reported in docetaxel 
prostate cancer resistant cells 162. Under radiation, MCF-7 cells can be quickly 
adapted to genotoxic condition via mTOR-mediated reprogramming of 
bioenergetics from predominantly glycolysis to OXPHOS 172. Recently, Wu Hao 
and colleagues revealed that lactic acidosis has been found to be a factor 
responsible for metabolic switch from aerobic glycolysis to dominant OXPHOS 
173. Interestingly, glycolysis rate can dramatically be reduced by the 0.4 unit 
decrease of pH due to alteration of glycolytic enzymes including HK and PFK1 
and also glucose transporters were sensitive to proton inhibition173. Although 
lactic acidosis could alter glucose metabolism in most cancer cells and has a 
capacity to feedback to glucose utilization/metabolism but this issue has not been 
addressed in CEM RES. Increased mRNA levels of Hk2, Pfkfb2, Slc2a1, and 
Slca4 were observed in cardiomyocytes treated with FK866 174. Inhibition of 
glycolysis, by the use of synthetic compound 2DG concealed the clue of 
glycolysis dependency that resistant cells compensated the decrease of 
OXPHOS activity, due to a limited availability of NAD/NADH at its turned due to 
the decrease of NAMPT enzyme. Similar event has been shown earlier in 
leukemia cells, in which the increased glycolysis rate is due to an up-regulation 
of several genes involved in glycolysis or glucose uptake and consequent an 
excessive production of lactate in ALL cell lines 175 and most of ALL cell lines are 
sensitive to 2DG 176. 
Susceptible to JPH203 a selective LAT-1 inhibitor of CEM RES lighted up the 
possibility that LAT1 involvement and tryptophan utilization served as an 
alternative source for NAMPT-independent NAD production. JPH203 inhibitor 
has been documented both in vitro and in vivo against HT-29 tumors transplanted 
in nude mice 177,178, and apoptosis induction in YD-38 human oral cancer cells 
179. In vivo assay, a dietary flavonoids (Proanthocyanidins) up-regulated hepatic 
SIRT mRNA and other specific genes involved in de novo NAD synthesis (Qprt 
and Nadsyn1) but not Tdo2 or any genes involved in salvage NAD+ biosynthesis 
pathway 180. Even though, intracellular NAD+ concentration and NAMPT levels 
was increased in LTKO mice (a triply null; FoxO1, FoxO3, and FoxO4) but there 
was no significant alteration of genes associated NAD synthesis pathway (Qprt, 
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Nadsyn1, Nmnat1-3) in LTKO mice 181 implying the dynamic mRNA regulation 
that might differ among different organs and tissues. We observed the stable in 
QPRT mRNA level upon FK866 re-exposure in CEM RES cells. But evidences 
of cell sensitivity to JPH203 and a synergistic effect of combined FK866 and 
JPH203 weightily indicated the involvement of LAT1 transporters responsible for 
amino acid translocation into the cells in particular tryptophan. IDO 
downregulation induces sensitivity to FK866 and others metabolic drugs such as 
gemcitabine and pemetrexed in human cancer cells 182. We detected a very low 
expression level of IDO in CCRF-CEM cells in compared to MDA MB231 cell line. 
Multi-drug resistance is not only solely achieved by enhanced efflux capacity but 
also by suppresses intake of the drug in leukemia 183,184. Even though, there was 
no significantly different in LAT1 expression between parental and resistant cells 
(Figure 30). But essential amino acid (AAE) was preferentially required to 
maintain cell survival in the resistance as well as tryptophan potentially rescued 
cell death during energetic stress from JPH203 and combined of FK866 and 
JPH203 (Figure 31 and 32). Consistent work was reported in Hela cells 
supporting that the CHOP gene is transcriptionally induced by amino acid 
starvation in particular leucine deprivation. Moreover, ATF4 and ATF2 were 
found to be involved in amino acid control of CHOP expression 86,185.  
MDA resistant model, a comparative model was developed to investigate the 
degree of generality of pharmacoresistance in cancer. Numerous common 
phenotypes were comparable to CEM RES cells including no alteration of ATP, 
restoration of NAD levels (Figure 19 and 38), dysfunction of translation control 
(Figure 20 and 39), and similarly down-regulation in NAMPT mRNA levels to 
escape from FK866 toxicity and likely potentiate an alternative biochemical 
mechanism of NAD production. Although two resistant models shared many 
common characteristics but they displayed distinct metabolic reprogramming 
acquiring energy source to fuel cell metabolism. Certainly, LAT1 was involved in 
CEM RES but not in MDA RES cells due to tryptophan served as a source to 
supply cell metabolism by sustained the production of NAD only in CEM RES 
cells. In a review of Chung and Gadupudi showed that tryptophan metabolites 
play a complementary role in promoting carcinogenesis in bladder tumor 186,187. 
Likewise, these metabolites from the IDO could also be involved in leukemia, 
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skin, breast, or lung cancer 186. However, here we revealed the dissimilar 
metabolic requirement between CEM RES and MDA RES cells by displaying an 
enhanced glycolysis dependency in CEM RES but not in MDA RES cells. In 
addition, phenomena in which cancer cells exhibit a cross-resistant phenotype 
which is known as multidrug resistance features such as enhanced drug efflux 
by overexpression of ABC transporters, decreased cellular uptake by changes in 
lipid membrane composition or drug detoxification by increases in drug 
metabolizing enzymes might be involved as causes for cell acquiring resistance 
as well as they could also be strategies to overcome drug resistance 153. 
Development of drug resistance commonly confers by gene mutation. Six 
mutations in the NAMPT gene have been reported in GNE-618 resistant cells 
derived from RD (rhabdosarcoma), MiaPaCa-2 (pancreatic cancer) and 
NCIH460 (non-small cell lung cancer) cell lines. Particularly, mutation at Ser 165 
residue of NAMPT in NCI-H460 cells turned cells to become resistant at high 
concentration of GNE-618 due to the unwinding of an α-helix that binds the 
NAMPT substrate PRPP 150. Additionally, we did not observe any mutations in 
NAMPT coding region neither in our CEM resistant nor parental cells. Down-
regulation of NAMPT level was observed in both CEM and MDA cells once cells 
gaining resistance to FK866 which was controversy to a report from Olesen and 
coworkers showing that over-expression of NAMPT associated with FK866 
resistance in HEK293T cells 69 denoting that high expressed NAMPT cancers 
display less sensitive to pharmacological events by NAMPT inhibitors. Genetic 
ablation of NAMPT might not be directly responsible for acquiring resistance to 
FK866. Most cancer cell lines were sensitive to FK866 treatment but diverse 
levels of NAMPT mRNA or NAD activity was not correlated with cells 
susceptibility to FK866 treatment. We unsuccessfully sought out the correlation 
between NAMPT or NAD levels to FK866 cell sensitivity (Figure 44). In this 
regard, the contribution of the different NAD+ biosynthetic pathway and the 
relevance of the utilization of extracellular NAD+ precursors to generate NAD 
may differ among different organs and tissues 188. Transiently overexpression of 
NAMPT failed to reestablish sensitivity of MDA RES toward FK866 in our system 
(Figure 43). This is probably due to cellular NAD level supplied from tryptophan, 
an alternative source of NAD synthesis was more dominant and sufficient to 
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sustain cell metabolism subsequent cell survival in the resistance, than those 
partial declined NAD level through inhibition of NAMPT by FK866 which exposed 
less impact to cell survival, as depicted in NAMPT overexpressed cells. 
Current strategies seek to address inevitable resistance mechanism such as the 
use of ganetespib (Hsp90 inhibitor) to overcome resistance of PARP inhibitors in 
breast cancer by targeting core protein in DNA repair machinery98. Recently, it 
has been demonstrated that treatment of cerdulatinib (dual SYK/JAK inhibitor) 
overcomes ibrutinib resistance in CLL by induced apoptosis 95 and targeting 
AMPK-ULK-mediated autophagy to combat BET inhibitor resistance has been 
explored in acute myeloid leukemia stemcells 97. The resistance to a standard 
chemotherapy of T-ALL, L-asparaginase has been found to link to ASNS 
expression which can be silenced through methylation 100. Most cancers express 
multiple genetic alterations or abnormalities, it is seldom very useful by only using 
one anticancer drug. Therefore, combination treatment displays promising 
results than single treatment. Combination of BRAF and MEK inhibitors has been 
reported to surpass outcomes compared with single therapy with either BRAF or 
MEK inhibitors alone in melanoma 189. Recently, costunolide and 
dehyrocostuslactone combination treatment has been shown to inhibit breast 
cancer by inducing apoptosis 190 as well as the use of Hsp90 inhibitor combined 
treatment with doxorubicin enhanced the cytotoxicity, apoptosis in non small cell 
lung cancer (NSCLC) 191. Similar report was shown by Bertaina and colleages 
that combination treatment of bortezomib with other chemotherapeutic agents 
including doxorubicin, vincristine and pegylated asparaginase provided 
therapeutic advance in childhood relapsed/refractory acute leukemia and 
lymphoma (ALL) 192. In addition, drug combination of NAMPT inhibitors with 
GMX1777(8) 193, PARP inhibitor 37, and CD73 inhibitor 188 have been found to 
improve the therapeutic levels in cancer. Indeed, here we documented that the 
great combination of FK866 with drugs associated amino acid metabolism 
including a LAT1 inhibitor (Figure 29) and L-asparaginase (Figure 34) effectively 
profound synergism in CEM RES cells, and in MDA RES cells (Figure 45E). 
Likewise, combined treatment of LDH inhibitors with phenformin or PFKPB3 
causes additive inhibition of bladder cancer cells 194. Furthermore, combined 
inhibition of glycolysis and pentose cycle selectively increases cytotoxicity in 
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breast and prostate cancer 171. High LDHA levels have been linked to poor 
prognosis in many cancers such as bone metastases, liver and lung cancer 195 
and with the concomitant of down regulation of LDHA levels in cancer cells by 
siRNA or shRNA stimulates mitochondrial respiration and reduces cellular 
proliferative and tumorigenic potential in vitro and in xenograft models 103,110,111. 
Suppression of LDHA by oxamate decreased the lactate production and inhibited 
tumor invasion in human gastric cancer cells 196, suppressed cell proliferation 
through induction of G2/M or G0/G1 in nasopharyngeal cells 197 as well as down-
regulated Warburg effect in glioblastoma 198. Oxamate is a pyruvate analogue 
which directly inhibits LDH and tissue lactate production in diabetes mice 199. 
Here in, we demonstrated that inhibition of LDHA was sufficient to induce 
significant cancer cell death promoted apoptosis in CEM RES cells (Figure 47). 
Consistently, treatment with quinolone 3-sulfonamids (a NADH-competitive 
LDHA inhibitor) promoted apoptosis in Snu398 cells 110. CEM RES could be more 
vulnerable to LDH blockade due to the overall lower capacity of their 
mitochondria function in cancer stem cells which has also been consistent to a 
recent report in CSCs isolated from glioblastoma 200. Ablation of LDHA in MDA-
RES cells by siRNA significantly increased the sensitivity of FK866-MDA RES 
cell towards FK866 treatment as evident by CHOP/ATF4 activation (Figure 51B, 
C). Interestingly, our current observations were consistent to the studies in 
human breast cancer where down-regulating LDHA by siRNA resensitized the 
sensitivity of Taxol-resistant cells to taxol treatment 104. Thus, by exploiting the 
altered metabolism of cancer resistance as reported here by targeting LDH, this 
may offer novel opportunities for selective therapeutic targeting of cancer cells 
particularly the cancer addicted to aerobic glycolysis for survival as part of 
combinatorial approach to other metabolic drugs. 
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CONCLUSION 
Loss of protein translation inhibition and down-regulation of NAMPT level were 
evidently observed in both CEM and MDA resistant models. Here in, we revealed 
the distinct in molecular of pharmacoresistance between two cell lines as 
summarized in Table 2. We highlighted that FK866 CEM RES cells utilized L-
tryptophan as an alternative source for NAMPT-independent NAD synthesis 
pathway and metabolic alterations once cells acquired resistance led to profound 
an enhanced glycolysis dependency consistent with the Warburg phenotypes 
which could be tracked by increase in glycolysis enzymatic activity and lactate 
production concomitant the reduction of mitochondria ATP production and low 
oxygen consumption. Eventhough, initial distinction in glycolytic status among 
CEM and MDA may cause the difference mechanism in FK866 resistance but 
LDH hypothetically plays pivotal roles in metabolic regulation and acquiring 
resistance to FK866. More importantly, our finding suggests the used of FK866 
in combination with other drugs targeting metabolism may improve the clinical 
strategy to overcome cancer resistance in particular of those rely on aerobic 
glycolysis for survival. 
  
	98	
Table 2 Summary of the characterization in parental and FK866 resistant 
models 
Treatments or categories 
Cell lines 
CEM PA CEM RES MDA PA MDA RES 
FK866  
(NAMPT inhibitor) 
Highly 
sensitive Resistant sensitive Resistant 
CHS-828  
(NAMPT inhibitor) 
Highly 
sensitive Resistant sensitive Resistant 
NAMPT levels  *down regulated  *down regulated 
Protein translation control arrested No inhibition arrested No inhibition 
ATP with FK866 treatment Highly sensitive no response 
Highly 
sensitive no response 
NAD with FK866 treatment Highly sensitive Partially sensitive 
Highly 
sensitive 
Partially 
sensitive 
JPH203  
(LAT1 inhibitor) 
Partially 
sensitive Highly sensitive - - 
L-Asparaginase Partially sensitive Highly sensitive 
Partially 
sensitive 
Partially 
sensitive 
2DG (inhibitor of glucose 
metabolism) 
Partially 
sensitive Highly sensitive - - 
Oligomycin (inhibitor of 
mitochodria ATP syntase) - - sensitive sensitive 
Metabolic alteration  *Enhanced glycolysis no alter no alter 
GSK (LDH inhibitor) sensitive Highly sensitive (Apoptosis) 
Partially 
sensitive Sensitive 
* Pair comparison was evaluated between parental vs resistance of each cell line. 
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SECOND PROJECT 
 
 
 
 
 
CHARACTERIZATION OF SMALL MOLECULE OF  
PKC INHIBITORS THAT SPECIFICALLY MODULATE YAP 
FUNCTIONALITY IN PDAC CELLS 
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BRIEF SUMMARY 
In 2016, we published a research article “The GSK3β inhibitor BIS I reverts 
YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs 
expression level” in Oncotarget Journal 201. This publication reflects my 
personal contribution to the work as the first-coauthor. For clarify, I myself 
performed and had fully involved in most experiments except initial drug 
screening, two-dimension western blotting analysis and ChIP assay which were 
conducted by Ilaria Castiglioni (Laboratory of Gene Expression and Muscular 
Dystrophy, San Raffaele Scientific Institute, Milan, Italy). I decided to describe 
this work in this session as the second project due to all results were published 
in Oncotarget Journal (2016) and I could not represent them all again as result 
figures in my thesis body. Full article is enclosed in Appendix (page 142). 
Research background, finding results represented as Figures following 201, and 
discussion were briefly summarized in this session. 
Background 
Pancreatic ductal adenocarcinoma (PDAC) is a type of exocrine pancreas which 
is the most common malignancy of pancreas 202. PDAC is generally thought to 
arise from pancreatic ductal cells 203. Molecular and pathological analysis of 
PDAC has discovered a characteristic pattern of genetic lesions. Mutations of 
KRAS, CDKN2A, TP53, BRCA2 and SMAD4/DPC4 have been shown to drive 
pancreatic neoplasia (Figure 52) 204. In particular mutation of KRAS has been 
reported to increase in frequency with disease progression, and frequently found 
in PDAC 202.  
The Hippo pathway is an evolutionarily conserved regulators for cell growth, 
apoptosis, development and migration in many cancers 205,206. It is also crucial 
for stem cell self-renewal and the maintenance of genomic stability 206. YAP 
functions have been found to be regulated by the multiple post-translational 
modifications (PTMs) 207. The Hippo signaling pathway, initially well-described as 
an organ size regulator in Drosophila 202. This kinase cascade is able to 
negatively regulate YAP localization and activity, by phosphorylating YAP at 
Ser127 201,205. Phosphorylation of YAP by the Hippo pathway leads to its 
accumulation in the cytoplasm and, by interaction with 14–3–3 proteins. YAP is 
degraded by a ubiquitination-dependent proteasomal process 205,206 as illustrated 
in Figure 53. Therefore, the Hippo pathway negatively regulates YAP 
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functionality and presence in the nucleus by modulating its cell distribution and 
its protein expression levels201. The Hippo pathway-induced phosphorylation of 
YAP is regulated according to cell density 205. Importantly, at low density, YAP is 
predominantly localized in the nucleus while YAP translocates to the cytoplasm 
at high cell density as depicted in PDAC cell lines 201. Nuclear localization of YAP 
protein is associated with TAZ which is its co-transcriptional activity 205,208. In 
addition, the core of the Wnt signaling pathway has been involved the regulation 
of β-catenin which is its nuclear transducer. Wnt cytoplasmic destruction complex 
consists of Axin that interacts with other factors, including adenomatous 
polyposis coli (APC), CK1, and glycogen synthase kinase-3 (GSK3) 209. In 
absence of Wnt signaling, the destruction complex targets β-catenin to 
degradation through β-catenin phosphorylation by GSK3 and its ubiquitination by 
β-TrCP. The presence of Wnt ligand results in functional inactivation of the 
destruction complex, leading to the accumulation of free β-catenin. Translocation 
of β-catenin to the nuclear where it forms complex to DNA-binding partners 
TCF/Lef triggering the downstream target of wnt signaling 205. Interestingly, some 
Wnt target genes are under joined control of both YAP/TAZ and β-catenin, in a 
sort of “double-assurance” mechanism 209,210. For example, both YAP/TEAD and 
β-catenin/TCF bind cooperatively to cognate promoter elements in the Sox2 and 
Snai2 genes in cardiomyocytes 210; and in colorectal cancer cells, YAP and  
β-catenin seem to share a common DNA-binding platform of TBX5 the 
transcription factor regulation the transcription of Birc5 and Bcl2/2 pro-survival 
genes 209. 
However, YAP has been shown the crosstalk to many signaling pathways. YAP 
function is mediated by the the upstream stimuli or the binding to its down-stream 
targets. TEAD family was found to be critical partners of YAP in the regulation of 
gene expression such as CTGF which has been identified as a direct target gene 
of YAP-TEAD in mammalian cells 201,211. CTGF is crucial in mediating the growth-
stimulating and oncogenic function of YAP-TEAD complex 212 but its 
transcriptional expression depends on the contribution from other YAP 
interacting transcription factors such as SMADs 208. Smad2/3, are direct targets 
of the TGFβ. The phosphorylation of Smad2 and Smad3 induces complex 
formations with Smad4 in the nucleus where triggering activators or repressors 
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orchestrate transcription (Figure 54) 207,213. In PDAC mouse models, YAP is a 
vital promoter of mutant KRAS oncogenic program, specifically inducing the 
expression of CTGF and CYR61 which are direct downstream target of YAP 204 
Moreover, YAP associated with FOS involved to Epithelial to Mesenchymal 
Transition (EMT) by regulating the expression of genes such as E-cadherin, 
SLUG, SNAIL and Vimentin 214. In pancreatic cancer development, YAP 
potentially plays an important role in EMT 201. Therefore, the identification of 
inhibitors of YAP activity could be suitable as a new therapeutic option for PDAC 
treatment.  
 
 
Figure 52 Genetic progression model of pancreatic adenocarcinoma. 
Pancreatic intraepithelial neoplasias (PanINs) seem to represent progressive stages of 
neoplastic growth that are precursors to pancreatic adenocarcinomas. Activating KRAS 
mutations are the first genetic changes that show the earliest stages of histological 
disturbance in pancreatic. The stage of onset of these lesions is depicted. The thickness 
of the line corresponds to the frequency of a lesion 203.  
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Figure 53 Schematic model of the Hippo signaling cascade in mammals 206. 
 
Figure 54 Schematic model of CTGF promoter activation through TGF-β/Smad 
signaling and Hippo pathway 
Genetic disturbance in NF2 and/or Lats2, Yap was dephosphorylated and constitutively 
translocated to the nucleus. On the other hand, upon TGF-β stimulation, Smad2/3 and 
Smad4 associate, move to the nucleus, make a complex with YAP/TEAD, and recruit 
p300 to the promoter to activate CTGF expression 207. 
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Results and discussion 
Refer to the publication of Thongon, et al. 2016 “The GSK3β inhibitor BIS I 
reverts YAP-dependent EMT signature in PDAC cell lines by decreasing 
SMADs expression level” in Oncotarget Journal 201. (page 141) 
We aimed to to identify compounds that can specifically modulate YAP 
functionality in PDAC cell lines. We initially performed a small-scale high-
content screening for the identification of PKC inhibitors which able to interfere 
with YAP localization and functionality. The screening part was conducted by 
Ilaria Castiglioni. This approach allowed us to assign to the widely used Receptor 
Tyrosine Kinase (RTK) Inhibitor, erlotinib, the ability to sequester YAP into the 
cytoplasm blocking its co-transcriptional function (as shown in Table 1, Thongon, 
et al. 2016). Importantly, we found a small molecule, GF 109203X (BIS I), induces 
YAP nuclear accumulation and activation. In this study, we showed that BIS I, an 
inhibitor of the PKCδ/GSK3β pathway, reverts the EMT transcriptional program 
in PDAC cell lines inhibiting the TGF-β pathway and de-potentiating YAP 
contribution to EMT via down-regulation of SMAD2/3.  
YAP regulates anchorage-independent growth in PDAC cell lines.  
Figure 1, figure title “Importance of YAP in PDAC cell lines”.  
I have contributed to all experiment in this figure. 
Expression level of YAP in a panel of four PDAC cell lines were determined using 
western blotting and qRT-PC. PANC1 and PK9 exhibited moderate to high YAP 
protein levels, respectively, in comparison to BXPC3 and MIAPACA2 cells 
(Figure 1A) indicating diverse expression levels of YAP among different cell 
lines. Cell density regulates phosphorylation and localization of YAP via the 
Hippo signaling pathway 206. At high density of cell, YAP predominantly localized 
in cytoplasm while YAP appears mainly in the nucleus in sparse cell condition 
which has been reported in breast cancer cells 205,215. We observed that sub-
cellular distribution of YAP protein was equivalent in both cases with PANC1 
cells, but YAP significantly shuttled from nucleus to the cytoplasm at high cell 
density in PK9 cells, as determined by high content imaging analysis (Figure 
1B). To understand the YAP functionality, we down-regulation YAP by using 
shRNA then evaluated CTGF and CYR61 mRNA levels, known targets of YAP. 
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they were significantly reduced in shYAP-PANC1 and shYAP-PK9 (Figure 1C). 
On the other hand, CTGF expression was found to be increased in YAP 
overexpression (O/E) both in PK9 and in PANC1 (Figure 1D). Interestingly, 
ablation of YAP inhibited anchorage-independent growth in PANC1 cells in soft 
agar (Figure 1E). Therefore, in PDAC cell lines cultured at high-density, YAP is 
partially redistributed in the cytoplasm, it has a transcriptional effect controlling 
the expression of known target genes, it regulates proliferation and the ability of 
PDAC cells to grow in anchorage-independent conditions.  
BIS I changes YAP co-transcriptional activity and inhibits anchorage 
independent growth.  
Figure 2, figure title “Identification of modulators of YAP localization” 
I have contributed in Figure 2B-D. Figure 2A and 2F were performed by Ilaria 
Castiglioni.  
From the screening, we found a small molecule BIS I that induces YAP nuclear 
accumulation and activation in PK9 cells (Figure 2A and Table 1). BIS I is a cell-
permeable and reversible inhibitor of protein kinases C (PKCs) both conventional 
and atypical, but also of GSK3β 216. We observed that BIS I activated TEA-
reporter and down-regulated CTGF and CYR61 mRNA expression (Figure 2B-
C), and induced YAP nuclear localization in PDAC cell lines, confirming the 
indication coming from the screening experiment (Figure 2D). Hippo signaling 
pathway was not directly involved in the observed PTMs because we did not 
observed a change at the phosphorylation state of YAP-S127 and LATS-S909 
(Figure 2F).  
Figure 3, figure title “BIS I treatment phenocopies YAP functional 
ablation” 
I have contributed in Figure 3A-B. Figure 3C was performed by Ilaria Castiglioni.  
BIS I amplified TEA reporter signaling in the basal conditions in PANC1 cells and 
during YAP overexpression both in PK9 and PANC1 cells (Figure 3A). 
Unexpectedly, BIS I significantly suppressed CTGF and CYR61 mRNA 
expression but slightly increased AREG and BIRC5 mRNA expression in PK9 
and PANC1 cells at 24 hours of treatment, indicating that functional roles of BIS I 
mimicking YAP ablation (Figure 3B). To evaluate if BIS I displaces YAP from 
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CTGF promoter, even though YAP is located in the nucleus but we performed 
chromatin immunoprecipitation of YAP and evaluated the amplification of the 
CTGF promoter [31]. Indeed, YAP was no more associated with the CTGF 
promoter during BIS I treatment, but TEAD1 was still present (Figure 3C).  
Figure 4, figure title “The CTGF expression level was modulated by the 
TGF-β and Hippo pathways in PDAC”  
I have contributed to all experiment in this figure. 
Interestingly, we observed that BIS I inhibited TGF-β induced CTGF expression 
in a YAP independent manner (Figure 4A) and it down-regulated SMAD2/3 
protein levels in PK9 cells (Figure 4B). Most importantly, BIS I was readily 
effective in reducing the anchorage-independent growth of PDAC cell lines. BIS 
I reduced the total number of colonies of PANC1, MIAPACA2, and PK9 and 
reduced the colony dimensions of PANC1 and PK9 but increasing MIAPACA2 
ones (Figure 4C). Taken together, BIS I induced YAP into the nucleus and 
triggered TEAD response. However, BIS I inhibited anchorage-independent 
cancer cell growth and proliferation, phenocopying YAP ablation and inhibiting 
TGFβ-dependent cell response by decreasing the expression of SMADs and 
SMAD/YAP co-regulated genes.  
Given the relative specificity of BIS I for PKCδ/GSK3β, while Go9676 is more 
specific for PKCα, we hypothesized that PKCδ/GSK3β ablation could mimic BIS 
I treatment. Transient silencing of PKCδ and GSK3β were performed in PK9 
cells. The results showed that CTGF decreased during PKCδ and GSK3β down-
regulation indicating the link of the activity of these two kinases in CTGF 
expression regulation (Figure 4D). Silencing of GSK3β activated TEA reporter 
only in the presence of YAP overexpression, similarly to BIS I treatment and 
reduced the expression of SMAD3 mRNA (Figure 4E) as BIS I treatment.  
CD133 gene expression is regulated by YAP and inhibited by BIS I. 
Figure 5, figure title “BIS I activates β-catenin and downregulates the 
expression level of cancer staminality genes” 
I have contributed to all experiment in this figure.  
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Since the association of YAP to the WNT/β-catenin destruction complex has 
been reported 209, we evaluated the activation of the WNT/β-catenin signaling in 
PDAC cell lines during BIS I treatment. We performed a reporter assay with a 
construct expressing luciferase under TCF binding site (TOPFlash) or a mutated 
one (FOPFlash). BIS I significantly induced WNT/β-catenin reporter activity in all 
of the PDAC cell lines and also in HEK293T cells (Figure 5A) as well as induced 
the accumulation of β-catenin in the nucleus (Figure 5B). Coherently, Go9676 
did not activate TCF/LEF reporter nor induced β-Catenin into the nucleus (Figure 
5A, 5B). Since, YAP and β-Catenin play role in regulating differentiation, we 
further investigated if BIS I could affect the expression levels of stemness 
markers of PDAC. Among of those checked markers, CD133 was up-regulated 
upon β-Catenin over-expression (Figure 5C) but it was suppressed during BIS I 
treatment (Figure 5D). Interestingly, only CD133 was affected by YAP and 
GSK3β silencing (Figure 5E and 5F). Moreover, YAP overexpression induced 
the up-regulation of CD133 that was blocked by BIS I (Figure 5G). Therefore, 
these results identified CD133 as a new gene regulated by YAP and GSK3β.  
YAP-dependent EMT transcriptional program is inhibited by BIS I.  
Figure 6, figure title “BIS I reverts YAP-induced EMT in PDAC cell lines” 
I have contributed to all experiment in this figure. 
BIS I induced YAP and β-Catenin nuclear accumulation by inhibiting the 
PKCδ/GSK3β pathway. CD133 is a new critical regulator of EMT in PDAC. We 
revealed the different expression levels of E-cadherin in PDAC (Figure 6A, 6B) 
in which PK9 and BxPC3 cell lines showed high E-cadherin protein expression 
whereas PANC1 and MIAPACA2 expressed very low to undetectable E-cadherin 
protein levels (Figure 6A). This expression profile of E-cadherin in PDAC is 
consistent with its mRNA levels (Figure 6B). Our results show that endogenous 
levels of E-cadherin are inversely correlated with the anchorage-independent 
growth ability of these PDAC cell lines (Figure 4C). Importantly, EMT signature 
was dependent on YAP as, in shYAP-PK9 and shYAP-PANC1, E-cadherin and 
CD133 expression was reverted.  
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Figure 7, figure title “Genetic ablation of YAP and BIS I treatment regulate 
cell migration” 
I have contributed to all experiment in this figure.  
During BIS I treatment, the clonogenic and migration abilities of PDAC, markers 
of EMT, were completely inhibited (Figure 4C, 7A). Migration of PANC1 cells 
decreased by administration of BIS I in shYAP PANC1 cells at 48 hours (Figure 
7A). More notably, BIS I was able to revert the EMT signature by restoring  
E-Cadherin expression, as well as by regulating other EMT markers as Vimentin, 
ZEB1 and CD133 also in the presence of TGF-β (Figure 5G, 7B, 7C, 7D).  
Conclusion 
In this study, we revealed that BIS I, an inhibitor of the PKCδ/GSK3β pathway by 
inducing displacement of YAP from CTGF promoter, displaying a loss of function 
of nuclear YAP on specific genes, likely driven by the loss of SMADs partner and 
de-potentiating YAP contribution to EMT via down-regulation of SMAD2/3. BIS I 
induced the downregulation of many cancer stem genes, CD133 included. We 
found that this new marker of EMT is highly regulated as YAP, GSK3β, and  
β-catenin modulated CD133 expression, addressing this gene as a co-regulated 
gene by these three factors which may establish critical roles in maintaining 
pancreatic cancer.  
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CONTRIBUTION PROJECTS 
During my PhD I have also been involved into 2 other side projects as following; 
1st project is mainly focus on the RNA binding protein HuR/ELAVL1, a widely 
characterized eukaryotic post-transcriptional regulator. HuR mediates cellular 
response to different kinds of stimuli, namely proliferation, survival and apoptosis, 
helping to determine cell fate by binding to many target mRNAs and influencing 
their splicing, shuttling, stability and translation efficiency. An impaired 
localization and activity of HuR have been associated with many forms of cancer 
and the protein has generated interest as a potent drug target. 
This project led to two publications, I have contributed as a co-author. 
“Targeting the Multifaceted HuR Protein, Benefits and Caveats”  
Zucal C et al., Curr Drug Targets 2015. 
“Dihydrotanshinone-I interferes with the RNA-binding activity of HuR 
affecting its posttranscriptional function” 
D’Agostino VG et al., Sci Rep 2015. 
2nd project is mainly focus on the effect of Dexamethasone and understanding 
the pharmacological features of NAMPT inhibitor and Dexamethasone cross 
resistance modulated by glucocorticoid receptor (GR) regulation in leukemia and 
glioblastoma. To date, it is an ongoing project in collaboration with Michele Cea 
(MD. PhD), and Alessio Nencioni (PhD) from Department of Internal Medicine, 
University of Genoa, Genoa, Italy.  
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LIST OF PUBLICATIONS 
 
No Publication Type Title 
1 Research article “The GSK3β inhibitor BIS I reverts YAP-dependent EMT 
signature in PDAC cell lines by decreasing SMADs expression 
level.”  
N. Thongon, I. Castiglioni, C. Zucal, E. Latorre, V. D’Agostino, I. 
Bauer, M. Pancher, A. Ballestrero, G. Feldmann, A. Nencioni, 
and A. Provenzani, Oncotarget, vol. 7, no. 18, 2016 (IF:5.008). 
 
2 Patent "Nuovi derivati aza-tanshinonici, procedimento per la loro 
preparazione e loro uso in terapia"  
Alla domanda è stato assegnato il seguente 
numero:102016000061247 (14/06/2016) 
 
3 Research article “EIF2a-dependent translational arrest protects leukemia cells 
from the energetic stress induced by NAMPT inhibition.”  
C. Zucal, V. G. D’Agostino, A. Casini, B. Mantelli, N. Thongon, 
D. Soncini, I. Caffa, M. Cea, A. Ballestrero, A. Quattrone, S. 
Indraccolo, A. Nencioni, and A. Provenzani, BMC Cancer, vol. 
15, no. 1, p. 855, Jan. 2015. (IF:3.265). 
 
4 Research article “Dihydrotanshinone-I interferes with the RNA-binding activity 
of HuR affecting its post-transcriptional function.” 
V. G. D’Agostino, P. Lal, B. Mantelli, C. Tiedje, C. Zucal,  
N. Thongon, M. Gaestel, E. Latorre, L. Marinelli, P. Seneci, M. 
Amadio, and A. Provenzani, Sci. Rep., vol. 5, no. October, p. 
16478, 2015. (IF: 5.228). 
 
5 Review article “Targeting the Multifaceted HuR Protein, Benefits and 
Caveats.”  
C. Zucal, V. D’Agostino, R. Loffredo, B. Mantelli, N. Thongon,  
P. Lal, E. Latorre, and A. Provenzani, Curr. Drug Targets, vol. 16, 
no. FEBRUARY, pp. 1–17, 2015. (IF:3.029). 
 
 Research article My thesis project, Molecular mechanism of 
phamacoresistance to NAMPT inhibitor in cancers 
(Manuscript preparation). 
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APPENDIX 
 
 
Supplementary Figure 1 Evaluation the activity of enzymes involved NAD 
biosynthesis pathway. 
CEM PA and CEM RES cells were treated with FK866 for 48h, they were then subjected 
for enzymatic assay evaluating for (A) NADS, (B) NAD, (C) NRK, (D) NMNAT, and (E, 
F) NMN as described in 146. 
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Table 3 Sequences of primers 
	
Name Primer sequence 5' ⇒ 3' 
NAMPT NC_000007.14 (sigma) 
LDHA NM_001135239 (sigma) 
HK2 NM_000189 (sigma) 
ND1 
FW ATGGCCAACCTCCTACTCCT 
RV TAGATGTGGCGGGTTTTAGG 
ND2 
FW CCGGACAATGAACCATAACC 
RV TCAGAAGTGAAAGGGGGCTA 
ND3 
FW CCCTCCTTTTACCCCTACCA 
RV GGCCAGACTTAGGGCTAGGA 
ND5 
FW ACCTGCCCCTACTCCTCCTA 
RV TATGCCTTTTTGGGTTGAGG 
NDL4 
FW TAACCCTCAACACCCACTCC 
RV GGCCATATGTGTTGGAGATTG 
COX3 
FW TCCACTCCATAACGCTCCTC 
RV GTGGCCTTGGTATGTGCTTT 
ATP8 
FW ATGGCCCACCATAATTACCC 
RV TTTTATGGGCTTTGGTGAGG 
CHOP 
FW       AGAACCAGGAAACGGAAACAGA 
RV       TCTCCTTCATGCGCTGCTTT 
ATF4 
FW      GTTCTCCAGCGACAAGGCTA 
RV       ATCCTGCTTGCTGTTGTTGG 
ASNS1 
FW GCACGCCCTCTATGACAATG 
RV TTCAACAGAGTGGCAGCAAC 
KYNU 
FW ATTCCTGCCATCACAAAAGC 
RV TTTCATGAATGAAGGCACCA 
QPRT 
FW1  CCCTCTGGGTCACACATCTT 
RV1 GTGCTCATTATCACCGCAGA 
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EIF2A-dependent translational arrest
protects leukemia cells from the energetic
stress induced by NAMPT inhibition
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Abstract
Background: Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ biosynthesis
from nicotinamide, is one of the major factors regulating cancer cells metabolism and is considered a promising
target for treating cancer. The prototypical NAMPT inhibitor FK866 effectively lowers NAD+ levels in cancer cells,
reducing the activity of NAD+-dependent enzymes, lowering intracellular ATP, and promoting cell death.
Results: We show that FK866 induces a translational arrest in leukemia cells through inhibition of MTOR/4EBP1
signaling and of the initiation factors EIF4E and EIF2A. Specifically, treatment with FK866 is shown to induce
5′AMP-activated protein kinase (AMPK) activation, which, together with EIF2A phosphorylation, is responsible for the
inhibition of protein synthesis. Notably, such an effect was also observed in patients’ derived primary leukemia cells
including T-cell Acute Lymphoblastic Leukemia. Jurkat cells in which AMPK or LKB1 expression was silenced or in
which a non-phosphorylatable EIF2A mutant was ectopically expressed showed enhanced sensitivity to the NAMPT
inhibitor, confirming a key role for the LKB1-AMPK-EIF2A axis in cell fate determination in response to energetic
stress via NAD+ depletion.
Conclusions: We identified EIF2A phosphorylation as a novel early molecular event occurring in response to
NAMPT inhibition and mediating protein synthesis arrest. In addition, our data suggest that tumors exhibiting an
impaired LBK1- AMPK- EIF2A response may be especially susceptible to NAMPT inhibitors and thus become an
elective indication for this type of agents.
Keywords: NAMPT, EIF2A, AMPK, Energetic stress, Translation arrest, UPR
Background
Aberrant activation of metabolic pathways has emerged as
an hallmark of proliferating cancer cells and pharmaceut-
ical approaches targeting cell metabolism hold potential
for treating cancer [1]. Nicotinamide adenine dinucleotide
(NAD+) plays a key role in different biochemical processes,
acting as a coenzyme in redox reactions or as a substrate
for NAD+ degrading enzymes, such as poly(ADP-ribose)
polymerases (PARPs), cluster of differentiation 38
(CD38), and sirtuins. Intracellular NAD+ is continuously
replenished utilizing either tryptophan, nicotinamide, nico-
tinic acid or nicotinamide riboside as a substrate [2], and
nicotinamide phosphoribosyltransferase, NAMPT, is the
rate-limiting enzyme for NAD+ biosynthesis from nicotina-
mide in mammalian cells [3]. High NAMPT levels, whose
activity appears to be also important in the differentiation
of myeloid cells [4], were shown to be required to support
cancer cell growth, survival and epithelial-mesenchymal
transition (EMT) transition [5, 6], and have been reported
in different types of tumors [7, 8]. In line with these no-
tions, several studies have highlighted a strong activity of
NAMPT inhibitors in preclinical models of inflammatory
and malignant disorders, including leukemia [2, 9–11].
FK866, a prototypical NAMPT inhibitor, was found to
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promote cell death in both lymphoid- and myeloid-derived
hematological malignancies and its activity clearly resulted
from intracellular NAD+ depletion [12–14]. Notably,
opposite to cancer cells, activated immune cells [10], along
with many other types of healthy cells, such as
hematopoietic stem cells [12], appear unaffected by
NAMPT inhibitors, and consistently, agents such as FK866
or CHS-828 are well tolerated in patients [15, 16].
The molecular consequences upon NAMPT inhibition
are only partially understood. The induced NAD+ deple-
tion clearly affects intracellular ATP levels resulting in
mitochondrial dysfunction and activation of cell death
pathways: reactive oxygen species generation and activa-
tion of the apoptotic cascade have both been involved in
cell demise in response to NAMPT inhibitors [17]. ATP
depletion has been related to the loss of plasma mem-
brane homeostasis invariably leading to oncosis cell death
[18]. Different groups have suggested a role for autophagic
cell death in the cytotoxic activity of these drugs [10, 12,
13, 19]. In particular, Cea and colleagues proposed that
FK866 would induce autophagy via activation of
transcription factor EB (TFEB), a master regulator of
the lysosomal-autophagic pathway [20], and through
MTORC1/AKT and ERK1/2 pathway inhibition [21].
There is also evidence that AMP-activated protein kinase
(AMPK), an important coordinator of metabolic pathways
in response to energetic fluctuations [22], is activated by
FK866 in prostate cancer cells affecting lipogenesis [23]
and in hepatocarcinoma cells with impact on MTOR/
4EBP1 signaling [24]. Moreover, NAMPT-dependent
AMPK activation associated with deacetylation of liver
kinase B1 (LKB1), an upstream kinase of AMPK, has been
linked with modulation of NAD levels and with significant
impact on neuron cell survival [25]. Translation inhibition
is often observed during cell stress [26] and this event
often involves a re-programming of translation leading to
differential regulation of mRNAs, occurring also via alter-
native mechanisms, aimed at reorganizing cell physiology
to respond to the insult.
In this study, we focused on the pre-toxic molecular
events induced by FK866 in acute lymphoblastic leukemia
cells, known to be sensitive to the drug [10], in order to
define the molecular mechanism favoring cell death or cell
survival. A marked global protein synthesis inhibition rep-
resented an early cellular response associated with the
FK866-induced energetic stress and here we show that
AMPK-EIF2A is a central hub in mediating this effect and
is responsible for cell fate decisions.
Methods
Cell lines, primary B-CLL cell and T-ALL PDX isolation
Human Jurkat T-cell acute lymphoblastic leukemia (T-
ALL) cells were purchased from the InterLab Cell Line
Collection bank (ICLC HTL01002). SUP-T1 cells were
purchased from ATCC (CRL-1942) and Molt-4 Clone 8
from NIH AIDS Reagent Program (Catalog #: 175).
Human lung carcinoma A594 (CCL-185) and H460
(HTB-177) cells were purchased from ATCC. These cells
were transduced with retroviral vectors encoding either
LKB1 cDNA (pBABE-LKB1) or the pBABE control vec-
tor. Cell lines were grown in complete RPMI 1640
(Gibco Life Technologies) supplemented with 10 % fetal
bovine serum (FBS, Lonza), 2 mM L-glutamine, 100 U/
ml penicillin-streptomycin (Lonza). All cell lines were
grown at 37 °C under 5 % CO2 and regularly tested for
mycoplasma contamination. For primary B-CLL cell iso-
lation, a 5 ml blood sample was obtained from patients
presenting with marked lymphocytosis (>20000/μl) ac-
cording to a protocol that was approved by the Ethics
Committee of the Hospital IRCCS AOU San Martino
IST in Genoa (#840, February 18th 2011). Patients’ writ-
ten informed consent was collected. B-CLL cells were
isolated by density gradient centrifugation on Ficoll-
Hypaque (Biotest). The phenotype of the obtained cell
preparations was confirmed by immunostaining with
anti-CD19, anti-CD5, and anti-CD23 (Immunotech), and
subsequent flow cytometric analysis. T-ALL xenografts
(PD T-ALL) were established from BM (bone marrow) of
newly diagnosed ALL pediatric patients, according to a
protocol approved by the ethics committee of the Univer-
sity of Padova (Project number 16B/2013). The PD T-ALL
cells used in this study have been published elsewhere
[27]. At time of PD T-ALL establishment, written in-
formed consent was obtained from the parents of the chil-
dren. In vitro studies were performed with T-ALL cultures
established from the spleen of the xenografts. Purity of the
cultures (in terms of percentage of human CD5+ cells)
was checked by flow cytometry and was always >85 %. Re-
search carried out on human material was in compliance
with the Helsinki Declaration.
Chemicals
FK866 (sc-205325) was bought from Santa Cruz, Com-
pound C (P5499), Nicotinic acid (N0761), Actinomycin
D (A9415), (S)-(+)-Camptothecin (C9911), Cyclohexi-
mide (C1988), MG-132 (M7449), Doxorubicin hydro-
chloride (D1515) and Dexamethasone (D4902) were
bought from Sigma-Aldrich, CHS-828 (200484-11-3)
from Cayman chemical, Torin 1 (S2827) and Rapamycin
(S1039) from Selleck Chemicals, Cisplatin (ALX-400-
040) from Enzo Life Sciences and Propidium Iodide
Staining Solution from BD Pharmingen. Jurkat cells were
treated with drugs dissolved in DMSO at the same cell
density (5X105 cells/ml).
Viability assays
Cell viability was assessed with the Annexin V-FITC
Apoptosis Detection Kit I and 7-Aminoactinomycin D
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(7-AAD) Staining Solution (BD Pharmingen) according
to manufacturer’s instruction. EC50 values of FK866 were
determined by nonlinear regression analysis (GraphPad
Prism software v5.01,) vs viable cells in mock conditions
(DMSO).
Jurkat, A549 and H460 cell lines were grown and
treated in 96 well-plate for 48 h. Cells were then assayed
for viability using Thiazolyl blue tetrazolium bromide
(MTT) M5655 (Sigma). In brief, MTT (5 mg/ml) at
10 % volume of culture media was added to each well
and cells were further incubated for 2 h at 37 °C. Then
100 μl of DMSO was used to dissolve formazan. Absorb-
ance was then determined at 565 nm by microplate
reader. Cell survival was calculated and EC50 values were
determined.
Determination of NAD+-NADH and ATP levels and
caspase/protease activity
Intracellular NAD+-NADH content was assessed with a
NAD+-NADH Quantification Kit (BioVision) according to
the manufacturer’s protocol. Intracellular ATP content
was determined using Cell titer Glo Luminescent Cell Via-
bility Assay (Promega). NAD+-NADH and ATP values
were normalized to the number of viable cells as deter-
mined using Trypan Blue (Lonza). EnzChek Protease
Assay Kit, containing a casein derivative labeled with
green-fluorescent BODIPY FL (Life Technologies), was
used to determine protease activity after treatment of
2x106 cells. Cells were washed once with PBS and lysed in
500 μl of 1X digestion buffer, sonicated and centrifuged
for 5 min at maximum speed. One μl of the BODIPY ca-
sein 100X was added to 100 μl of the supernatant and in-
cubated for 1 h protected from light. Fluorescence was
measured and normalized to protein concentration in the
cell lysates (Bradford Reagent, Sigma). Caspase-Glo 3/7
Assay (Promega) was used to quantify caspase activity.
RNA and protein click-iT labeling kits
Click-iT RNA Alexa Fluor 488 Imaging Kit (Life Tech-
nologies) was used to quantify the level of global RNA
synthesis by flow-cytometry. Jurkat cells (3x106/sample)
were treated for 45 h with FK866 (or DMSO) and then
incubated for 3 h with 1X EU working solution without
removing the drug-containing media. EU detection was
performed following the manufacturer’s protocol after
cell fixation and permeabilization. Click-iT AHA Alexa
Fluor 488 Protein Synthesis Assay (Life Technologies)
was used to measure the rate of translation. Cells
(3x106/sample) were treated for 45 h with FK866, centri-
fuged and incubated for 3 h with 50 μM AHA in L-
methionine-free medium (RPMI Medium 1640,
Sigma-Aldrich) containing the drug (or DMSO). After
fixation and permeabilization, AHA incorporation was
assessed by flow cytometry. 7-AAD Staining Solution
(0.25 μg/sample) allowed the exclusion of non-viable cells.
Western blotting, antibody list and plasmids
Cells were lysed for 5 min on ice in RIPA lysis buffer
supplemented with Protease Inhibitor Cocktail (Sigma-
Aldrich). After sonication and clarification, equal amounts
of proteins were separated by SDS–PAGE and blotted
onto PVDF membranes (Immobilon-P, Millipore), as in
[28]. The antibodies used were: 4EBP1 (sc-6936), p-4EBP1
(Ser 65/Thr 70; sc-12884), EIF4E (sc-9976), p-EIF4E (Ser
209; sc-12885), AKT1/2/3 (sc-8312), p-AKT1/2/3 (Ser
473; sc-7985), MTOR (sc-8319), BCL-2 (sc-509), NAMPT
(sc-130058) from Santa Cruz; EIF2S1 (ab26197), p-EIF2S1
(Ser 51; ab32157), and p-MTOR (Ser 2448; ab1093) from
Abcam; AMPKα (2603), p-AMPKα (Thr 172; 2531), ACC
(3676) and p-ACC (Ser 79; 3661) and MCL1 (4572) from
Cell Signaling. A mouse anti-β-actin antibody (3700, Cell
Signaling) was used as a protein loading control. eIF2a 1
(Addgene plasmid # 21807), eIF2a 2 (Addgene plasmid #
21808) and eIF2a 3 (Addgene plasmid # 21809) were a gift
from David Ron. A549 cells were transfected using Lipo-
fectamine 3000 Reagent from Life Technologies. Cells
were plated in 6 well and transfected at 70 % confluence
for 24 h with 1 μg of DNA. Jurkat cells were transfected
for 48 h with 1 μg of DNA in 24- well plate.
Real-time PCR
Total RNA was extracted with Quick-RNA MiniPrep kit
(Zymo Research) and treated with DNAse. cDNA was
synthesized using RevertAid First Strand cDNA Synthe-
sis Kit (Fermentas) following the manufacturer’s recom-
mendation. Real-time PCR reactions were performed
using the KAPA SYBR FAST Universal qPCR Kit on a
CFX96 Real-Time PCR Detection System (BioRad). Rela-
tive mRNA quantification was obtained with the ΔCq
method using β-actin (ACTB) as housekeeping gene.
Primers’ sequences are reported as follows: BiP/Grp78
(Fw: TGTTCAACCAATTATCAGCAAACTC Rev: TTC
TGCTGTATCCTCTTCACCAGT) ACTB (Fw: CTGGA
ACGGTGAAGGTGACA Rev: AGGGACTTCCTGTAA
CAATGCA) STK11/LKB1 (Fw: GAGCTGATGTCGGT
GGGTATG Rev: CACCTTGCCGTAAGAGCCT).
Lentiviral particles production and luciferase assay
Lentiviral particles were produced using the pHR-SIN-R-
Myc-F, pHR-SIN-F-HCV-R and pHR-SIN-F-CrPV-R
transfer vectors [29], coding for reporter genes controlled
by a cMyc-5′UTR, HCV or CrPV IRESes regulated trans-
lation, by co-transfection of 293 T cells with the packaging
plasmid pCMV-deltaR8.91 and the VSV envelope-coding
plasmid pMD2.G. Five thousand Jurkat cells/sample were
transduced. After treatment with FK866, luciferase activity
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was measured using the Dual-Glo Luciferase Assay Sys-
tem (Promega) and normalized for protein concentration.
Silencing with shRNAs
The pLKO.1-based lentiviral plasmids containing AMPKa1
shRNA (TRCN0000000859), AMPKa2 shRNA (TRCN0000
002169) or NAMPT shRNA expression cassette (TRCN
0000116180) and (TRCN0000116181) were purchased
from Sigma-Aldrich. Scramble shRNA (Addgene plas-
mid #1864 [30]) was used as a control. Vectors were
produced in 293 T cells by cotransfection of the dif-
ferent transfer vectors with the packaging plasmid
pCMV-deltaR8.91 and the VSV envelope-coding plas-
mid pMD2.G. 1 million of Jurkat cells were trans-
duced with lentiviral particles expressing the control
(shSCR) or NAMPT-silencing short hairpin RNA
(shNAMPT) by spinning them down with vector-con-
taining supernatants for 2 h at 1600xg at room
temperature and leaving them incubate overnight at 37 °C
without replacing the transduction supernatant. After
changing the medium, the cells were further incubated for
72 h before collection for WB.
For AMPK silencing experiments, Jurkat cells were
first transduced with the shRNA vector targeting the α1
subunit (shAMPKα1) as reported before. After 24 h
from the first transduction the cells were then trans-
duced again, following the same protocol, with the lenti-
viral vector coding for the shRNA targeting the AMPK
α2 subunit (shAMPKα2). After changing the medium
the next morning, the cells were further incubated for
48 h and then treated for additional 48 h with or without
(DMSO) 5 nM of FK866.
To obtain LKB1 silencing, pLKO.1 transfer vectors
were prepared by cloning annealed oligos coding for
shRNAs (clone TRCN0000000408 for LKB1-A and clone
TRCN0000000409 for LKB1-B) into the TRC cloning
vector (Addgene plasmid #10878 [31] according to the
TRC standard protocol. Cells were transduced by spin-
ning them down with vector-containing supernatants
and leaving them incubate overnight. After changing the
medium, the cells were incubated for 72 h and then
treated for additional 48 h with or without FK866.
Statistical analysis
Experiments were performed in biological triplicates. T-
test was used to calculate final p-values, without assum-
ing variances to be equal (Welch’s t-test). P-value <0.05
was considered statistically significant.
Results
Sensitivity of leukemia cells to the NAMPT inhibitor
FK866
FK866 was previously shown to have cytotoxic activity
at nanomolar concentrations against different types of
hematological malignancies, including myeloid and
lymphoid leukemias and multiple myeloma [12, 21]. We
monitored FK866-induced cell death in Jurkat cells by
quantifying early and late apoptosis with 7AAD and
Annexin V staining. In line with previous reports, FK866
cytotoxic activity started to become evident between 48
and 72 h of exposure with approximately 74 and 47 % of
viable cells left at these time points when cells are
treated with FK866 100 nM (Fig. 1a), respectively. This
suggests the existence of a lag phase through which cells
can cope with the energetic shortage. Starting from a
concentration of 10 nM, FK866 cytotoxic activity
reached a plateau and an EC50 of 5.3 nM could be esti-
mated after 48 h of exposure (Fig. 1a). Indeed, at 120 h
we measured an effective IC50 of 10 nM, highlighting
the inability of these cells to compensate for the ener-
getic stress induced by FK866 in long term treatment
(Fig. 1a). Cell cycle analysis of FK866-treated cells, at
48 h, showed a non-significant accumulation of cells in
G2/M phase, while, as predicted, serum starvation re-
sulted in accumulation of cells in G0/G1 phase (Fig. 1b
and Additional file 1A). Forty-eight hours treatment
with FK866 led to approximately 25 % of cell death, but
did not lead to massive protease or caspase activation
(Fig. 1c and d). However, 5 nM FK866 was sufficient to
effectively reduce NAD+(H) and ATP levels in Jurkat
cells, representing a pre-toxic experimental condition to
apply for further experiments (Fig. 1e).
FK866 and NAMPT ablation blocks cap-dependent
translation, but not gene transcription, through MTOR/
4EBP1, EIF4E, and EIF2A inhibition in cancer cells
We assessed the impact of FK866 on global transcrip-
tional and translational efficiencies in Jurkat cells. Global
RNA transcription and translation were monitored using
the Click-it chemistry and flow-cytometry by the incorp-
oration of the nucleoside analog 5‑ethynyl uridine (EU)
and of an aminoacid analog (AHA), respectively. In the
viable Jurkat cell population, FK866 caused a reduction
in the incorporation of EU in a dose–dependent manner,
with 70 and 55 % of transcriptionally active cells in the
presence of 5 and 100 nM FK866, respectively. Thus,
despite NAD+ and ATP depletion, cells treated with
FK866 for 48 h essentially retained their ability to per-
form RNA transcription. By contrast, even 5 nM FK866
determined a striking reduction (up to 30 %) of the frac-
tion of viable cells showing active protein synthesis
(Fig. 2a and Additional file 1B). The utilization of bicis-
tronic reporter assays to test the efficacy of cap or IRES
(Internal Ribosome Entry Site) dependent translation
confirmed that FK866 induced a strong translation arrest
with a major impact on cap-dependent translation in
Jurkat cells (Additional file 2).
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Since the initiation phase is considered the limiting
step of translation [32], we evaluated the activation of
three signaling pathways regulating the canonical cap-
dependent translation process. The Mammalian Target
of Rapamycin (MTOR) kinase regulates the p70 riboso-
mal S6 kinase (p70-S6K) and the eukaryotic translation
initiation factor 4E-binding protein 4EBP1, whose phos-
phorylation determines EIF4E availability for its interact-
ing partner EIF4G, which is involved in mRNA
recruitment to the ribosomes for protein translation
[32]. It has been recently shown that FK866 induces
MTOR de-phosphorylation [24], thereby inducing au-
tophagic cell death in multiple myeloma cells [21, 33].
As shown in Fig. 2b, Jurkat cells treated with FK866
indeed showed a marked de-phosphorylation of MTOR
and 4EBP1. Enhanced AKT phosphorylation at Ser-473
was also observed (Fig. 2b), which is in line with the
paradoxical activation of AKT by MTORC2 complex fol-
lowing inhibition of MTOR as reported with different
MTOR inhibitors in multiple myeloma cells [34]. Not-
ably, treatment with FK866 led to a previously unappre-
ciated de-phosphorylation of EIF4E on serine 209,
suggesting that the MAP Kinase Interacting Serine/
Threonine Kinase (MNK)-dependent pathway is also af-
fected [35] (Fig. 2c), and to an increased phosphorylation
on Ser-51 of EIF2A, an initiation factor that transfers
methionyl-initiator tRNA (Met) to the small ribosomal
subunit. When phosphorylated (Fig. 2c), EIF2A loses its
Fig. 1 FK866 affects NAD+(H) and ATP levels in Jurkat cells leading to cell death. a Flow-cytometric quantification of cell viability with AnnexinV
(FITC) and 7AAD (PerCP-Cy5-5-A) staining. Jurkat cells were treated with FK866 for 48,72 and 120 h. Mock, 5 nM FK866 and 100 nM FK866 (at 48
and 72 h) are shown as representative samples. Flow-cytometry experiments were carried out on two biological replicates and statistics were
based on the acquisition of 10000 events/sample. b Cell-cycle analysis with PI staining of the nuclei after 48 h of treatment. Overnight serum
starvation is shown as positive control of induced cell cycle synchronization in G0/G1 phase. Histograms quantify the cell cycle phase distribution.
Flow-cytometry experiments were carried out on two biological replicates and statistics were based on acquisition of 30000 events/sample. Cell
cycle phase analysis was done using ModFit LT 3.2 software and the Sync Wizard model. c Jurkat cells were treated with FK866 for 48 h. Alternatively,
cells were exposed to 5 μM of Camptothecin for 4 h as a positive control. Protease activity in cell extracts was assessed with a commercially available
kit and values were normalized to the protein concentration in the same extracts. d Caspase 3/7 activity was measured in Jurkat cells treated as in c. e
Jurkat cells were treated with FK866 for 48 h. Thereafter, intracellular NAD+(H) and ATP levels were evaluated in comparison with control Jurkat cells.
RLUs were normalized to number of viable cells. In c-e the means with SD of at least three independent experiments are shown. Statistical significance
was calculated with t-test (* and # indicates p-value <0.05)
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ability to exchange GDP and GTP, impairing the forma-
tion of a complex with the EIF2B subunit and thus pre-
venting translation initiation [36]. Analogously, SUP-T1
and Molt-4 Clone 8 T-ALL cell lines presented the same
FK866-induced inhibition of the activation of 4EBP1,
supporting the existence of a general mechanism under-
lying the FK866-induced translational arrest in leukemia
cells (Fig. 2d, e). These effects were also observed using
another inhibitor of NAMPT enzymatic activity, CHS-
828 (Additional file 3A), but not with other commonly
used chemotherapeutics as cisplatin, doxorubicin, dexa-
methasone and rapamycin, at equivalent pre-toxic doses.
Indeed, FK866 induced a stronger protein synthesis ar-
rest than the MTOR inhibitor rapamycin suggesting that
this event is a molecular hallmark of FK866. Addition-
ally, FK886 concomitantly induced EIF2A phosphoryl-
ation and 4EBP1 de-phosphorylation, uniquely among
all the other drugs, thus mechanistically supporting the
strong protein synthesis arrest. The other drugs tested
were ineffective (Additional file 3B, C, D). In conclusion,
these experiments show the modulation of several hubs
of the signaling apparatus controlling translation initi-
ation in response to FK866, providing a robust
explanation for the marked protein synthesis inhibition
observed after drug treatment.
FK866 induces AMPK and EIF2A phosphorylation in Jurkat
and primary leukemia cells
In view of the strong translation inhibition and consider-
ing its energy-sensing activity in controlling translation
[37], we investigated in Jurkat cells the impact of FK866
and CHS-828 on the phosphorylation status of AMPK,
whose activation has been previously shown to be induced
by FK866 in prostate and hepatic cancer cells [23, 24].
FK866 caused a partial reduction in total AMPK levels at
the highest dose used, but, at a same time, a parallel dose-
dependent increase of the phosphorylation of its Thr-172
and of its bona fide target ACC (Acetyl-CoA Carboxylase)
(Fig. 3a), indicating a significant activation of AMPK. We
evaluated the effect of FK866 on two important antiapop-
totic factors, MCL1 (Myeloid Cell Leukemia 1) and BCL-2
(B-Cell Lymphoma 2). BCL-2 protein levels were essen-
tially not affected by FK866 treatment as compared to the
strong down-regulation of MCL1 (Fig. 3a). Notably, nico-
tinic acid (NA) supplementation, which blocks FK866
cytotoxic activity by allowing NAD+ biosynthesis through
Fig. 2 FK866 inhibits the signaling cascades controlling protein synthesis in T-ALL cell lines. a RNA synthesis was determined by monitoring EU
incorporation with Click-it chemistry. Jurkat cells were treated for 48 h with or without (Mock) the indicated concentration of FK866 or for 3 h with
5 μM Actinomycin D, an RNA synthesis blocking agent. The histogram quantifies the dose-dependent transcription inhibition induced by FK866
in the viable cell population. In the lower part, Click-it chemistry based on the incorporation of an aminoacid analog (AHA) was used to monitor
protein synthesis. Jurkat cells were treated for 48 h with or without (Mock) the indicated concentration of FK866 or for 3 h with 350 μM Cycloheximide,
as a positive control for protein synthesis inhibition. The histogram quantifies FK866-induced protein synthesis arrest in the viable cell population.
Flow-cytometry experiments were carried out on two biological replicates and statistics were based on acquisition of 50000 events/sample. b Jurkat cells
were treated for 48 h with or without (Mock) the indicated concentration of FK866. Thereafter, cells were lysed and the levels of total and p-Akt (Ser-473),
total and p-MTOR (Ser-2448), total and p-4EBP1 (Ser-65 and Thr-70), c) total and p-EIF4E (Ser-209), total and p-EIF2A (Ser-51) were detected by
immunoblotting. d Molt-4 cells were treated with FK866 for 48 h and the levels of total 4EBP1 and p-4EBP1 were evaluated. e Western blot analysis as
in d in SupT1 cells. b-e, one representative experiment out of at least three biological replicates is presented and β-actin was used as loading control
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an alternative pathway (via nicotinic acid phosphoribosyl-
transferase, NAPRT1), completely prevented AMPK phos-
phorylation in primary B-CLL (Fig. 3b, Additional file 3E),
confirming that NAD+ depletion is responsible for AMPK
activation. In patient-derived T-ALL xenografts (PD T-
ALL) the drug induced cell death and activated AMPK as
well as EIF2A phosphorylation (Fig. 3c and d), demon-
strating that this molecular event is not limited to cell line
models but is also present in primary leukemia cells.
EIF2A phosphorylation precedes 4EBP1 de-
phosphorylation in Jurkat cells
NAMPT expression level during FK866 treatment
remained unchanged as expected (Fig. 4a). Genetic abla-
tion of NAMPT by lentiviral transduction in Jurkat cells
(Fig. 4b) lowered NAD+(H) level to 75 % of the control
while ATP level was not significantly decreased thus in-
ducing an intermediate condition of energetic stress
compared to the one obtained with 5 nM FK866
administration (Fig. 4c). In these conditions of mild
stress, AMPK was marginally activated but, nevertheless,
we observed a significant phosphorylation of EIF2A but
not the de-phosphorylation of 4EBP1, suggesting that
the first event precedes the second one (Fig. 4d). Import-
antly, we observed a clear down-regulation of MCL1, as
observed with FK866 treatment (Fig. 3a), suggesting that
EIF2A activation is an early response to NAD+(H)
shortage.
FK866-induced AMPK activation regulates EIF2A
phosphorylation
To formally assess the role of AMPK in FK866-induced
translational arrest, we pharmacologically blocked
AMPK with Compound C, a small molecule inhibitor of
this enzyme, although not selective [38]. In addition, we
down-regulated AMPK using lentiviral transduction of
shRNAs. Compound C administration to Jurkat cells
treated with FK866 abrogated AMPK phosphorylation,
Fig. 3 FK866 induces AMPK and EIF2A phosphorylation in primary leukemia cells. a Jurkat cells were treated for 48 h with or without (Mock) the
indicated concentration of FK866. Thereafter, cells were lysed and the levels of total and p-AMPK (Thr-172), ACC and p-ACC, BCL-2, MCL1 and
β-actin as loading control were detected by immunoblotting. One representative experiment out of three biological replicates. b primary B-CLL
cells (source: peripheral blood; RAI stage III, 86 years, CD38-pos) were treated for 48 h with or without FK866 in the presence or absence of 1 mM
NA. Thereafter, protein lysates were immunoblotted for AMPK and p-AMPK. c Cell viability with respect to Mock condition, measured by CellTiter
Glo, of three different T-ALL xenografts (PD T-ALL 12, 19 and 25) after treatment with FK866 5nM for 48 h. d WB of PD T-ALL 12 as representative
of T-ALL xenografts samples. Cells were treated with 5 and 50 nM FK866 for 48 h. Histogram shows the densitometric analysis of p-AMPK and
p-EIF2A in the three T-ALL xenografts (PD T-ALL 12, 19 and 25)
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reactivated the MTOR/4EBP1 pathway and restored
EIF2A in its un-phosphorylated state (Fig. 5a). Rescue
experiments with Compound C did not show any down-
regulation of MCL1 protein level with no change in
BCL2 expression (Fig. 5a). Co-treatment with Com-
pound C partially reverted FK866-induced ATP loss but
activated the apoptotic response (Fig. 5b). Down-
regulation of AMPK was achieved by targeting both
AMPKα1 and AMPKα2 isoforms (shAMPK cells). We
then exposed silenced and control (scramble) cells to 5
nM of FK866 for 48 h (Fig. 5c). In shAMPK cells we ob-
served a significant decrease of EIF2A phosphorylation
but not of 4EBP1 de-phosphorylation. This supports the
notion that FK866-induced AMPK activation is primar-
ily involved in the regulation of EIF2A phosphorylation
and subsequently in 4EBP1 de-phosphorylation (Fig. 5c).
Importantly, shAMPK Jurkat cells showed an increased
sensitivity to FK866 with respect to control cells, as re-
vealed by PI staining and flow-cytometry (Fig. 5d),
pointing out the protective effect of AMPK in FK866-
induced stress conditions.
EIF2A mediates the AMPK pro-survival effect during
FK866 treatment
Given the protective role of AMPK in a context of
FK866-sensitive cancer cell, we hypothesized that the
liver kinase B1 (LKB1), a well-established AMPK regula-
tor, can also exert the same protective effect. Indeed,
genetic ablation of LKB1 in Jurkat cells led to an in-
crease toxicity of FK866 treatment (Fig. 6a). Accordingly,
we used two lung adenocarcinoma cell lines (H460 and
A549), bearing genetic inactivation of LKB1 to prove the
dependency of FK866 efficacy on the activation of the
LKB1/AMPK pathway. These results provide a rationale
for the utilization of NAMPT inhibitors in cancers with
this type of genetic background. The cells were stably
transduced with retroviral vectors encoding parental
LKB1 cDNA (LKB1 WT) or with a control vector
Fig. 4 NAMPT genetic ablation induces EIF2A phosphorylation and MCL1 down-regulation. a Expression levels of NAMPT. Jurkat cells were treated
with 5 and 100 nM FK866 for 48 h. One representative experiment out of three biological replicates is presented. b WB analysis indicated 50 % of
NAMPT silencing (p < 0.001) in Jurkat cells by using lentiviral particles expressing two NAMPT-silencing shRNAs (shNAMPT-1 and −2). c Intracellular
NAD+(H) and ATP levels in shNAMPT cells (transduced with shNAMPT-1 and −2) were evaluated in comparison with scramble Jurkat cells. Thirty
percent reduction of NAD+(H) levels was observed in shNAMPT cells (p-value < 0.01). RLUs were normalized to number of viable cells. Mean and SD of
a biological triplicate. d WB analysis of AMPK, p-AMPK, EIF2A, p-EIF2A, p-4EBP1 and MCL1 in shNAMPT (transduced with shNAMPT-1 and −2) cells.
Histogram shows the densitometric analysis of p-AMPK, p-EIF2A and MCL1 (* indicates p-value <0.05). Mean and SD of a biological triplicate
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Fig. 5 AMPK regulates EIF2A phosphorylation and is a pro-survival factor in Jurkat cells. a Jurkat cells were treated with or without FK866 at the
indicated concentrations in the presence or absence of Compound C 5 μM for 48 h. Thereafter, cells were lysed and the levels of p-AMPK (Thr-172),
p-MTOR, 4EBP1, p-4EBP1, BCL-2, MCL1, EIF2A and p-EIF2A were revealed by immunoblotting. Histogram shows the densitometric analysis of p-AMPK
and p-EIF2A. b In the same samples, caspase 3/7 activity was quantified and relative ATP levels were determined and then normalized to the number
of viable cells (* indicates p-value <0.05). a and b are representative of a biological triplicate (mean and SD). c Jurkat cells were transduced with
lentiviral particles containing scramble or shAMPK (targeting the α1 and the α2 subunit), then treated for 48 h with or without 5 nM FK866. Cell lysates
were used for total AMPK, EIF2A, p-EIF2A, 4EBP1, p-4EBP1 and β-actin immunoblotting. WB analysis indicated 40 % of AMPK silencing (p-value < 0.05)
and densitometric analysis shows the significant decrease of p-EIF2A in shAMPK Jurkat cells (p-value < 0.03). Mean and SD of a biological triplicate. d
Jurkat scramble and shAMPK cells were treated for 48 h with the indicated doses of FK866. Cell viability was determined by PI staining and flow-
cytometry (two biological replicates and statistics based on the acquisition of 10000 events/sample)
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(pBABE). FK866 treatment induced AMPK and EIF2A
phosphorylation in addition to 4EBP1 de-phosphorylation
only when LKB1 was active. On the other hand, albeit to a
different extent among the two cell lines, FK866 was not
able to activate AMPK or EIF2A but was still effective in
de-phosphorylating 4EBP1 when LKB1 was inactive. Via-
bility assays indicated an increased sensitivity of LKB1
negative, EIF2A un-phosphorylated cells to FK866 com-
pared to LKB1 expressing cells (Fig. 6b and Additional file
4A). Finally, in order to assess the relevance of EIF2A in
mediating the AMPK induced protection from FK866, we
treated with the drug A549 and Jurkat cells transfected
with EIF2A, its phosphomimetic mutant S51D or with the
non-phosphorylatable mutant S51A. In the context of in-
active LKB1, the overexpression of EIF2A and the EIF2A-
S51D isoform led to a protective effect, while the alanine
mutant induced an increase of cell toxicity (Fig. 6c). The
same trend was observed also in Jurkat cells (Additional
file 4B). Therefore, these data indicate that the translation
arrest induced by EIF2A mediates the protective effect of
AMPK from FK866 induced stress.
EIF2A balances pro-survival and pro-death pathways
EIF2A is a key factor regulating the translation machin-
ery in response to a myriad of factors including nutrient
depletion, presence of exogenous mRNA and the Un-
folded Protein Response (UPR) following the induction
of Endoplasmic Reticulum (ER) stress [39]. Indeed,
FK866 induced the overexpression of BiP/Grp78 mRNA,
coding for a chaperone involved in the folding of ER
proteins (Fig. 6d), thus indicating UPR activation in
Jurkat cells after 48 h treatment. Moreover, FK866 in-
duced MCL1 down-regulation was dependent on prote-
asome activation as demonstrated by the rescue of its
expression level by MG132 treatment in Jurkat cells
(Fig. 6e) [40]. In conclusion, FK866 induces an AMPK-
Fig. 6 Protective role of EIF2A and FK866 induced UPR. a Expression level of LKB1 mRNA, evaluated in Jurkat cells after 120 h of lentiviral
transduction with shRNAs expressing the control sequence (scramble) or two LKB1-silencing shRNAs (shLKB1-a and –b), in the upper panel. Cells
were transduced for 72 h and then treated with FK866 for 48 h. Viability was measured by MTT assay in comparison with Mock (DMSO) condition,
in the lower panel. Mean and SD of a biological triplicate (*, p-value < 0.05). b WB analysis indicated the levels of AMPK, p-AMPK, p-EIF2A, p-4EBP1
in A594 cells expressing LKB1 (LKB1 WT) or transduced with an empty vector (pBABE) treated or not (Mock) with 100 nM FK866 for 48 h, left
panel. A549 cells were treated with indicated concentration of FK866 for 48 h and cell viability as shown in dose–response curve was evaluated
by MTT assay, right panel. Mean and SD of three biological replicates. c A549 viability after 48 h of treatment with FK866 100 nM in un-transfected
(NTC) cells and transfected with EIF2A wild type, EIF2A-S51A, EIF2A-S51D (mean and SD of three experiments,*, p-value < 0.05). d Expression level of
BiP mRNA, evaluated in Jurkat cells after 48 h of treatment with FK866 5nM (*, p-value < 0.0005). Mean and SD of a biological triplicate. e WB analysis
of MCL1 in Jurkat cells treated with FK866 for 48 h and with the proteasome inhibitor MG132 1 μM for 24 h. MG132 was added after 24 h of FK866
treatment. One representative experiment out of three biological replicates
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EIF2A mediated translational arrest, which is responsible
for MCL1 down-regulation and the activation of the
UPR response, that is a strategic pausing step necessary
to protect cells from FK866-induced energetic stress.
Discussion
We investigated the link between NAD+(H) depletion
and cell death using a T-ALL cell model after induc-
tion of the primary effects of NAMPT inhibition,
namely NAD+(H) and ATP depletion, while nearly
preserving total cell viability. The functional conse-
quences of NAD+(H) depletion upon FK866 treatment
resulted in a marked inhibition of the three major
pathways regulating the translation process and in a
striking arrest of protein synthesis. Interestingly,
FK866 efficacy in blocking protein synthesis was
higher than all the other chemotherapeutics tested
and even higher than the MTOR inhibitor rapamycin,
suggesting that this is a crucial event in the cell re-
sponse to FK866. This phenomenon is general be-
cause it was observed in primary leukemic samples,
coming both from B-CLL and T-ALL patients, and in
T-ALL derived cancer cell lines. Nicotinic acid rescue
experiments, treatment with the FK866 analog CHS-
828 and NAMPT genetic ablation showed that trans-
lation arrest was dependent on the shortage of ATP
and NAD+(H) induced by the inhibition of the
NAMPT catalytic function and not by unspecific
FK866 effects. FK866 has been shown to have con-
trasting effects on AMPK. In neuronal cells FK866
decreased AMPK activation and was detrimental for
neuronal survival [25], however in cancer cells that
have a dysregulated metabolic demand, it has been
observed the opposite. In prostate cancer cells, FK866
treatment reduced fatty acid and phospholipid synthe-
sis, partly via AMPK activation [23]. FK866 induced
activation of AMPK and subsequent decreased phos-
phorylation of 4EBP1 by MTOR has been observed in
hepatocarcinoma cells. Given the importance of
MTOR in sustaining cancer cell growth, this event
was proposed as an effective mechanism to target
cancer cells [23]. By evaluating the early molecular effects
of FK866 treatment on protein synthesis, we observed the
involvement of the same pathway but, in addition, we
showed a protective role for AMPK and EIF2A. In our ex-
perimental conditions, the inactivation of MTOR by
AMPK and consequent protein synthesis arrest had a pro-
tective effect conferring temporary resistance to the
FK866-induced energetic stress. Additionally, we deter-
mined that AMPK-induced hyper-phosphorylation of
EIF2A is regulated by the fluctuations of NAD availability
at the intracellular level. This molecular mechanism, lead-
ing to inhibition of translation initiation, followed AMPK
activation. In fact, genetic AMPK down-regulation of both
isoforms of the α catalytic subunit rescued the FK866 in-
duced hyper-phosphorylation of EIF2A. As a further con-
firmation, the same results were obtained by AMPK
functional ablation using the inhibitor Compound C or by
inactivation of its upstream regulator LKB1. Indeed, res-
cue of 4EBP1 phosphorylation levels was observed only
after Compound C administration, suggesting that EIF2A
is a preferential target of the AMPK signaling cascade, at
least in the initial phase of cell response to FK866. Inter-
estingly, in our cell model and at the doses we used, we
did not observe Compound C-induced phosphorylation of
EIF2A as recently reported in different cancer cells [41].
Our cell model resembles the AICAR-induced AMPK ac-
tivation that leads to EIF2A phosphorylation in adipocytes,
an event shown to be crucial for AMPK-induced apoptosis
[42], and supports the idea that FK866 induced activation
of the AMPK-EIF2A axis can be a novel pathway to be in-
vestigated to elucidate the pharmacology of FK866.
Many types of cancer, as sporadic lung, cervical, and
endometrial cancers, carry LKB1 deficiency that can be
exploited with metabolic drugs since these cells are un-
able to appropriately respond to metabolic stress [43].
Given the protective role of LKB1/AMPK pathway
against FK866, our study suggests the utilization of
FK866 as a metabolism-based cancer therapeutic to se-
lectively target LKB1-deficient tumors. Indeed in cells
lacking a functional LKB1 pathway, metabolic stress has
been demonstrated to result in rapid apoptosis as the
cells are unable to sense energetic stresses and activate
mechanisms to restore energy homeostasis [44].
Previous studies have shown that inhibition of the
MTOR/4EBP1 pathway in leukemia cells leads to a re-
duction in the levels of the anti-apoptotic protein
MCL1, with important implications for chemosensitivity
[45]. Down-regulation of MCL1 through inhibition of
translation has been clearly associated with enhanced le-
thality in Jurkat cells [46]. Importantly, FK866 adminis-
tration led to smooth death [40] via EIF2A-dependent
MCL1 down-regulation consequent to translation arrest
and simultaneous proteasome activation. Indeed, MCL1
intracellular levels were shown to be strictly dependent
on the activation of EIF2A [47] and AMPK [48], and to
the subsequent translation arrest. This could provide a
molecular explanation for the anti-leukemic activity of
NAMPT inhibitors. Notably, the ectopic expression of
the non-phosphorylatable mutant EIF2A-S51A increased
FK866 toxicity. Therefore the activation of the AMPK-
EIF2A axis is essential for the tumor cell to adapt to the
shortage of NAD+(H). For example, the increased ex-
pression level of BiP mRNA is a specific adaptive re-
sponse observed in the integrated stress response (ISR)
and translational repression [49]. The exacerbation of
proteasome inhibition with bortezomib has been shown
to potentiate FK866 efficacy through the activation of
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the caspases’ cascade [40]. Here we show the relevance
of EIF2A activation in this mechanism. Additionally, the
synergistic effect of FK866 with cyclosporine in leukemia
cells has been ascribed to the activation of the UPR [50].
This suggests that the exacerbation of the UPR, which is
dependent on EIF2A, can be thought as a relevant strat-
egy to potentiate the effect of FK866 in conditions in
which activation of the EIF2A-dependent UPR is desir-
able, i.e., diabetes, atherosclerosis, or neurodegenerative
disorders [51]. Indeed, FK866 effects on translation re-
semble the ones induced by metformin, a well-known
AMPK activator with antidiabetic and antitumoral prop-
erties [52, 53]. Finally, de-phosphorylation of EIF4E,
never linked to NAMPT inhibitors or AMPK activation
before, completes the general picture of a global inhib-
ition of the translation process, even though the mech-
anism leading to upstream MNK activation has not been
investigated yet.
Conclusions
In conclusion, this work describes the activation of a
complex signaling network in which the AMPK-EIF2A
axis is responsible for the early cellular response to the
metabolic stress produced by FK866. In an experimental
condition in which catastrophic proteolytic cascades are
not yet started but the energetic demand is high, EIF2A
acts as an early master regulator of cell fate, blocking
anabolic processes and, at the same time, modulating
cell death and adaptive pathways. Therefore EIF2A-
dependent processes, such as protein synthesis and UPR,
acquire fundamental relevance in explaining the mech-
anism of action of NAMPT inhibitors.
Additional files
Additional file 1: Cell-cycle analysis and Click-iT detection of RNA
and Protein synthesis. A) Cell-cycle analysis with PI staining of the
nuclei after 48 h of treatment. Overnight serum starvation is shown as a
positive control of induced cell cycle synchronization in G0/G1 phase. Cell
phase analysis was done with ModFit LT 3.2 software by using the Sync
Wizard model (30000 cells/sample in biological duplicate). B) Jurkat cells
were treated for 48 h with or without (Mock) the indicated concentration
of FK866 or for 3 h with 5 μM Actinomycin D, an RNA synthesis blocking
agent, then subjected to Click-it biochemistry and flow-cytometry
analyses including 7-AAD to identify living cells. C) Jurkat cells were
treated for 48 h with or without (Mock) the indicated concentration of
FK866 or for 3 h with 350 μM Cycloheximide, as a positive control for
protein synthesis inhibition, then stained as in B. In B and C. Experiments
were carried out on two biological replicates (50000 events/sample).
(PDF 1562 kb)
Additional file 2: Luciferase assays. A) Light units, normalized to
protein concentration, of RLuc-cMyc 5′UTR IRES-FLuc reporter vector
transduced in Jurkat cells with lentiviral particles after 48 h of treatment
with or without (Mock) the indicated concentration of FK866. Two hour
treatment with 250 nM of Torin 1 served as a positive control for IRES-
dependent protein translation (p-value <0.05). B) Light units, normalized
to protein concentration, of FLuc-HCV-RLuc and FLuc-CrPV-RLuc reporter
vectors transduced in Jurkat cells with lentiviral particles. Cap-dependent
translation (FLuc) was strongly reduced with 5 nM and 100 nM FK866
(48 h) in comparison to Mock condition (p-value <0.0001). RLuc signal is
not shown because of its low level and its variability between technical
and biological replicates. Cells transduced with the pHR-SIN-F-HCV-R were
serum starved for 5 h as a positive control of IRES activation, as shown in
the graph (p-value <0.05). In A and B data are represented as mean and
SD of three independent experiments. (PDF 584 kb)
Additional file 3: Effects of CHS-828 and chemotherapeutics on
protein translation. A) Jurkat cells were treated for 48 h with or without
(Mock) the indicated concentration of CHS-828. Caspase 3/7 activity was
quantified (using 5 μM of Camptothecin for 4 h as a positive control of
apoptosis) and relative ATP levels were determined and then normalized
to the number of viable cells. The levels of total AMPK, p-AMPK, total
EIF2A and p-EIF2A, total 4EBP1, p-4EBP1 were evaluated by WB. Histogram
shows the densitometric analysis of p-AMPK and p-EIF2A (* indicates p-value
<0.05). Mean and SD of a biological triplicate. B) Jurkat cells were treated with
the indicated concentration of drugs for 48 h and cell viability was measured
by Cell Titer Glo. Data are represented as mean and SD of three independent
experiments. C) Click-it chemistry based on the incorporation of an aminoacid
analog (AHA) was used to monitor protein synthesis. Jurkat cells were treated
for 48 h with or without (Mock) the indicated concentration of FK866,
Rapamycin (RAPA), Doxorubicin (DOXO), Cisplatin (CIS) and Dexamethasone
(DEXA). The histogram quantifies the % of AHA positive cells (active protein-
synthesizing cells) in the viable cell population. Flow-cytometry experiments
were carried out on two biological replicates and statistics were based on
acquisition of 20000 events/sample. D) Jurkat cells were treated as in C and
the level of p-EIF2A and p-4EBP1 was evaluated. Histogram shows the
densitometric analysis of p-EIF2A (* indicates p-value <0.05). Mean and SD of
a biological triplicate. E) Primary B-CLL cells were treated for 48 h with or
without 30 nM FK866 in the presence or absence of 1 mM NA. Histogram
shows the densitometric analysis of p-AMPK/AMPK. (PDF 691 kb)
Additional file 4: Protective role of EIF2A. A) WB analysis indicated
the levels of AMPK, p-AMPK, p-EIF2A, p-4EBP1 in H460 cells expressing
LKB1 (LKB1 WT) or transduced with an empty vector (pBABE) treated or
not (Mock) with 100 nM FK866 for 48 h, left panel. H460 cells were
treated with indicated concentration of FK866 for 48 h and cell viability
as shown in dose–response curve was evaluated by MTT assay, right
panel. Mean and SD of three biological replicates. B) Jurkat viability after
48 h of treatment with FK866 5nM in un-transfected (NTC) cells and
transfected with EIF2A wild type, EIF2A-S51A, EIF2A-S51D (mean and SD
of three experiments,§, p-value < 0.1). (PDF 274 kb)
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 ABSTRACT 
 The Yes-associated protein, YAP, is a transcriptional co-activator, mediating the 
Epithelial to Mesenchymal Transition program in pancreatic ductal adenocarcinoma 
(PDAC). With the aim to identify compounds that can specifi cally modulate YAP 
functionality in PDAC cell lines, we performed a small scale, drug-based screening 
experiment using YAP cell localization as the read-out. We identifi ed erlotinib as an 
inducer of YAP cytoplasmic localization, an inhibitor of the TEA luciferase reporter 
system and the expression of the  bona fi de YAP target gene, Connective Tissue 
Growth Factor CTGF. On the other hand, BIS I, an inhibitor of PKCδ and GSK3β, caused 
YAP accumulation into the nucleus. Activation of β-catenin reporter and interfering 
experiments show that inhibition of the PKCδ/GSK3β pathway triggers YAP nuclear 
accumulation inducing YAP/TEAD transcriptional response. Inhibition of GSK3β by 
BIS I reduced the expression levels of SMADs protein and reduced YAP contribution 
to EMT. Notably, BIS I reduced proliferation, migration and clonogenicity of PDAC 
cells  in vitro , phenocopying YAP genetic down-regulation. As shown by chromatin 
immunoprecipitation experiments and YAP over-expressing rescue experiments, BIS 
I reverted YAP-dependent EMT program by modulating the expression of the YAP 
target genes  E-cadherin ,  vimentin ,  CTGF and of the newly identifi ed target,  CD133 . 
In conclusion, we identifi ed two different molecules, erlotinib and BIS I, modulating 
YAP functionality although  via different mechanisms of action, with the second one 
specifi cally inhibiting the YAP-dependent EMT program in PDAC cell lines. 
 INTRODUCTION 
 The Yes-associated protein, YAP, is a transcriptional 
co-activator containing a proline-rich region responsible 
for the interaction with SH3 domains of c-Yes and 
many other proteins [ 1 ]. Multiple post-translational 
modifi cations (PTMs) regulate the functions of YAP. 
The Hippo signaling pathway, initially defi ned as a tissue 
growth and organ size regulator in  Drosophila , is a kinase 
cascade able to negatively regulate YAP localization 
and activity, by phosphorylating YAP at Serine127. 
Phosphorylation of YAP by the Hippo pathway leads to 
its accumulation in the cytoplasm and, by interaction with 
14–3–3 proteins, YAP is degraded by a ubiquitination-
dependent proteasomal process. Therefore, the Hippo 
pathway negatively regulates YAP functionality and 
presence in the nucleus by modulating its cell distribution 
and its protein expression levels too. Importantly, the 
Hippo pathway-induced phosphorylation of YAP rules 
its functionality according to cell density. At low density, 
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YAP is predominantly localized in the nucleus while 
YAP translocates to the cytoplasm at high cell density 
[ 2 ]. Cytoplasmic YAP has been found associated with 
numerous protein complexes that mainly mediate its 
sequestration and consequent functional inactivation. As 
an example, Angiomotins recruit YAP to Tight Junctions 
or the actin cytoskeleton, in a Hippo pathway-independent 
manner, resulting in reduced YAP nuclear localization 
[ 3 , 4 ]. On the same line, when the WNT pathway is off, the 
association of YAP with beta-catenin leads to reciprocal 
inhibition of both proteins [ 5 – 7 ]. GSK3β inhibition 
by 6-bromoindirubin-30-oxime (BIO) promotes the 
activation of YAP  via de-activation of the Hippo pathway 
[ 6 ]. Nuclear localization of YAP protein is associated with 
its co-transcriptional activity. However, YAP is at the 
crossroad of many signaling pathways, where it plays a 
role depending on the upstream stimuli and the binding 
to its multiple targets. Among the transcription factors 
bound to YAP, members of the TEAD family were found 
to be critical partners of YAP in the regulation of gene 
expression. CTGF has been identifi ed as a direct target 
gene of YAP-TEAD in mammalian cells, and is crucial in 
mediating the growth-stimulating and oncogenic function 
of YAP-TEAD complex [ 8 ], but its transcriptional 
expression depends on the contribution from other YAP 
interacting transcription factors such as SMADs [ 9 ]. 
Additionally, many other transcription factors have been 
found associated with YAP such as p73 [ 10 ], showing 
that YAP can mediate oncosuppressive gene expression 
program according to the cell context. Several pieces of 
evidence support an important role of YAP in different 
types of cancer [ 11 , 12 ], pancreatic ductal adenocarcinoma 
(PDAC) included [ 13 , 14 ]. Indeed, YAP expression,  via 
immunohistochemistry studies in pancreatic tumor tissues, 
was reported as moderate to strong in the nucleus and 
cytoplasm of the tumor cells compared to adjacent normal 
tissues. In cell lines, YAP localization was modulated by 
cell density and its genetic ablation led to a decrease of 
growth in soft agar of pancreatic cancer cells [ 12 , 13 ]. 
In PDAC mouse models, YAP has been shown to be an 
essential promoter of mutant KRAS oncogenic program, 
specifi cally inducing the expression of secreted factors 
as CTGF and CYR61 [ 15 ] and associating with FOS to 
regulate the expression of Epithelial to Mesenchymal 
Transition genes as  E-cadherin ,  SLUG ,  SNAIL and 
 Vimentin [ 16 ]. These pieces of evidence suggest a role of 
YAP in pancreatic cancer development, potentially playing 
an important role in the Epithelial to Mesenchymal 
Transition (EMT) of pancreatic cancer cells. Therefore, 
the identifi cation of inhibitors of YAP activity could be 
suitable as a new therapeutic option for PDAC treatment. 
 However, an intricate network of signaling pathways 
contributes to EMT in PDAC. TGFβ signaling pathway is 
frequently genetically altered in PDAC [ 17 ], and the “late 
TGFβ signature” [ 18 ] actively promotes late EMT also 
cooperating with YAP [ 9 ] and activating the RAS-ERK 
pathway promoting the expression of EMT transcription 
factors such as SNAIL and ZEB1 [ 19 ]. CD133 is a well-
known cancer stem marker [ 20 ] which has been included 
to the plethora of genes responsible for EMT promotion by 
activating SRC pathway [ 21 – 23 ]. 
 We performed a small-scale high-content screening 
for the identifi cation of compounds able to interfere 
with YAP localization and functionality. This approach 
allowed us to assign to the widely used Receptor Tyrosine 
Kinase (RTK) Inhibitor, erlotinib, the ability to sequester 
YAP into the cytoplasm blocking its co-transcriptional 
function. Additionally, we found that a small molecule, 
GF 109203X (BIS I), induces YAP nuclear accumulation 
and activation, however, modulating its co-transcriptional 
activity by blocking the YAP-dependent EMT program 
downregulating SMAD2/3. 
 RESULTS 
 YAP regulates anchorage-independent growth 
in PDAC cell lines 
 We measured the expression level of YAP in a 
panel of four PDAC cell lines using western blotting 
and qRT-PCR: PANC1 and PK9 exhibited moderate to 
high YAP protein levels, respectively, in comparison to 
BXPC3 and MIAPACA2 cells ( Figure 1A ). Cell density 
regulates phosphorylation and localization of YAP  via
the Hippo signaling pathway. High cell density predicts a 
cytoplasmic YAP localization while YAP appears mainly 
localized in the nucleus in sparse cell culture of breast 
cancer cells [ 24 ]. We investigated whether cell density 
regulates YAP localization in pancreatic cancer cells. We 
assessed the expression level and localization of YAP at 
different cell densities using immunofl uorescence in PK9 
and PANC1 cells. Sub-cellular distribution of YAP protein 
was equivalent in both cases with PANC1 cells, but YAP 
signifi cantly shuttled from nucleus to the cytoplasm at high 
cell density in PK9 cells, as determined by high content 
imaging analysis ( Figure 1B ). To investigate the functional 
role of YAP, we interfered YAP expression in PK9 and 
PANC1 cells using lentiviral transduction of specifi c 
shRNA (Supplementary Figure S1A). shYAP-PANC1 and 
shYAP-PK9 cells showed a decrease of 90% and 40% of 
YAP mRNA compared to (SCR) control cells, respectively 
( Figure 1C ).  CTGF and  Cyr61 mRNA expression,  bona 
fi de YAP targets, were signifi cantly reduced in shYAP-
PANC1 and shYAP-PK9 ( Figure 1C ), whereas other 
targets like  AREG and  BIRC5 were distinctly up-regulated 
in silenced cells, indicating a transcriptional impact due 
to YAP modulation. On the other hand,  CTGF expression 
was found increased in the case of YAP overexpression 
(O/E) both in PK9 and in PANC1.  CYR61 expression was 
increased in PK9 O/E YAP. ( Figure 1D ). Phenotypically, 
both YAP stable silencing (shYAP) and its transient 
functional ablation inhibited anchorage-independent 
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 Figure 1: Importance of YAP in PDAC cell lines.  A. YAP is expressed in PDAC lines at different levels. Western blot analysis 
of endogenous level of YAP in PDAC cell lines and qRT-PCR analysis of YAP mRNA expression. The relative intensity of the bands 
(left) and YAP mRNA level (right) are shown.  B. Localization of YAP is regulated by cell density in PK9. PK9 and PANC1 cells were 
cultured sparsely (LOW) and densely (HIGH) onto glass cover slides (Left panel) and in 96 well-plate (right panel) for 48H. Cells were 
fi xed and nuclei were counterstained with DAPI. The localization of YAP was visualized using a Zeiss Observer Z1 microscope equipped 
with Apotome module, with a Plan Apochromatic (63X, NA 1.4) objective. Images were acquired using Zen 1.1 (blue edition) imaging 
software (Zeiss) and assembled with Adobe Photoshop CS3 (Left panel). Quantitative analysis of sub-cellular localization of YAP was 
quantifi ed using Operetta instrument and Harmony 3.5.2 software. Ratio of YAP Nuc/Cyto is shown. (*p<0.05).  C. YAP functional 
ablation down-regulates  CTFG and  CYR61 but not  AREG and  BIRC5 mRNA levels. PANC1 (left) and PK9 cells (right) were stably 
transduced with a lentiviral vector encoding shRNA targeting YAP or a non-targeting control shRNA (SCR). After stable selection with 
puromycin, the relative levels of endogenous  YAP and its target genes,  CTGF ,  CYR61 ,  AREG and  BIRC5 mRNA were measured by 
qRT-PCR (mean±SD). (**P<0.0, **P<0.01 versus SCR).  D. Overexpression of YAP increases  CTGF and  CYR61 levels in PK9 cells.
PK9 and PANC1 cells were transiently transfected with pEGFP-YAP or empty vector (pEGFPN1) for 24H. Overexpression of YAP 
was confi rmed by qRT-PCR analyses. The expression levels of  CTGF and  CYR61 were then evaluated.  E. YAP functional ablation 
attenuates anchorage-independent growth in soft agar. PANC1 cells were stably transduced with a lentiviral vector encoding shRNA 
targeting YAP or a non-targeting control shRNA (SCR). These clones (1.5x10 4 cells) were seeded in 0.35% agar (top agar) medium in 
6 well-plates coated with 0.7% agar (based agar) for 2 weeks. Total colony number and colony diameter were measured using Operetta 
and Harmony 3.5.2 software (below). 
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growth of PANC1 cells in soft agar ( Figure 1E ) and 
slowed their proliferation rate (Supplementary Figure 
S1B), in good agreement with previous data [ 14 ,  25 ]. 
Therefore, in PDAC cell lines cultured at high-density, 
YAP is partially redistributed in the cytoplasm, it has a 
transcriptional effect controlling the expression of known 
target genes, it regulates proliferation and the ability of 
PDAC cells to grow in anchorage-independent conditions. 
 Identifi cation of modulators of YAP localization 
 To gain further insight into the molecular players 
regulating YAP localization, we performed a small-scale 
nucleo-cytoplasmic high content assay to quantify YAP 
protein subcellular localization in PDAC cells. As a 
cell model, we used PK9 cells as YAP was re-localizing 
into the cytoplasm at high cell density ( Figure 1B ). We 
used a library of 80 characterized kinase inhibitors (see 
methods) with the aim to fi nd molecules that could 
modulate accumulation of YAP in the cytoplasm or the 
nucleus, to identify the signaling cascade responsible 
for these subcellular re-localizations and the biological 
effects caused by its sub-cellular re-distribution. Most 
of the molecules did not affect YAP localization being 
the Z-score values of the nuclear/cytoplasmic intensity 
close to controls ( Figure 2A ,  Table 1 , Supplementary 
Table S1). Few compounds were further increasing 
cytoplasmic YAP compared to control, and only two 
compounds led to signifi cant YAP accumulation into the 
nucleus. Interestingly, fi rst hits among YAP cytoplasmic 
accumulators were inhibitors of tyrosine kinase receptors 
(RTKIs) such as Genistein and Tyrphostins and one 
inhibitor of the RAS pathway as ZM336372. On the other 
hand, inducers of YAP nuclear shuttling were BIS I and Ro 
31-8220, two representatives of the bisindolylmaleimide 
family of Ser/Thr kinase inhibitors, as PKCs ( Table 1 ). 
 Cytoplasmic inducers marginally modulate 
YAP co-transcriptional activity 
 As the receptor tyrosine kinase inhibitors identifi ed 
belong to the family of tyrphostin [ 26 ], precursors of 
the more potent and clinically used inhibitors of RTKIs, 
such as erlotinib and lapatinib, we decided to use these 
two drugs for further investigation. Moreover, given 
the importance of the constitutive activation of the 
RAS pathway in PDAC [ 27 ], we also evaluated the 
effi cacy of ZM336372 in inhibiting YAP-dependent 
transcriptional effects by using TEA luciferase reporter 
system as a readout. Only erlotinib inhibited modestly, 
but signifi cantly, TEA reporter and reduced the expression 
level of  CTGF but with no effi cacy on  Cyr61 ( Figure 2B, 
2C ). On the contrary, lapatinib and ZM336372 increased 
CTGF and  Cyr61 expression levels ( Figure 2C ). Summing 
up, only erlotinib showed a minimal, although signifi cant, 
negative modulation of YAP co-transcriptional activity. 
 BIS I changes YAP co-transcriptional activity 
and inhibits anchorage independent growth 
 Bisindolylmaleimide chemical family of compounds 
are strong inhibitors of several kinases in the nanomolar 
range and, therefore, it is diffi cult to associate a molecular 
target directly to its effi cacy. BIS I is a cell-permeable 
and reversible inhibitor of protein kinases C (PKCs) 
both conventional and atypical, but also of GSK3β 
[ 28 ]. Moreover, compounds of the same class show 
differential selectivity towards the same serine/threonine 
kinases. For example, Go9676 was reported to be more 
specifi c for PKCα than for PKCδ [ 29 ], while BIS I 
behaves oppositely [ 30 ]. Since bisindolylmaleimides are 
fl uorescent compounds and could have interfered with 
the immunofl uorescence-based screening, we performed 
nuclear/cytoplasmic separation and Western blots analyzes 
of YAP levels upon drug treatments. We observed that 
BIS I induced YAP nuclear localization in PDAC cell 
lines, confi rming the indication coming from the HCS 
experiment ( Figure 2D ). Then we evaluated the stability 
of YAP protein during BIS I treatment, and, in the time 
frame of 48 hours, YAP protein was stable, suggesting 
that we observed a pure subcellular re-localization 
not affected by changes in protein expression level 
(Supplementary Figure S1C). During re-localization, the 
YAP post-translation status was deeply changed, as many 
phosphorylation spots were present in the two-dimensional 
western blots ( Figure 2E ). Hippo signaling pathway was 
not directly involved in the observed PTMs because the 
phosphorylation state of YAP-S127 and LATS-S909 
did not change ( Figure 2F ). Additionally, we observed 
a decrease in the expression level of LATS protein, an 
effect that is likely independent of the activation of the 
Hippo signaling but might contribute to the translocation 
of YAP into the nucleus. BIS I amplifi ed TEA reporter 
signal in the basal conditions in PANC1 cells and during 
YAP overexpression both in PK9 and PANC1 cells 
( Figure 3A ) and induced TEA reporter signal reduction 
during functional ablation of YAP. Therefore, the effect 
of BIS I on TEA reporter depends on the presence of 
YAP ( Figure 2B ,  3A ). Unexpectedly, BIS I signifi cantly 
suppressed  CTGF and  Cyr61 mRNA expression and 
slightly increased  AREG and  BIRC5 mRNA expression in 
PK9 and PANC1 cells at 24 hours of treatment, mimicking 
YAP ablation ( Figure 3B ). To evaluate if BIS I displaces 
YAP from  CTGF promoter, despite YAP presence in the 
nucleus, we performed chromatin immunoprecipitation 
of YAP and evaluated the amplifi cation of the  CTGF
promoter [ 31 ]. Indeed, YAP was no more associated 
with the  CTGF promoter during BIS I treatment, but 
TEAD1 was still present ( Figure 3C ). Additionally, we 
observed that BIS I inhibited TGF-β induced  CTGF
expression in a YAP independent manner but activated 
TEA reporter in a TGF-β independent manner ( Figure 4A 
and Supplementary Figure S1D). BIS I treatment reduced 
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the expression level of  SMAD2/3 mRNAs and proteins 
in a YAP independent manner ( Figure 4A ,  Figure 4B , 
Supplementary Figure S1E). BIS I phenocopied the 
effects of YAP functional ablation: it slowed down cell 
proliferation and induced an accumulation in the S-phase 
(Supplementary Figure S1B, S1F). Most importantly, 
BIS I was readily effective in reducing the anchorage-
independent growth of PDAC cell lines. Among the four 
cell lines tested, PANC1 and MIAPACA2 formed colonies 
within two weeks, while PK9 took longer and we could not 
detect BXPC3 colony formation. BIS I reduced the total 
number of colonies of PANC1, MIAPACA2, and PK9 and 
reduced the colony dimensions of PANC1 and PK9 but 
increasing MIAPACA2 ones ( Figure 4C ). Summing up, 
 Figure 2: Identifi cation of modulators of YAP localization.  A. High-content screening evaluating YAP localization. A kinase 
inhibitor’s library was administrated to PK9 cells using a high-throughput approach (1μM, 24H). The ratio between nuclear and 
cytoplasmic regions was calculated and normalized to untreated controls. The Z-score was reported in a graph, positive and negative 
values indicate nuclear accumulation and cytoplasmic localization, respectively. Fixed cells were incubated with antibody against YAP 
and DAPI staining. Sub-cellular localization of endogenous YAP protein was detected by Operetta and analyzed with Harmony 3.5.2 
software.  B. Modulation of TEA reporter by hit compounds. PK9 cells were transiently co-transfected with pEGFPN1 or YAP, TEA 
reporter (8xGTIIC-Luc reporter), and  Renilla luciferase to record YAP/TAZ-dependent transcriptional activity. Cells were then treated 
with different compounds for 24 H and the fi refl y luciferase signals were normalized to the ones of  Renilla luciferase. Data are globally 
normalized to MOCK and are presented as mean±SD.  C. Modulation of  CTGF and  CYR61 by hit compounds. The panel represent qRT-
PCR for YAP/TAZ target genes  CTGF and  Cyr61 , relative to  GAPDH expression. PK9 cells were treated with 5μM of different compounds 
and data, normalized to MOCK, are presented as mean±SD. (*p<0.05 and **p<0.01).  D. BIS I induces YAP nuclear accumulation.
Western blot analysis of nuclear fraction and cytosolic fraction of YAP in PK9 and PANC1 cell lines after treatment with 1μM and 10μM 
of BIS I for 24H. The relative intensities of the bands are also shown (right). Data are normalized to MOCK and presented as mean±SD. 
(*p<0.05 and **p<0.01).  E. BIS I induces YAP post-translational modifi cations. Filters were blotted with antibodies against YAP and 
YAP Ser127-P. As negative control for phosphorylation the treated sample was incubated with calf intestinal alkaline phosphatase (CIAP). 
As positive control for phosphorylation at Ser127, cell lysates from high density culture was used.  F. BIS I does not affect the Hippo 
pathway. Western blot analysis of an upstream regulator of YAP, LATS1 and its phosphorylated form (Ser909). PK9 cells were treated 
with BIS I 10μM for 24 H. Phosphorylation of YAP and LATS1 was measured by western blot. The relative intensities of the bands were 
normalized to β-actin levels (right). 
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BIS I induced YAP into the nucleus and triggered TEAD 
response; however, it inhibited anchorage-independent 
cancer cell growth and proliferation, phenocopying YAP 
ablation and inhibiting TGFβ-dependent cell response by 
decreasing the expression of SMADs and SMAD/YAP co-
regulated genes. 
 CD133 gene expression is regulated by YAP 
and inhibited by BIS I 
 To further investigate the molecular mechanism 
of bisindolylmaleimides leading to YAP nuclear 
accumulation, we evaluated four of them for their ability 
to modulate  CTGF expression levels. BIS I and BIS II 
reduced  CTGF expression in PK9 and PANC1 cells, 
although to a different extent, while Go9676 increased 
 CTGF expression. BIS IV showed an increase of  CTGF 
expression only in PK9 cells with no activity in the 
other cell lines (Supplementary Figure S2A). None of 
the bisindolylmaleimides tested showed toxic effects 
(Supplementary Figure S2B). Given the relative specifi city 
of BIS I for PKCδ/GSK3β, while Go9676 is more specifi c 
for PKCα, we hypothesized that PKCδ/GSK3β ablation 
could phenocopy BIS I treatment. Transient silencing of 
PKCδ and GSK3β showed that  CTGF decreased in both 
cases linking the activity of these two kinases in  CTGF 
expression regulation ( Figure 4D , Supplementary Figure 
S2C). Short-term treatment with the GSK3β inhibitor LiCl 
induced the expression of  CTGF mRNA, but long-term 
treatment decreased  CTGF expression [ 32 ]. Interestingly, 
the downregulation of  SMAD2 mRNA occurred only at 
a late time point whereas  SMAD3 was already down-
regulated at 6 hours (Supplementary Figure S2D). BIS I 
induced the downregulation of both  SMADs already at 6 
hours. Silencing of GSK3β activated TEA reporter only 
in the presence of YAP overexpression, similarly to BIS 
I treatment (Supplementary Figure S2E) and reduced 
the expression of  SMAD3 mRNA ( Figure 4E ) as BIS I 
treatment. Since the association of YAP to the destruction 
complex has been reported [ 5 ], we evaluated the activation 
of the WNT/β-catenin signaling in PDAC cell lines 
during BIS I treatment. We performed a reporter assay 
with a construct expressing luciferase under the control 
of tandem repeats of TCF binding site (TOPFlash) or a 
mutated one (FOPFlash). BIS I strongly activated WNT/β-
catenin reporter activity in all of the PDAC cell lines used 
and in HEK293T cells ( Figure 5A , Supplementary Figure 
S2F) as well as induced the accumulation of β-catenin 
in the nucleus ( Figure 5B ). Coherently, Go9676 did not 
activate TCF/LCF reporter nor induced β-Catenin into the 
nucleus ( Figure 5A ,  5B ). 
 Given the importance of YAP and β-Catenin in 
regulating differentiation, we investigated if BIS I could 
affect the expression levels of stemness markers of PDAC. 
In our case, pancreatic stemness gene  CD133 was up-
regulated upon β-Catenin over-expression ( Figure 5C ). 
These stemness genes were down-regulated during BIS I 
treatment ( Figure 5D ), but, interestingly, only  CD133 was 
affected by YAP and GSK3β ablation ( Figure 5E and  5F ). 
Moreover, YAP overexpression induced the up-regulation 
of  CD133 that was blocked by BIS I ( Figure 5G ), therefore 
identifying  CD133 as a new gene regulated by YAP and 
GSK3β. To sum up, BIS I induced YAP and β-Catenin 
nuclear accumulation by inhibiting the PKCδ/GSK3β 
pathway. Moreover, BIS I treatment decreased the level 
of cancer stem cell markers, but only the effect on  CD133
could be ascribed to a loss of YAP functionality. Notably, this 
gene is a new critical regulator of EMT in PDAC [ 21 , 23 ]. 
 Table 1: Hits from High-Content Screening  
 Z-score  Molecule  Molecular Target 
  YAP Nuclear Accumulators  
 0.915  GF 109203X  PKC 
 0.971  Ro 31-8220  PKC 
  YAP Cytoplasmic Accumulators  
 1.382  Tyrphostin AG 1295  Tyrosine kinases 
 1.355  ZM 336372  cRAF 
 1.238  Genistein  Tyrosine Kinases 
 1.182  N9-Isopropyl-olomoucine  CDK 
 1.18  SP 600125  JNK 
 1.171  AG-1296  PDGFRK 
 1.169  Kenpaullone GSK3β
 1.132  AG-494  EGFRK, PDGFRK 
Lower values indicate higher nuclear accumulation, higher values indicate higher cytoplasmic accumulation
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 Figure 3: BIS I treatment phenocopies YAP functional ablation.  A. BIS I modulates TEA reporter in YAP-dependent 
manner. Left panel: BIS I activates TEA reporter activity. PK9 and PANC1 cells were transiently co-transfected with YAP (O/E YAP) or 
without YAP (pEGFPN1) and TEA reporter (8xGTIIC-Luc reporter), then treated with BIS I 5μM for 24H. Right panel: YAP is required 
for TEA reporter activation. Stably YAP silenced PANC1 cells were co-transfected with TEA reporter (8xGTIIC-Luc reporter) or its 
empty vector (pGL4), and  Renilla . The fi refl y luciferase signals were normalized to the ones of  Renilla. (mean±SD from biological 
triplicates) (*p<0.05 and **p<0.01 versus MOCK of PK9 and #p<0.05 and ##p<0.01 versus MOCK of PANC1).  B. BIS I modulates 
YAP target genes. PK9 (left panel) and PANC1 (right panel) cells were treated with 5μM BIS I for 24H. Quantitative RT-PCRs of  CTGF , 
Cyr61 ,  BIRC5 ,  AREG , YAP/TAZ target genes and  YAP relative to  GAPDH expression with respect to MOCK are presented as mean±SD. 
(*p<0.05 and **p<0.01 versus MOCK).  C. BIS I displaces YAP from CTGF promoter. Map of CTGF promoter region with positions 
of the two primers used for ChIP analysis. TSS indicates the transcription start site, while TRE indicate the previously identifi ed TEAD 
responsive elements. Chromatin immunoprecipitation (ChIP) at CTGF promoter was performed using antibodies against YAP, TEF-1 and 
IgG as negative control. After DNA extraction and qRT-PCR, results were normalized to non immunoprecipitated sample (INPUT) and 
compared to IgG for statistical signifi cance. BIS I was able to reduce the DNA enrichment observed for YAP, whereas it was ineffective 
against TEF-1 DNA-binding protein. 
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 YAP-dependent EMT transcriptional program is 
inhibited by BIS I 
 EMT signature, in PDAC, in mainly driven by the 
activation of the RAS pathway in association with the 
transcriptional program induced by FOS, SMADs, and 
YAP [ 16 ] and the loss of E-cadherin is a major event during 
EMT [ 22 ]. Our cell lines exhibit different expression levels 
of E-cadherin ( Figure 6A ,  6B ). PK9 and BxPC3 cell lines 
showed high protein level of E-cadherin whereas PANC1 
and MIAPACA2 had low to undetectable E-cadherin protein 
levels ( Figure 6A ). This expression profi le of E-cadherin 
in PDAC is consistent with its mRNA levels ( Figure 6B ). 
Our results show that endogenous levels of E-cadherin 
are inversely correlated with the anchorage-independent 
growth ability of these PDAC cell lines ( Figure 4C ).
Importantly, EMT signature was dependent on YAP as, in 
shYAP-PK9 and shYAP-PANC1, E-cadherin and CD133 
expression was reverted ( Figure 6C ,  Figure 5E ,  5G ). During 
BIS I treatment, the clonogenic and migration abilities of 
 Figure 4: The CTGF expression level was modulated by the TGF-β and Hippo pathways in PDAC.  A. BIS I inhibits 
TGF-β induced  CTGF expression and reduces  SMAD2/3 gene expression levels.  PK9 cells were stably transduced with a lentiviral 
vector encoding shRNA targeting YAP (shYAP) or a non-targeting control shRNA (SCR). They were then treated with BIS I 5μM in the 
presence and absence of TGF-β 50ng/ml for 24H. The expression levels of  CTGF, SMAD2 and  SMAD3 were then evaluated. (*p<0.05 and 
***p<0.001 versus MOCK).  B. BIS I down-regulated Smad2/3 protein levels. PK9 cells were seeded and treated with BIS I 10μM for 
24H. The endogenous protein level of Smad2/3 was evaluated by western blotting against Smad2/3 antibody. The relative intensities of the 
bands normalized by β-actin are shown below. (***p<0.001 versus MOCK).  C. BIS I inhibits anchorage-independent growth of PDAC.
PDAC (1.5x10 4 cells) were seeded on 0.35% agar (top agar) culture medium in 6 well-plated coated with 0.7% agar (based agar). Cells were 
treated with BIS I 10μM for 2 weeks. Total colony number and colony diameter were measured using Operetta instrument.  D. The CTGF 
expression level was modulated by PKCδ and GSK3β in PK9 cells. PK9 cells were incubated with siRNA targeting PKCδ, GSK3β, and 
non-targeting control (SCR) for 72H. Quantitative RT-PCRs of  CTGF relative to  GAPDH expression with respect to SCR are presented as 
mean+SD. (*p<0.05 and **p<0.01 versus SCR).  E. Genetic ablation of GSK3β suppresses SMAD expression levels in PK9. PK9 cells 
were incubated with siRNA targeting GSK3β, and non-targeting control (SCR) for 72H. Quantitative RT-PCRs of  CTGF relative to  GAPDH
expression with respect to SCR are presented as mean+SD. (***p<0.01 versus SCR). 
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PDAC, markers of EMT, were completely inhibited ( Figure 
4C ,  7A ). BIS I was able to revert the EMT signature by 
restoring E-Cadherin expression, as well as by regulating 
other EMT markers as  vimentin ,  ZEB1 and  CD133 also in 
the presence of TGFβ ( Figure 5G ,  7B ,  7C ,  7D ). Migration 
of PANC1 cells decreased by administration of BIS I 
in sh-YAP PANC1 cells at 48 hours ( Figure 7A ). More 
notably, the effect of BIS I on the modulation of  CTGF, 
E-cadherin, vimentin, and CD133 was rescued by YAP 
overexpression showing that BIS I mechanism of action 
 Figure 5: BIS I activates β-catenin and downregulates the expression level of cancer staminality genes.  A. BIS I activates 
β-catenin signaling pathway. β-catenin induced activation of TOP-fl ash (TCF/LEF) luciferase reporter was performed in HEK293T and 
PDAC cells lines. Cells were co-transfected with TOP-fl ash luciferase reporter and in the presence and absence of β-catenin. BIS I and 
Go6976 5μM were used for 24H treatment after transfection. Data are presented as average fold induction relative to MOCK. (*p<0.05 
and **p<0.01).  B. BIS I modulates β-catenin nuclear localization. Western blot analysis of nuclear fraction and cytosolic fraction 
of β-catenin in PK9 cells after treatment with BIS-I and Go6976 10μM for 24H. The relative intensities of the bands are shown below. 
The relative intensities of the bands was normalized by β-actin and lamin A/C for cytosolic and nuclear protein levels, respectively. 
C. β-catenin regulates CD133 expression. PK9 cells were transiently transfected with indicated β-catenin plasmid for 24H. Quantitative 
RT-PCRs of  CD133 and OCT4 relative to  GAPDH expression with respect to MOCK are presented as mean±SD. (*p<0.05 and **p<0.01). 
D. BIS I inhibits expression of staminality markers in PK9. PK9 cells were treated with BIS I 5μM for 24H and expression levels 
of  ABCG2 ,  CD133 ,  MUL1 ,  OCT4 ,  PAX6 , and  SOX2 were analyzed by qRT-PCR relative to GAPDH expression. Data are presented as 
mean±SD. (**p<0.01 versus MOCK).  E. Genetic ablation of YAP down-regulates CD133 expression. Stemness markers were measured 
by qRT-PCR in stably YAP silenced PK9 cells. Data are presented as mean±SD. (**p<0.01 versus SCR).  F. Genetic ablation of GSK3β 
down-regulates CD133 expression. PK9 cells were incubated with siRNA targeting GSK3β, and non-targeting control (SCR) for 72H. 
Quantitative RT-PCRs of  CD133 relative to  GAPDH expression with respect to SCR are presented as mean±SD. (***p<0.01 versus SCR). 
G. BIS-I treatment reverts the CD133 up-regulation induced by YAP overexpression. PK9 cells were transiently co-transfected with 
indicated plasmids (YAP and pEGFPN1) and in the presence and absence of BIS I treatment for 24H.  CD133 expression was measured by 
qRT-PCR. Data are presented as mean±SD. (*p<0.05 and **p<0.01 versus MOCK). 
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relies on the inhibition of the EMT-related, YAP-dependent 
transcriptional program ( Figure 5G ,  7D ). In sum, we show 
that BIS I inhibits EMT in PDAC cell lines triggering the 
expression of epithelium markers by down-regulating 
SMAD2/3 and blunting YAP co-transcriptional activity. 
 DISCUSSION 
 In this study, we show that BIS I, an inhibitor of the 
PKCδ/GSK3β pathway, reverts the EMT transcriptional 
program in PDAC cell lines inhibiting the TGFβ pathway 
and de-potentiating YAP contribution to EMT  via down-
regulation of SMAD2/3. 
 In agreement with previous reports [ 14 , 33 , 34 ], 
we observed that, in PDAC cell lines, YAP mainly 
regulates anchorage-independent growth, migration, and 
proliferation. However, YAP governs the expression of 
only some of the  bona fi de YAP target genes in these cell 
lines as only  CTGF and  CYR61 , but not  AREG or  BIRC5 , 
decreased during YAP functional ablation. Indeed, in a 
KRAS mutant context, YAP, being post-translationally 
modulated by KRAS/MAPK signaling cascade, promotes 
 Figure 6: BIS I reverts YAP-induced EMT in PDAC cell lines.  A. Endogenous protein level of E-cadherin in PDAC cell 
lines. Western blot analysis of endogenous level of E-cadherin in PDAC cell lines.  B. Expression level of E-cadherin mRNA in PDAC 
cell lines. qRT-PCR analysis of  CDH1 mRNA expression was performed in PDAC cell lines.  C. Both genetic ablation of YAP and BIS I 
treatment induce E-cadherin expression levels. SCR or stably YAP-silenced PK9 and PANC1 cells were treated with BIS I 5μM for 24H. 
Western blot analysis of endogenous level of YAP and E-cadherin was performed. The relative levels of endogenous E-cadherin protein 
(left) and mRNA levels from these lysates (right) were evaluated by immunoblot and qRT-PCR, as shown below. 
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the expression of pro-proliferative secretory factors as 
CTGF and  CYR61 , preferentially [ 15 ]. From our small-
scale screening of kinase inhibitors, using as reporter 
system the localization of the endogenous YAP protein, 
we found out that general inhibitors of RTKs and one RAS 
inhibitor induced YAP accumulation into the cytoplasm. 
This fi nding suggests a functional link between the 
EGFR and RAS pathway and YAP activity as observed 
in Drosophila [ 35 ], liver carcinoma [ 36 ], NSCLC cells 
[ 37 ] and pancreas itself [ 16 ]. Unfortunately, none of these 
inhibitors was potent enough to inhibit TEA reporter 
system and decrease  CTGF expression, suggesting that 
the residual amount of nuclear YAP was still active. 
Only erlotinib showed a small but signifi cant trend 
towards inhibition of YAP co-transcriptional activity. 
Indeed, erlotinib arrests NRG1-ERBB4-YAP signaling 
in breast cancer cell lines [ 38 ], and suggests a further 
rationale for the utilization of erlotinib in PDAC [ 39 ]. 
Additionally, we found of interest the behavior of YAP 
nuclear accumulators, i.e. bisindolylmaleimides. The 
mechanistic explanation can be linked to the pleiotropic 
effect of BIS I. One possibility is that BIS I induced arrest 
of the proteasome leading to accumulation of β-catenin 
[ 40 ,  41 ] and YAP, being both proteins targeted for 
degradation. Alternatively, the BIS I induced inhibition 
of PKCδ/GSK3β activity can lead to the degradation of 
the destruction complex as proved by β-catenin and YAP 
nuclear accumulation. Inhibition of the GSK3β by BIS 
I led to osteogenic differentiation and suppression of 
adipocyte differentiation by β-catenin stabilization [ 42 , 
 43 ]. More importantly, these data are in agreement with the 
inhibition of the GSK3β by BIO that led to the activation 
of YAP/TEAD response [ 6 ]. We did not observe a clear 
inactivation of the Hippo pathway but a down-regulation 
 Figure 7: Genetic ablation of YAP and BIS I treatment regulate cell migration.  A. BIS I reduces cell migration synergizing 
with YAP silencing. Scratch assay was performed in SCR or stably YAP-silenced PANC1 cells. Images of invaded cells at 0, 24, and 48 H 
after scratching and treatment with BIS I were taken from a time-lapse sequence of PANC1 cell migration; wounds with consistent shape 
within each well were generated using 200 μl tip. Percentage of invaded cells at different time point is indicated (right panels) as calculated 
by ImageJ softwre. (*p<0.05 and **p<0.01).  B. BIS I down-regulates  VIM and  ZEB1 mRNAs. PK9 cells were treated with BIS I for 
24H. Expression level of  VIM and  ZEB1 were measured by qRT-PCR. Data are presented as mean±SD. (**p<0.01 versus MOCK).  C. BIS 
I inhibits TFG-β induced ZEB1 expression. PK9 cells were stably transduced with a lentiviral vector encoding shRNA targeting YAP 
(shYAP) or a non-targeting control shRNA (SCR). They were then treated with BIS I 5μM in the presence and absence of TGF-β 50ng/
ml for 24H. The expression levels of  ZEB1 was evaluated. (*p<0.05, **p<0.01 and ***p<0.001).  D. Overexpression of YAP reverts the 
effect of BIS-I on the expression of  CTGF ,  CDH1 and  VIM . PK9 cells were transiently co-transfected with YAP and pEGFPN1 plasmids 
and treated with BIS I for 24H.  CTGF ,  CDH1 ,  VIM , and  ZEB1 expression levels were measured by qRT-PCR. Data are presented as 
mean±SD. (*p<0.05 and **p<0.01). 
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of LATS that explains the nuclear translocation of YAP, 
also in an independent manner from the association 
to the destruction complex [ 6 ]. Indeed, we observed 
the activation of the TEA reporter system during BIS I 
treatment, but, at the same time, a clear, YAP-dependent, 
decrease of  CTGF and  CYR61 mRNAs.  CTGF promoter 
region is highly regulated, and several transcription factors 
contribute to the activation of this locus. In mesangial and 
gingival cells, BIS I blockage of basal and TGFβ-induced 
regulation of  CTGF [ 44 , 45 ] was explained by inhibition 
of GSK3β. Moreover, in hepatocarcinoma cells, PKCδ-
mediated TGFβ signaling led to  CTGF expression by 
inhibiting the phosphatase PPM1A, which is responsible 
for the SMAD2/3 inactivation [ 46 ]. Downregulation of 
 CTGF upon functional ablation of PKCδ and GSK3β 
highlights that the similar mechanisms occur in PDAC 
cell lines ( Figure 4D ) and can be explained by  SMAD3 
mRNA downregulation ( Figure 4E ). GSK3β inhibition 
by LiCl induces a biphasic  CTGF expression regulation: 
an initial burst of expression, coherent with YAP nuclear 
accumulation, is followed by a long-term downregulation 
of the gene. This secondary response is likely due to the 
parallel downregulation of  SMAD2/3 (Supplementary 
Figure S2D, S2E). BIS I down-regulated  CTGF and 
 SMAD2/3 already at 6 hours, therefore showing a strong 
potency in blocking TGFβ in a  SMAD4 defi cient context, 
a frequent lesion in PDAC [ 47 ] and our cell lines. The 
same mechanism applies to YAP/SMADs co-regulated 
genes and, given the importance of this association in 
promoting EMT [ 48 ], it explains the specifi c reversion of 
EMT markers. Therefore, the down-regulation of SMADs 
dampens the YAP co-transcriptional activity of EMT 
genes. Indeed, YAP overexpression rescued phenotypically 
the ability to migrate and grow in anchorage-independent 
condition, and, molecularly, it inhibited the re-expression 
of E-cadherin and blunted the downregulation of  CTGF , 
 CD133, and  Vimentin . Additionally, we showed that BIS 
I induced displacement of YAP from  CTGF promoter, 
showing a loss of function of nuclear YAP on specifi c 
genes, likely driven by the loss of SMADs partner. Finally, 
we observed that BIS I induced the downregulation of 
many cancer stem genes, CD133 included, and we found 
that this new marker of EMT is highly regulated as YAP, 
GSK3β, and β-catenin modulated CD133 expression, 
addressing this gene as a co-regulated gene by these three 
factors. Further experiments are necessary to clarify this 
point. However, it suggests that inhibition of the SRC 
pathway  via dasatinib [ 23 , 49 ] may infl uence EMT in 
PDAC by modulating YAP activity. 
 MATERIALS AND METHODS 
 Antibodies, plasmids and reagents 
 The following antibodies were used: Anti-YAP (sc-
101199), anti TEF-1 (sc-376113), Anti-GSK3β (sc-9166), 
Anti phospho GSK3β Ser9 (sc-11757), Anti β-catenin (sc-
7199) (Santa Cruz Biotechnology). Anti-Lats1 (3477), 
Anti-phospho Lats1 Ser909 (9157), Anti-Smad2/3 (8685) 
and Anti-phospho-YAP (S127) (4911), Anti β-actin (3700) 
(Cell Signaling). Alexa Fluor 488-conjugated secondary 
antibodies (Invitrogen). The chemicals were used in this 
study: GF 109203X (B6292), Go6976 (G1171), phorbol 
12-myristate 13-acetate (PMA) (Sigma, P1585) were 
purchased from sigma. Lapatinib (S1028), Erlotinib 
(S1023) were purchased from Selleckchem. Recombinant 
human transforming growth factor 1 (TGF-β) (PHG9204) 
was purchased from Life technologies. The plasmids 
were used: 8xGTIIC-luciferase (#34615), YAP-GFP 
(12), pEGFP-N1 (Clontech), pGL4 (Promega), human 
B-catenin pcDNA3 (#16828), c-Flag pcDNA3 (#20011), 
TOP fl ash and FOP fl ash were gifted from Dr. Arthit [ 50 ]. 
 Cell culture and transfections 
 Human pancreatic carcinoma cell lines (PK9, 
MIAPACA2, PANC1, BxPC3) were kindly provided by 
G. Feldmann [ 12 ] and HEK293T were cultured at 37°C 
in high glucose Dulbecco’s modifi ed Eagle’s medium 
(DMEM) supplemented with 10% Fetal bovine serum 
(FBS) (Invitrogen), 1X vitamin solution (Sigma), 1X non-
essential amino-acid solution (NEAA, Biosource), 1X 
Sodiumpyruvate (Gibco) and 1X Penicillin-Streptomycin 
(LONZA) in a humidifi ed incubator with 5% CO2. 
Transfections were carried out in 6 or 24 well-plates using 
Lipofectamine 3000 kit (Life Techonologies) as described 
by the manufacturer. siRNAs for knockdown of PKCδ 
(sc-36253) and GSK3β (sc-35527) and control siRNA 
(sc-37007) were transfected using INTERFERIN siRNA 
transfection reagent (Polyplus transfection) according to 
manufacturer’s protocol. After 72 h of incubation, proteins 
were extracted for analysis by western blot analysis as 
describe below. 
 Lentriviral particles production and stable 
clones selection 
 To generate shYAP expressing stable PK9 and 
PANC1 cells, The pLKO.1-based lentiviral plasmid 
containing YAP shRNA (NM006106) expression cassettes 
were purchased from Sigma-Aldrich. Scramble shRNA 
(Addgene plasmid 1864) was used as a control. Vectors 
were produced in HEK293T cells by co-transfection of 
the different transfer vectors with the packaging plasmid 
pCMV-deltaR8.91 and the VSV envelope-coding plasmid 
pMD2.G. After transfection (48h), lentiviral supernatant 
was fi ltered through a 0.45 μm syringe fi lter and used to 
infect YAP into PK9 and PANC1 cells by spinning them 
down with vector containing supernatants for 90 min at 
1500xg at room temperature and leaving them incubate 
overnight at 37°C, then the fresh medium were replaced 
the transduction supernatant. Cells were then further 
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incubated for 72H before collection for WB. Stable silent 
cells were selected using 3 μg/ml puromycin (Sigma) in 
the culture medium. 
 Immunofl uorescence staining and drug screening 
 PK9 and PANC1 cells were cultured sparsely 
(LOW) and densely (HIGH) onto glass cover slides and in 
96 well-plate for 48 H. Cells were fi xed and localization 
of YAP was visualized and nuclei were counterstained 
with DAPI. Immunofl uorescence analysis was performed 
using a Zeiss Observer Z1 microscope equipped with 
Apotome module, with a Plan Apochromatic (63X, NA 
1.4) objective. Images were acquired using Zen 1.1 (blue 
edition) imaging software (Zeiss) and assembled with 
Adobe Photoshop CS3. Drug screening, PK9 cells were 
seeded on OptiPlate-96 Black, Black Opaque 96-well 
Microplate (PerkinElmer) at a density of 5000 cells/well, 
to obtain a 70% confl uence at the end of the assay. The 
library of known kinase inhibitors was re-suspended in 
DMSO and diluted in PBS 1X. The compounds were 
administrated at the fi nal concentration of 1μM for 24H. 
Cells were fi xed as previously described [ 52 ], primary 
antibody against YAP (1:500) and secondary fl uorophore 
conjugated (Alexa 488) antibody (1:10000) were diluted in 
PBS + BSA 0.2%. DAPI (1.5 μg/ml) in PBS + BSA 0.2% 
was used to detect nuclei. PerkinElmer image plate reader 
Operetta was used for imaging and evaluation. The ratio 
between nuclear and cytoplasmic signal represents the 
mean of single cells for every well and it were normalized 
to untreated control. The Z score was calculated to 
evaluate the signifi cance of results from the screening. Z 
score was calculated as follow: Z = (X–mean)/standard 
deviation. X = normalized sample ratio [ 51 ]. 
 Soft-agar and cell migration assay 
 Each 6-well plate was coated with 1 ml of bottom 
agar (DMEM containing 10% FBS with and 0.7% agar). 
PDAC cell lines, shYAP expressing stable PANC-1 
(1.5x104 cells) were resuspended in 1ml of top agar 
(DMEM containing 10% FBS with and 0.35% agar) 
into each well. Cells were treated with 1ml of BIS I and 
incubated for 2-3 weeks. They were replaced with fresh 
medium with/without treatment every 3 days. PerkinElmer 
image plate reader Operetta was used for imaging and 
colony evaluation. 
 Cell migration assay. Confluent cells were seeded 
in 6-well plate and wounded by a 200μl pipette tip. 
Media were replaced with BIS I treatment. Images of 
the same field were acquired immediately (0h), after 
24 and 48 hours using a Leica DM IL Led microscope 
(5X magnification). Wounded-open areas were 
photographed and measured at the time of scratch and 
2 days. Relative invaded area was measured using 
Image-J software. 
 Western blot and sub-cellular fractionation 
 Cells were treated for 24H then they were 
lysed in cold modifi ed cytosolic lysis buffer (10mM 
HEPES pH 7.0, 10mM KCl, 1mM EDTA, 0.5%
NP-40, 1mM DTT, and Protease inhibitor cocktail). The 
supernatant containing cytosolic fraction was collected by 
centrifugation at 3000xg for 5 minutes at 4°C. Nuclear 
pellets were then re-suspended in cold modifi ed nuclear 
lysis buffer (10mM HEPES pH 7.0, 400mM NaCl, 
1mM EDTA, 25% Glycerol, 1mM DTT, and Protease 
inhibitor cocktail). The nuclear extract was harvested by 
centrifugation at 12000xg for 15 minutes at 4°C. Equal 
quantities of proteins were separated by electrophoresis 
on a 12% SDS-page gels. The blots were incubated with 
YAP1, Phospho-YAP-1 (Ser127), β-catenin antibodies 
overnight at 4°C. β-actin and Lamin A/C served as the 
loading controls for the cytosolic and nuclear fraction, 
respectively. 
 Luciferase reporter assay. HEK293T, PK9 and 
PANC1 were seeded in 24 well-plates then indicated 
plasmids were co-transfected using Lipofectamine 3000 
(Invitrogen) or TransIT-LT1 Transfection Reagent (Mirus). 
After transfection (24H), cells were treated with BIS 
family compounds including GF 109203X or BIS I (5μM), 
Go6976 (5μM), Erlotinib (5μM), Lapatinib (5 μM), and 
PMA (1 μM) for 24H. Cells were lysed and luciferase 
activity was assayed using the enhanced luciferase assay 
kit (Promega) following the manufacturer’s instructions. 
The fi refl y luciferase activity levels were measure and 
normalized to Renilla luciferase activity. 
 RNA isolation, real-time PCR and ChIP assay 
 Total RNA was extracted using RNA isolation 
Mini Kit (Agilent Technologies and successively treated 
with RNA-free DNase. RNA was subjected for reverse 
transcription (RT) with iScript reverse transcriptase (Bio-
rad). cDNA was then diluted and 50ng total of cDNA was 
used for qRT-PCR with gene-specifi c primers using KAPA 
SYBR FAST qPCR master mix (Kapa biosystem) or HOT 
FIREPol EvaGreen qPCR Mix (Solis BioDyne). Relative 
abundance of mRNA was calculated by normalization 
to GAPDH mRNA. The reactions were carried out on 
a CFX96TM real-time system (BIO-RAD). For ChIP 
assay, DNA was extracted by phenol/chloroform/
isoamyl alcohol, ethanol precipitated and re-suspended 
in water. In mRNA expression experiments, Ct values 
of every gene were normalized to the housekeeping 
GAPDH, while in ChIP assays, the normalization were 
calculated by the following formula: (X–IgG)/INPUT, 
where X is the Ct of the sequence of interest derived 
from the immunoprecipitated DNA bound to the protein 
of interest; IgG is the Ct of the same sequence derived 
from the DNA immunoprecipitated with an irrelevant 
antibody and INPUT is the Ct derived from the total DNA 
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before immunoprecipitation. Primers for quantitative real 
time PCR (for ChIP assay) were obtained from MWG/
Operon, with the following sequences: Forward: 5′ 
TTGGTGCTGGAAATACTGCG 3′, Reverse: 5′ CTCA
GCGGGGAAGAGTTGTT 3′. Other primers used in this 
work are listed in Supplementary Table S2. 
 Cell cycle and real-time cell proliferation assay 
 Cells were incubated in a 96-well plate (200 ul 
of medium/well) with the tested compounds for 24H 
and cell viability was quantitatively determined by a 
colorimetric MTT assay. In brief, MTT (5mg/ml) at 
10% volume of culture media was added to each well 
and cells were further incubated for 2H at 37°C. Then 
supernatant containing MTT was replaced by 100μl 
of DMSO to dissolve formazan. Absorbance was then 
determined at 565nM by microplate reader. Cell survival 
was calculated and EC50 values were determined. Cell 
cycle was measured by FACS analysis at 24H after 
treatment using propidium iodide (PI) staining. Real time 
cell proliferation assay: PK9 were seeded 5000 cells/well 
in E-plates (Roche), in triplicates. The cell growth curves 
were automatically recorded on the xCELLigence System 
(Roche) in real time. The cell attachment was monitored 
every 15 minutes by a cell electronic system. The doubling 
times were calculated according with cell index. The 
cell index is an arbitrary unit for displaying inpedence. 
SCR or siRNAs transfection PK9 cells were performed 
by replacing cell medium, including untreated control to 
operate at the same working conditions. 
 Two-dimensional electrophoresis 
 The experiment was performed according to 
previous protocols [ 52 ]. Proteins were extracted using a 
lysis buffer (8M urea, 4% CHAPS, 50mM dithioerythritol 
and 0,0002% Bromophenol blue) and rehydrated with 
8M urea, 2% CHAPS, 20mM dithioerythritol, 0.8% 
IPG buffer, carrier ampholytes pH 6-11 linear. The fi rst 
dimension isoelectric focusing (IEF) was performed in 
immobiline dry strips (GE) with a pH range from 7 to 
4. IEF was performed on IPGphor (GE) according to 
the manufacturer recommendations. The gels were then 
equilibrated in 6M urea, 3% SDS, 375mM Tris pH 8.6, 
30% glycerol, 2% DTE and then incubated with 3% 
iodoacetamide (IAA) and traces of bromophenol blue 
(BBP). The second dimension was performed using an 8% 
SDS-PAGE gel. Transfer and detection were carried out as 
previously described. 
 Statistical analysis 
 The Data are presented as mean±SD and the 
standard deviation of the mean (SD) in this study were 
calculated for 3 replicates in each of the 3 independent 
experiments. Statistical comparisons were assessed with 
analysis of Student’s test and One-way ANOVA calculated 
with GraphPad Prism version 5.0 for Windows (GraphPad 
Software). P<0.05 was considered statistically signifi cant 
difference and P<0.01, and P<0.001 were considered as 
highly signifi cant difference. 
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